varname,LABEL,file,MEMNAME,picsure_type
ID,Unique patient identifier (randomized),phaseiii_abdominal_sonogram.csv,ABDOMINAL_SONOGRAM,continuous
VISIT,VISIT NUMBER,phaseiii_abdominal_sonogram.csv,ABDOMINAL_SONOGRAM,categorical
READER,Reader Number,phaseiii_abdominal_sonogram.csv,ABDOMINAL_SONOGRAM,continuous
LABEL,Label Number,phaseiii_abdominal_sonogram.csv,ABDOMINAL_SONOGRAM,continuous
RIGHT_L,RIGHT KIDNEY: LENGTH (cm),phaseiii_abdominal_sonogram.csv,ABDOMINAL_SONOGRAM,continuous
RIGHT_AP,RIGHT KIDNEY: ANTERIOR - POSTERIOR (cm),phaseiii_abdominal_sonogram.csv,ABDOMINAL_SONOGRAM,continuous
RIGHT_T,RIGHT KIDNEY: TRANSVERSE (cm),phaseiii_abdominal_sonogram.csv,ABDOMINAL_SONOGRAM,continuous
LEFT_L,LEFT KIDNEY: LENGTH (cm),phaseiii_abdominal_sonogram.csv,ABDOMINAL_SONOGRAM,continuous
LEFT_AP,LEFT KIDNEY: ANTERIOR - POSTERIOR (cm),phaseiii_abdominal_sonogram.csv,ABDOMINAL_SONOGRAM,continuous
LEFT_T,LEFT KIDNEY: TRANSVERSE (cm),phaseiii_abdominal_sonogram.csv,ABDOMINAL_SONOGRAM,continuous
RIGHT_VOL,RIGHT KIDNEY VOLUME (cm^3),phaseiii_abdominal_sonogram.csv,ABDOMINAL_SONOGRAM,continuous
LEFT_VOL,LEFT KIDNEY VOLUME (cm^3),phaseiii_abdominal_sonogram.csv,ABDOMINAL_SONOGRAM,continuous
PROCEDURE_DT_DAYS,Date of Procedure (recode: number of days after date of eligibility or ineligibility),phaseiii_abdominal_sonogram.csv,ABDOMINAL_SONOGRAM,continuous
OBS,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
ID,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
VISIT,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
SEQNO,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
ACTIVISIT,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
ACTSEQNO,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
AE_TYPE,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
OTHER_AE_SPECIFY,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,categorical
AE_TERM,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,categorical
HXFEVNCR,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,categorical
EVENT_IS_SAE,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
DEATH,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
DTH_LOC,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
LIFETHRTNG,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
HOSPTLZD,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
LONGHOSP,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
ICU,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
SAE_TRTRLTD,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
SAE_EVNTTYPE,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
ACSNINF,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
ACSSRAP,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
ACSOXADM,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
ACSMVENT,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
SPLNSIZE,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
SPLNHMGL,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
SPLPTCNT,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
SEPSBACT,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
SEPORGGN,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,categorical
SEPORGSS,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,categorical
MENINGTS,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
MNGTBACT,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
ACOSTORG,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
ACOSTBON,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,categorical
LOS_CONS,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
CHG_MENT,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
SPEECH,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
PARALYS,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
DIFFSWAL,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
DIFF_SEE,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
BALANCE,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
SEIZURE,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
HEADACHE,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
F50MRI,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
F50CTBR,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
F50PTBR,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
F50MRA,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
F50TCD,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
F50ARTGR,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
F50NEUR,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
NUMDAYS,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
SEVERITY,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
ATTR_TRT,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
DIAGUNXP,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
OUTCOME,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
TRTEVENT,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
TRANSFUS,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
TR_TYPE,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
TRVOLWBL,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
TRVOLPR2,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
CHRTRAN,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
BMT,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
SPLCTMY,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
CHOLCTMY,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
PAR_ANTI,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
BUTYRATE,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
CONTRAHU,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
DIALYS_L,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
DIALYS_C,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
RENTRANS,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
TRTEVENT_OTHER,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
TRTEVENT_SPCFY,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,categorical
AE_OUTPTTRT,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
AE_RQRHOSP,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
LLT_CODE,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
LLT_NAME,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,categorical
PT_CODE,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
PT_TERM,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,categorical
HLT_CODE,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
HLT_TERM,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,categorical
HLGT_CODE,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
HLGT_TERM,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,categorical
SOC_CODE,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
SOC_TERM,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,categorical
ADM_DT_DAYS,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
DEATH_DT_DAYS,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
DISCH_DT_DAYS,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
E_END_DT_DAYS,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
ONSET_DT_DAYS,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
RSLTN_DT_DAYS,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
START_DT_DAYS,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
TSTOP_DT_DAYS,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
TSTRT_DT_DAYS,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
VIS_DT_DAYS,,phaseiii_bhrct_fm50.csv,BHRCT_FM50,continuous
ID,Unique patient identifier (randomized),phaseiii_bhug_pneumo_lab.csv,BHUG_PNEUMO_LAB,continuous
OPBLLBL,LABEL OF SERUM OPSONOPHAGOCYTIC+PNEUMOCOCCAL ANTIBODY AT STUDY ENTRY,phaseiii_bhug_pneumo_lab.csv,BHUG_PNEUMO_LAB,continuous
OPBLT26,RESULT OF SERUM OPSONOPHAGOCYTIC+PNEUMOCOCCAL ANTIBODY(TYPE 26) AT STUDY ENTRY,phaseiii_bhug_pneumo_lab.csv,BHUG_PNEUMO_LAB,continuous
OPBLT51,RESULT OF SERUM OPSONOPHAGOCYTIC+PNEUMOCOCCAL ANTIBODY(TYPE 51) AT STUDY ENTRY,phaseiii_bhug_pneumo_lab.csv,BHUG_PNEUMO_LAB,continuous
PCAB2YLB,LABEL OF ANTIBODY RESPONSE TO PNEUMO 23(TYPE 51) AT AGE OF 23 MONTHS,phaseiii_bhug_pneumo_lab.csv,BHUG_PNEUMO_LAB,continuous
PCAB2YT26,RERULT OF ANTIBODY RESPONSE TO PNEUMO 23(TYPE 26) AT AGE OF 23 MONTHS,phaseiii_bhug_pneumo_lab.csv,BHUG_PNEUMO_LAB,continuous
PCAB2YT51,RERULT OF ANTIBODY RESPONSE TO PNEUMO 23(TYPE 51) AT AGE OF 23 MONTHS,phaseiii_bhug_pneumo_lab.csv,BHUG_PNEUMO_LAB,continuous
OC2YLBL,LABEL OF SERUM OPSONOPHAGOCYTIC+PNEUMOCOCCAL ANTIBODY 2-6 WEEKS AFTER VACCINATIONS AT AGE OF 24 MONTHS,phaseiii_bhug_pneumo_lab.csv,BHUG_PNEUMO_LAB,continuous
OC2YT26,RESULT OF SERUM OPSONOPHAGOCYTIC+PNEUMOCOCCAL ANTIBODY(TYPE 26) 2-6 WEEKS AFTER VACCINATIONS AT AGE OF 24 MONTHS,phaseiii_bhug_pneumo_lab.csv,BHUG_PNEUMO_LAB,continuous
OC2YT51,RESULT OF SERUM OPSONOPHAGOCYTIC+PNEUMOCOCCAL ANTIBODY(TYPE 51) 2-6 WEEKS AFTER VACCINATIONS AT AGE OF 24 MONTHS,phaseiii_bhug_pneumo_lab.csv,BHUG_PNEUMO_LAB,continuous
OCAEOSLB,LABEL OF SERUM OPSONOPHAGOCYTIC+PNEUMOCOCCAL ANTIBODY AT STUDY EXIT,phaseiii_bhug_pneumo_lab.csv,BHUG_PNEUMO_LAB,continuous
OCAEOST26,RESULT OF SERUM OPSONOPHAGOCYTIC+PNEUMOCOCCAL ANTIBODY(TYPE 26) AT STUDY EXIT,phaseiii_bhug_pneumo_lab.csv,BHUG_PNEUMO_LAB,continuous
OCAEOST51,RESULT OF SERUM OPSONOPHAGOCYTIC+PNEUMOCOCCAL ANTIBODY(TYPE 51) AT STUDY EXIT,phaseiii_bhug_pneumo_lab.csv,BHUG_PNEUMO_LAB,continuous
OPBLDT_DAYS,DATE OF STUDY ENTRY (PRE-TREATMENT):SERUM OPSONOPHAGOCYTIC+PNEUMOCOCCAL ANTIBODY (recode: number of days after date of eligibility or ineligibility),phaseiii_bhug_pneumo_lab.csv,BHUG_PNEUMO_LAB,continuous
PCAB2YDT_DAYS,DATE OF 23-MONTH-OF-AGE BLOOD SAMPLES:ANTIBODY RESPONSE TO PNEUMO 23 (recode: number of days after date of eligibility or ineligibility),phaseiii_bhug_pneumo_lab.csv,BHUG_PNEUMO_LAB,continuous
OC2YDT_DAYS,DATE OF 2-8 WEEKS AFTER 24-MONTH OF AGE VACCINATIONS:SERUM OPSONOPHAGOCYTIC + PNEUMOCOCCAL ANTIBODY (recode: number of days after date of eligibility or ineligibility),phaseiii_bhug_pneumo_lab.csv,BHUG_PNEUMO_LAB,continuous
OCAEOSDT_DAYS,DATE OF STUDY EXIT:SERUM OPSONOPHAGOCYTIC+PNEUMOCOCCAL ANTIBODY (recode: number of days after date of eligibility or ineligibility),phaseiii_bhug_pneumo_lab.csv,BHUG_PNEUMO_LAB,continuous
DT_RECD_DAYS,DATE OF RECORD (recode: number of days after date of eligibility or ineligibility),phaseiii_bhug_pneumo_lab.csv,BHUG_PNEUMO_LAB,continuous
ID,Unique patient identifier (randomized),phaseiii_consent_dt.csv,CONSENT_DT,continuous
ELIGSTAT,STATUS OF ELIGIBILITY (1 = ELIGIBLE; 2 = INELIGIBLE),phaseiii_consent_dt.csv,CONSENT_DT,continuous
TRT_GRP,TREATMENT GROUP (1 = HU; 2 = Placebo),phaseiii_consent_dt.csv,CONSENT_DT,continuous
DATA_CONSENT,Subject Consented for Data Sharing?,phaseiii_consent_dt.csv,CONSENT_DT,categorical
CONSENT_DT_DAYS,Consent Date (recode: number of days after date of eligibility or ineligibility),phaseiii_consent_dt.csv,CONSENT_DT,continuous
SCRN_DT_DAYS,DATE OF SCREENING (recode: number of days after date of eligibility or ineligibility),phaseiii_consent_dt.csv,CONSENT_DT,continuous
EXIT_DT_DAYS,DATE OF EXIT (recode: number of days after date of eligibility or ineligibility),phaseiii_consent_dt.csv,CONSENT_DT,continuous
TRT_DT_DAYS,DATE OF TREATMENT INITIATION (recode: number of days after date of eligibility or ineligibility),phaseiii_consent_dt.csv,CONSENT_DT,continuous
ID,Unique patient identifier (randomized),phaseiii_cystatin.csv,CYSTATIN,continuous
LABEL,Label Number,phaseiii_cystatin.csv,CYSTATIN,continuous
VISIT,VISIT NUMBER,phaseiii_cystatin.csv,CYSTATIN,categorical
FIRST_MEASUREMENT,CYSTATIN C: FIRST MEASUREMENT (mg/L),phaseiii_cystatin.csv,CYSTATIN,continuous
SECOND_MEASUREMENT,CYSTATIN C: SECOND MEASUREMENT (mg/L),phaseiii_cystatin.csv,CYSTATIN,continuous
VIS_DT_DAYS,Visit Date (recode: number of days after date of eligibility or ineligibility),phaseiii_cystatin.csv,CYSTATIN,continuous
ID,Unique patient identifier (randomized),phaseiii_dpta.csv,DTPA,continuous
VISIT,F22 I_4VIS   SUBJECT CLINICAL VISIT NUMBER,phaseiii_dpta.csv,DTPA,categorical
DTPA_GFR,GFR from DTPA (ml/min/1.73m2),phaseiii_dpta.csv,DTPA,continuous
VIS_DT_DAYS,F22 I_5      SUBJECT CLINICAL VISIT START DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_dpta.csv,DTPA,continuous
ID,Unique patient identifier (randomized),phaseiii_fm04.csv,FM04,continuous
FORM,F04 FORM     STUDY FORM NUMBER,phaseiii_fm04.csv,FM04,continuous
REV,F04 REV      NUMBER OF THE FORM REVISONS,phaseiii_fm04.csv,FM04,continuous
VISIT,F04 I_4VIS   SUBJECT CLINICAL VISIT NUMBER FOR FIRST SCREENING,phaseiii_fm04.csv,FM04,categorical
SEQNO,F04 I_4SEQ   SUBJECT VISIT SEQUENCE NUMBER,phaseiii_fm04.csv,FM04,continuous
DIAGHBSS,F04 II_1     DIAGNOSIS OF HB-SS OR HB S-BETA-0-THAL?,phaseiii_fm04.csv,FM04,continuous
AGEINCL4,F04 II_2B    IS THE CHILD CHILD BETWEEN 9 AND 17 MONTHS OF AGE INCLUSIVE?,phaseiii_fm04.csv,FM04,continuous
WILL1217,"F04 II_2C    WILL THE CHILD BE BETWEEN 9 AND 17 MONTHS OF AGE INCLUSIVE, DURING THE STUDY RECRUITMENT PERIOD?",phaseiii_fm04.csv,FM04,continuous
CONSNT04,F04 II_3     HAS INFORMED CONSENT BEEN OBTAINED?,phaseiii_fm04.csv,FM04,continuous
HIPAA04,F04 II_4     HAS HIPAA AUTHORIZATION FORM BEEN OBTAINED?,phaseiii_fm04.csv,FM04,continuous
PHONE04,F04 II_5     DOES THE FAMILY HAVE TELEPHONE SERVICE FOR CONTACT AS REQUIRED?,phaseiii_fm04.csv,FM04,continuous
SPLENCBL,F04 III_1A   SPLENECTOMY?,phaseiii_fm04.csv,FM04,continuous
CHRTRFBL,F04 III_1B   CHRONIC TRANSFUSION PROGRAM?,phaseiii_fm04.csv,FM04,continuous
TRN2MO04,F04 III_1C   TRANSFUSION WITHIN LAST TWO MONTHS?,phaseiii_fm04.csv,FM04,continuous
HERPHFBL,F04 III_1D   KNOWN HEREDITARY PERSISTENCE OF HB-F?,phaseiii_fm04.csv,FM04,continuous
STROKEBL,F04 III_1E   STROKE OR GRADE III/IV INTRACRANIAL HEMORRHAGE?,phaseiii_fm04.csv,FM04,continuous
MALIGBL,F04 III_1F   MALIGNANCY?,phaseiii_fm04.csv,FM04,continuous
PALSYBL,F04 III_1G   CEREBRAL PALSY AND/OR MENTAL RETARDATION?,phaseiii_fm04.csv,FM04,continuous
OTHCHRBL,F04 III_1H   OTHER CONDITION OR SEVERE CHRONIC ILLNESS?,phaseiii_fm04.csv,FM04,continuous
SBTHALBL,F04 III_1I   S-BETA+ THALASSEMIA?,phaseiii_fm04.csv,FM04,continuous
PRVHUBL,F04 III_1J   PREVIOUS OR CURRENT HYDROXYUREA THERAPY?,phaseiii_fm04.csv,FM04,continuous
ANTISKBL,F04 III_1K   PREVIOUS OR CURRENT USE OF  OTHER ANTISICKLING AGENT?,phaseiii_fm04.csv,FM04,continuous
TRIALSBL,F04 III_1L   CURRENT PARTICIPATION IN OTHER INTERVENTION TRIAL(S)?,phaseiii_fm04.csv,FM04,continuous
CERT_SIG,F04 V_1B     SIGNATURE OF THE PERSON WHO FILLS OUT THE FORM,phaseiii_fm04.csv,FM04,continuous
GEN_CMNT,F04 V_1C     GENERAL COMMENTS REGARDING TO THE FILLED OUT FORM,phaseiii_fm04.csv,FM04,continuous
SIBLING,"F04 IV_1A    IF YES, WHAT'S THE SIBLING'S PATIENT ID?",phaseiii_fm04.csv,FM04,continuous
SIB_ENR,F04 IV_1     DOES THE CHILD HAVE A SIBLING EITHER ENROLLED OR IN SCREENING IN BABY HUG?,phaseiii_fm04.csv,FM04,continuous
VIS_DT_DAYS,F04 I_5      SUBJECT CLINICAL VISIT DATE OF FIRST SCREENING (recode: number of days after date of eligibility or ineligibility),phaseiii_fm04.csv,FM04,continuous
TRN04_DT_DAYS,F04 III_1CDT TRANSFUSION DATE IF TRANSFUSED WITHIN LAST TWO MONTHS (recode: number of days after date of eligibility or ineligibility),phaseiii_fm04.csv,FM04,continuous
ID,Unique patient identifier (randomized),phaseiii_fm05.csv,FM05,continuous
FORM,F05 FORM     STUDY FORM NUMBER,phaseiii_fm05.csv,FM05,continuous
REV,F05 REV      NUMBER OF THE FORM REVISONS,phaseiii_fm05.csv,FM05,continuous
VISIT,F05 I_4VIS   SUBJECT CLINICAL VISIT NUMBER FOR SECOND SCREENING,phaseiii_fm05.csv,FM05,categorical
SEQNO,F05 I_4SEQ   SUBJECT VISIT SEQUENCE NUMBER,phaseiii_fm05.csv,FM05,continuous
AGEINCL5,F05 1A       IS THE SUBJECT BETWEEN 9 AND 17 MONTHS OF AGE?,phaseiii_fm05.csv,FM05,continuous
TRN2MO05,F05 1B       HAS THE SUBJECT HAD TRANSFUSION WITHIN LAST 2 MONTHS?,phaseiii_fm05.csv,FM05,continuous
CONSNT05,F05 2A       HAS INFORMED CONSENT BEEN OBTAINED?,phaseiii_fm05.csv,FM05,continuous
HIPAA05,F05 2B       HAS HIPAA AUTHORIZATION FORM BEEN OBTAINED?,phaseiii_fm05.csv,FM05,continuous
PHONE05,F05 2C       DOES THE FAMILY HAVE TELEPHONE SERVICE FOR CONTACT AS REQUIRED?,phaseiii_fm05.csv,FM05,continuous
PAPRVCCD,F05 2D       CONCURRENCE THAT PARTICIPATION APPROPRIATE BY CLINICAL CENTER DIRECTOR?,phaseiii_fm05.csv,FM05,continuous
PAPRVPFA,F05 2E       CONCURRENCE THAT PARTICIPATION APPROPRIATE  BY PATIENT-FAMILY ADVOCATE?,phaseiii_fm05.csv,FM05,continuous
BLOODCOL,F05 III_1    WERE ANY BLOOD SPECIMENS COLLECTED?,phaseiii_fm05.csv,FM05,continuous
NOVENACS,F05 III_1A1  REASON(S) SPECIMEN NOT COLLECTED: (1). NO ACCESS,phaseiii_fm05.csv,FM05,continuous
PTNTDCLN,F05 III_1A2  REASON(S) SPECIMEN NOT COLLECTED: (2). PATIENT DECLINED OR BLOOD DRAW NOT POSSIBLE TODAY,phaseiii_fm05.csv,FM05,continuous
PRNTREFS,F05 III_1A3  REASON(S) SPECIMEN NOT COLLECTED: (3). PARENT REFUSED,phaseiii_fm05.csv,FM05,continuous
SCHEMAT,F05 III_1B1  SPECIMEN LABEL: (1). HEMATOLOGY,phaseiii_fm05.csv,FM05,continuous
SCBIOCH,F05 III_1B2  SPECIMEN LABEL: (2). BIOCHEMISTRY SPECIMEN COLLECTED JUST PRIOR TO URINE OSMOLALITY SPECIMEN,phaseiii_fm05.csv,FM05,continuous
SCPITCEL,F05 III_1B3  SPECIMEN LABEL: (3). PITTED CELL COUNT SPECIMEN COLLECTED AND PREPARED WITHIN 1 HOUR OF COLLECTION,phaseiii_fm05.csv,FM05,continuous
SCCYTOG,F05 III_1B4  SPECIMEN LABEL: (4). CYTOGENETICS,phaseiii_fm05.csv,FM05,continuous
SCDNA,F05 III_1B5  SPECIMEN LABEL: (5). DNA,phaseiii_fm05.csv,FM05,continuous
SCIMMUN,F05 III_1B6  SPECIMEN LABEL: (6). IMMUNOLOGY(RECORD LABELS ON FORM 42),phaseiii_fm05.csv,FM05,continuous
SCPENCIL,F05 III_1B7  SPECIMEN LABEL: (7). PENICILLIN COMPLIANCE,phaseiii_fm05.csv,FM05,continuous
SCCONS1,F05 III_1B8  IS THE SPECIMEN CONSENTED TO BE USED FOR OTHER PURPOSES?,phaseiii_fm05.csv,FM05,continuous
SCCONS2,F05 III_1B9  IS THE SPECIMEN CONSENTED FOR OTHER DOCTORS TO STUDY DISEASES NOT RELATED TO SCA?,phaseiii_fm05.csv,FM05,continuous
SEDMRI,F05 IV_1C1   SEDATION,phaseiii_fm05.csv,FM05,continuous
MRI_NPO,F05 IV_1C2   HOW MANY HOURS NPO IN MRI SCAN?,phaseiii_fm05.csv,FM05,continuous
ABD_NPO,F05 IV_1D1   HOW MANY HOURS NPO IN ABDOMINAL ULTRASOUND SCAN?,phaseiii_fm05.csv,FM05,continuous
TRNDP_ND,F05 IV_1HND  TRANSCRANIAL DOPPLER NOT DONE,phaseiii_fm05.csv,FM05,continuous
TRNDNP,F05 IV_1H1   REASON FOR TRANSCRANIAL DOPPLER NOT ATTEMPTED,phaseiii_fm05.csv,FM05,continuous
TRNDNPSP,F05 IV_1H1A  SPECIFY THE OTHER REASONS WHY TRANSCRANIAL DOPPLER NOT ATTEMPTED,phaseiii_fm05.csv,FM05,continuous
REDCELLS,F05 IV_2A    URINALYSIS: DEGREE OF RED CELLS,phaseiii_fm05.csv,FM05,continuous
WHTCELLS,F05 IV_2B    URINALYSIS: DEGREE OF WHITE CELLS,phaseiii_fm05.csv,FM05,continuous
URIN_PH,F05 IV_2C    URINALYSIS: URINE PH VALUE,phaseiii_fm05.csv,FM05,continuous
URINPR,F05 IV_2D    URINALYSIS: DEGREE OF PROTEIN,phaseiii_fm05.csv,FM05,continuous
URINHB,F05 IV_2E    URINALYSIS: DEGREE OF HEMOGLOBIN,phaseiii_fm05.csv,FM05,continuous
URINSG,F05 IV_2F    URINALYSIS: URINE SPECIFIC GRAVITY,phaseiii_fm05.csv,FM05,continuous
URN_NPO,F05 IV_3A    HOW MANY HOURS NPO IN URINE CONCENTRATING ABILITY ANALYSIS?,phaseiii_fm05.csv,FM05,continuous
URINOS,F05 IV_3B    URINE OSMOLALITY SPECIMEN COLLECTED JUST AFTER BIOCHEMISTRY SPECIMEN,phaseiii_fm05.csv,FM05,continuous
O2SAT,"F05 IV_4A    O2 SATURATION (PULSE OXYMETRY), FIRST MEASUREMENT",phaseiii_fm05.csv,FM05,continuous
O2SATSM,"F05 IV_4B    O2 SATURATION (PULSE OXYMETRY), SECOND MEASUREMENT",phaseiii_fm05.csv,FM05,continuous
HEIGHT1,"F05 IV_5A    SUBJECT'S RECUMBENT LENGTH, FIRST MEASUREMENT",phaseiii_fm05.csv,FM05,continuous
HEIGHT2,"F05 IV_5B    SUBJECT'S RECUMBENT LENGTH, SECOND MEASUREMENT",phaseiii_fm05.csv,FM05,continuous
HEIGHT3,"F05 IV_5C    SUBJECT'S RECUMBENT LENGTH, THIRD MEASUREMENT",phaseiii_fm05.csv,FM05,continuous
HEIGHT,F05          AVERAGE OF THE SUBJECT'S RECUMBENT LENGTH,phaseiii_fm05.csv,FM05,continuous
HAIRHGHT,F05 IV_5D    RATE HAIR STYLE INTERFERENCE ON SUBJECT'S LENGTH,phaseiii_fm05.csv,FM05,continuous
WEIGHT1,"F05 IV_6A    SUBJECT'S WEIGHT, FIRST MEASUREMENT",phaseiii_fm05.csv,FM05,continuous
WEIGHT2,"F05 IV_6B    SUBJECT'S WEIGHT, SECOND MEASUREMENT",phaseiii_fm05.csv,FM05,continuous
WEIGHT3,"F05 IV_6C    SUBJECT'S WEIGHT, THIRD MEASUREMENT",phaseiii_fm05.csv,FM05,continuous
WEIGHT,F05          AVERAGE OF SUBJECT'S WEIGHT,phaseiii_fm05.csv,FM05,continuous
HEADC1,"F05 IV_7A    SUBJECT'S HEAD CIRCUMFERENCE, FIRST MEASUREMENT",phaseiii_fm05.csv,FM05,continuous
HEADC2,"F05 IV_7B    SUBJECT'S HEAD CIRCUMFERENCE, SECOND MEASUREMENT",phaseiii_fm05.csv,FM05,continuous
HEADC3,"F05 IV_7C    SUBJECT'S HEAD CIRCUMFERENCE, THIRD MEASUREMENT",phaseiii_fm05.csv,FM05,continuous
HEADC,F05          AVERAGE OD SUBJECT'S HEAD CIRCUMFERENCE,phaseiii_fm05.csv,FM05,continuous
HAIR,F05 IV_7D    RATE HAIR STYLE INTERFERENCE ON SUBJECT'S HEAD CIRCUMFERENCE,phaseiii_fm05.csv,FM05,continuous
CERT_NO,F05 V_1A     CERTIFICATION NUMBER OF THE PERSON WHO FILLS OUT THE FORM,phaseiii_fm05.csv,FM05,continuous
CERT_SIG,F05 V_1B     SIGNATURE OF THE PERSON WHO FILLS OUT THE FORM,phaseiii_fm05.csv,FM05,continuous
GEN_CMNT,F05 V_1C     GENERAL COMMENTS REGARDING TO THE FILLED OUT FORM,phaseiii_fm05.csv,FM05,continuous
VIS_DT_DAYS,F05 I_5      SUBJECT CLINICAL VISIT DATE OF SECOND SCREENING (recode: number of days after date of eligibility or ineligibility),phaseiii_fm05.csv,FM05,continuous
MSRMT_DT_DAYS,F05 IV_8     ANTHROPOMETRY MEASUREMENT DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm05.csv,FM05,continuous
TRN05_DT_DAYS,F05 1B1DT    THE SUBJECT TRANSFUSION DATE IF TRANSFUSED WITHIN LAST TWO MONTHS (recode: number of days after date of eligibility or ineligibility),phaseiii_fm05.csv,FM05,continuous
URNLS_DT_DAYS,F05 IV_1ADT  DATE OF URINALYSIS PERFORMED (recode: number of days after date of eligibility or ineligibility),phaseiii_fm05.csv,FM05,continuous
URNCA_DT_DAYS,F05 IV_1BDT  DATE OF URINE CONCENTRATING ABILITY PERFORMED (recode: number of days after date of eligibility or ineligibility),phaseiii_fm05.csv,FM05,continuous
MRI_DT_DAYS,F05 IV_1CDT  MRI/MRA DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm05.csv,FM05,continuous
LIVSP_DT_DAYS,F05 IV_1CDT  DATE OF LIVER-SPLEEN SCAN PERFORMED (recode: number of days after date of eligibility or ineligibility),phaseiii_fm05.csv,FM05,continuous
ABULT_DT_DAYS,F05 IV_1DDT  DATE OF ABDOMINAL ULTRASOUND PERFORMED (recode: number of days after date of eligibility or ineligibility),phaseiii_fm05.csv,FM05,continuous
NEFCH_DT_DAYS,F05 IV_1EDT  DATE OF NEUROLOGICAL EVALUATION PERFORMED (recode: number of days after date of eligibility or ineligibility),phaseiii_fm05.csv,FM05,continuous
BAYL_DT_DAYS,F05 IV_1FDT  DATE OF BAYLEY'S TEST PERFORMED (recode: number of days after date of eligibility or ineligibility),phaseiii_fm05.csv,FM05,continuous
VINLD_DT_DAYS,F05 IV_1GDT  DATE OF VINELAND TEST PERFORMED (recode: number of days after date of eligibility or ineligibility),phaseiii_fm05.csv,FM05,continuous
TRNDP_DT_DAYS,F05 IV_1HDT  DATE OF TRANSCRANIAL DOPPLER PERFORMED (recode: number of days after date of eligibility or ineligibility),phaseiii_fm05.csv,FM05,continuous
ID,Unique patient identifier (randomized),phaseiii_fm06.csv,FM06,continuous
FORM,F06 FORM     STUDY FORM NUMBER,phaseiii_fm06.csv,FM06,continuous
REV,F06 REV      NUMBER OF THE FORM REVISONS,phaseiii_fm06.csv,FM06,continuous
VISIT,F06 I_4VIS   SUBJECT CLINICAL VISIT NUMBER FOR PHYSICAL EXAMINATION,phaseiii_fm06.csv,FM06,categorical
SEQNO,F06 I_4SEQ   SUBJECT VISIT SEQUENCE NUMBER,phaseiii_fm06.csv,FM06,continuous
SCDIAG,F06 II_1     SUBJECT SICKLE CELL DIAGNOSIS (HB-SS OR HB S-BETA-0-THAL),phaseiii_fm06.csv,FM06,continuous
GEST_AGE,F06 II_2     GESTATIONAL AGE AT BIRTH,phaseiii_fm06.csv,FM06,continuous
GESTAGNA,F06 II_2NA   GESTATIONAL AGE AT BIRTH NA,phaseiii_fm06.csv,FM06,continuous
HOSPBL,F06 II_3A    NUMBER OF EPISODES OF HOSPITALIZATION(S),phaseiii_fm06.csv,FM06,continuous
HOSP_NA,F06 II_3ANA  HOSPITALIZATION(S) NA,phaseiii_fm06.csv,FM06,continuous
FEVERBL,F06 II_3A1   NUMBER OF EPISODES THE CHILD HAS HAD SINCE BIRTH: FEVER,phaseiii_fm06.csv,FM06,continuous
FEVER_NA,F06 II_3A1NA FEVER NA,phaseiii_fm06.csv,FM06,continuous
DACTBL,F06 II_3B    NUMBER OF EPISODES THE CHILD HAS HAD SINCE BIRTH: DACTYLITIS,phaseiii_fm06.csv,FM06,continuous
DACTBLNA,F06 II_3BNA  DACTYLITIS NA,phaseiii_fm06.csv,FM06,continuous
AGEDACT,F06 II_3B1   SUBJECT AGE OF FIRST DACTYLITIS,phaseiii_fm06.csv,FM06,continuous
AGEDACNA,F06 II_3B1NA AGE OF FIRST DACTYLITIS NA,phaseiii_fm06.csv,FM06,continuous
PAINBL,F06 II_3C    NUMBER OF EPISODES THE CHILD HAS HAD SINCE BIRTH: PAIN,phaseiii_fm06.csv,FM06,continuous
PAINBLNA,F06 II_3CNA  PAIN NA,phaseiii_fm06.csv,FM06,continuous
ASCBL,F06 II_3D    NUMBER OF EPISODES THE CHILD HAS HAD SINCE BIRTH: ACUTE CHEST SYNDROME,phaseiii_fm06.csv,FM06,continuous
ASCBL_NA,F06 II_3DNA  ACUTE CHEST SYNDROME NA,phaseiii_fm06.csv,FM06,continuous
PRIAPBL,F06 II_3E    NUMBER OF EPISODES THE CHILD HAS HAD SINCE BIRTH: PRIAPISM,phaseiii_fm06.csv,FM06,continuous
PRIAPNA,F06 II_3ENA  PRIAPISM NA,phaseiii_fm06.csv,FM06,continuous
SPLSEQBL,F06 II_3F    NUMBER OF EPISODES THE CHILD HAS HAD SINCE BIRTH: SPLENIC SEQUESTRATION,phaseiii_fm06.csv,FM06,continuous
SPLSEQNA,F06 II_3FNA  SPLENIC SEQUESTRATION NA,phaseiii_fm06.csv,FM06,continuous
TRNSFBL,F06 II_3G    NUMBER OF EPISODES THE CHILD HAS HAD SINCE BIRTH: TRANSFUSION,phaseiii_fm06.csv,FM06,continuous
TRNS_NA,F06 II_3GNA  TRANSFUSION NA,phaseiii_fm06.csv,FM06,continuous
SEPSISBL,F06 II_3H    NUMBER OF EPISODES THE CHILD HAS HAD SINCE BIRTH: BACTEREMIA/SEPSIS OTHER THAN MENINGITIS,phaseiii_fm06.csv,FM06,continuous
SEPSISNA,F06 II_3HNA  BACTEREMIA/SEPSIS OTHER THAN MENINGITIS NA,phaseiii_fm06.csv,FM06,continuous
MENINBL,F06 II_3I    NUMBER OF EPISODES THE CHILD HAS HAD SINCE BIRTH: MENINGITIS,phaseiii_fm06.csv,FM06,continuous
MENIN_NA,F06 II_3INA  MENINGITIS NA,phaseiii_fm06.csv,FM06,continuous
APLCRBL,F06 II_3J    NUMBER OF EPISODES THE CHILD HAS HAD SINCE BIRTH: APLASTIC CRISIS,phaseiii_fm06.csv,FM06,continuous
APLCR_NA,F06 II_3JNA  APLASTIC CRISIS NA,phaseiii_fm06.csv,FM06,continuous
TIABL,F06 II_3K    NUMBER OF EPISODES THE CHILD HAS HAD SINCE BIRTH: TRANSIENT ISCHEMIC ATTACK,phaseiii_fm06.csv,FM06,continuous
TIABL_NA,F06 II_3KNA  TRANSIENT ISCHEMIC ATTACK NA,phaseiii_fm06.csv,FM06,continuous
SEIZNFBL,F06 II_3L    NUMBER OF EPISODES THE CHILD HAS HAD SINCE BIRTH: SEIZURES (NON-FEBRILE),phaseiii_fm06.csv,FM06,continuous
SEIZNFNA,F06 II_3LNA  SEIZURES (NON-FEBRILE) NA,phaseiii_fm06.csv,FM06,continuous
SEIZFBBL,F06 II_3M    NUMBER OF EPISODES THE CHILD HAS HAD SINCE BIRTH: SEIZURES (FEBRILE),phaseiii_fm06.csv,FM06,continuous
SEIZFBNA,F06 II_3MNA  SEIZURES (FEBRILE) NA,phaseiii_fm06.csv,FM06,continuous
OSTEOMBL,F06 II_3N    NUMBER OF EPISODES THE CHILD HAS HAD SINCE BIRTH: OSTEOMYELITIS,phaseiii_fm06.csv,FM06,continuous
OSTEOMNA,F06 II_3NNA  OSTEOMYELITIS NA,phaseiii_fm06.csv,FM06,continuous
SPLNMDCL,F06 III_1A   SPLEEN: MIDCLAVICULAR LINE,phaseiii_fm06.csv,FM06,continuous
SPLNINTC,F06 III_1B   SPLEEN: ANTERIOR AXILLARY LINE,phaseiii_fm06.csv,FM06,continuous
LIVRCMBL,F06 III_2    LIVER: PALPATED BELOW THE RIGHT COSTAL MARGIN,phaseiii_fm06.csv,FM06,continuous
HEIGHT1,F06 III_3A   CHILD'S REUMBENT LENGTH MEASUREMENT #1,phaseiii_fm06.csv,FM06,continuous
HEIGHT2,F06 III_3B   CHILD'S REUMBENT LENGTH MEASUREMENT #2,phaseiii_fm06.csv,FM06,continuous
HEIGHT3,F06 III_3C   CHILD'S REUMBENT LENGTH MEASUREMENT #3,phaseiii_fm06.csv,FM06,continuous
HEIGHT,F06          CHILD'S AVERAGE RECUMBENT LENGTH,phaseiii_fm06.csv,FM06,continuous
HAIRHGHT,F06 III_3D   RATE HAIR STYLE INTERFERENCE ON CHILD'S LENGTH,phaseiii_fm06.csv,FM06,continuous
WEIGHT1,F06 III_4A   CHILD'S WEIGHT MEASUREMENT #1,phaseiii_fm06.csv,FM06,continuous
WEIGHT2,F06 III_4B   CHILD'S WEIGHT MEASUREMENT #2,phaseiii_fm06.csv,FM06,continuous
WEIGHT3,F06 III_4C   CHILD'S WEIGHT MEASUREMENT #3,phaseiii_fm06.csv,FM06,continuous
WEIGHT,F06          CHILD'S AVERAGE WEIGHT,phaseiii_fm06.csv,FM06,continuous
HEADC1,F06 III_5A   CHILD'S HEAD CIRCUMFERENCE MEASUREMENT #1,phaseiii_fm06.csv,FM06,continuous
HEADC2,F06 III_5B   CHILD'S HEAD CIRCUMFERENCE MEASUREMENT #2,phaseiii_fm06.csv,FM06,continuous
HEADC3,F06 III_5C   CHILD'S HEAD CIRCUMFERENCE MEASUREMENT #3,phaseiii_fm06.csv,FM06,continuous
HEADC,F06          CHILD'S AVERAGE HEAD CIRCUMFERENCE,phaseiii_fm06.csv,FM06,continuous
HAIR,F06 III_5D   RATE HAIR STYLE INTERFERENCE ON CHILD'S HEAD CIRCUMFERENCE,phaseiii_fm06.csv,FM06,continuous
VIS_DT_DAYS,F06 I_5      FORM COMPLETED DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm06.csv,FM06,continuous
MSRMT_DT_DAYS,F06 III_6    ANTHROPOMETRY MEASUREMENT DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm06.csv,FM06,continuous
ID,Unique patient identifier (randomized),phaseiii_fm07.csv,FM07,continuous
FORM,F07 FORM     STUDY FORM NUMBER,phaseiii_fm07.csv,FM07,continuous
REV,F07 REV      NUMBER OF THE FORM REVISONS,phaseiii_fm07.csv,FM07,continuous
VISIT,F07 I_4VIS   SUBJECT CLINICAL VISIT NUMBER,phaseiii_fm07.csv,FM07,categorical
SEQNO,F07 I_4SEQ   SUBJECT VISIT SEQUENCE NUMBER,phaseiii_fm07.csv,FM07,continuous
ASIAN,F07 II_1B    ASIAN,phaseiii_fm07.csv,FM07,continuous
NHWNOPIS,F07 II_1C    NATIVE HAWAIIAN/OTHER PACIFIC ISLANDER,phaseiii_fm07.csv,FM07,continuous
ETHUNKN,F07 II_1F    RACIAL STATUS UNKNOWN OR NOT REPORTED,phaseiii_fm07.csv,FM07,continuous
CARIBBN,F07 II_3     CARIBBEAN,phaseiii_fm07.csv,FM07,continuous
GENDER,F07 II_4     SUBJECT'S GENDER,phaseiii_fm07.csv,FM07,continuous
ROOMS,F07 II_5     HOW MANY ROOMS ARE IN THE PATIENT'S RESIDENCE?,phaseiii_fm07.csv,FM07,continuous
CHLDN,F07 II_6A    NUMBER OF PEOPLE UNDER 18 LIVE IN THE PATIENT'S HOUSEHOULD NOT COUNTING THE PATIENT,phaseiii_fm07.csv,FM07,continuous
ADULT,F07 II_6B    NUMBER OF PEOPLE 18 AND OVER LIVE IN THE PATIENT'S HOUSEHOULD,phaseiii_fm07.csv,FM07,continuous
PCFTWORK,F07 II_9A    EMPLOYMENT STATUS OF THE PATIENT'S PRIMARY CARETAKER: FULL-TIME WORK (35 HOURS WEEK OR MORE),phaseiii_fm07.csv,FM07,continuous
PCPTWORK,F07 II_9B    EMPLOYMENT STATUS OF THE PATIENT'S PRIMARY CARETAKER: PART-TIME WORK (LESS THAN 35 HOURS/WEEK),phaseiii_fm07.csv,FM07,continuous
PCUNEMPL,"F07 II_9C    EMPLOYMENT STATUS OF THE PATIENT'S PRIMARY CARETAKER: LAID OFF, UNEMPLOYED OR CURRENTLY LOOKING FOR WORK",phaseiii_fm07.csv,FM07,continuous
PCKHOUSE,F07 II_9F    EMPLOYMENT STATUS OF THE PATIENT'S PRIMARY CARETAKER: KEEPING HOUSE,phaseiii_fm07.csv,FM07,continuous
PCAS35HM,F07 II_9G    EMPLOYMENT STATUS OF THE PATIENT'S PRIMARY CARETAKER: ATTENDING SCHOOL 35 HOURS A WEEK OR MORE,phaseiii_fm07.csv,FM07,continuous
PCAS35HL,F07 II_9H    EMPLOYMENT STATUS OF THE PATIENT'S PRIMARY CARETAKER: ATTENDING SCHOOL LESS THAN 35 HOURS A WEEK,phaseiii_fm07.csv,FM07,continuous
PCVRWORK,F07 II_9I    EMPLOYMENT STATUS OF THE PATIENT'S PRIMARY CARETAKER: DOING VOLUNTEER WORK,phaseiii_fm07.csv,FM07,continuous
PCEMP5YR,F07 II_9K    EMPLOYMENT STATUS OF THE PATIENT'S PRIMARY CARETAKER: EMPLOYED IN THE LAST 5 YEARS,phaseiii_fm07.csv,FM07,continuous
OCFTWORK,F07 II_12A   EMPLOYMENT STATUS OF THE PATIENT'S FATHER OR OTHER CARETAKER: FULL-TIME WORK (35 HOURS WEEK OR MORE),phaseiii_fm07.csv,FM07,continuous
OCPTWORK,F07 II_12B   EMPLOYMENT STATUS OF THE PATIENT'S FATHER OR OTHER CARETAKER: PART-TIME EMPLOYMENT (LESS THAN 35 HOURS/WEEK),phaseiii_fm07.csv,FM07,continuous
OCUNEMPL,"F07 II_12C   EMPLOYMENT STATUS OF THE PATIENT'S FATHER OR OTHER CARETAKER: LAID OFF, UNEMPLOYED OR CURRENTLY LOOKING FOR WORK",phaseiii_fm07.csv,FM07,continuous
OCKHOUSE,F07 II_12F   EMPLOYMENT STATUS OF THE PATIENT'S FATHER OR OTHER CARETAKER: KEEPING HOUSE,phaseiii_fm07.csv,FM07,continuous
OCAS35HM,F07 II_12G   EMPLOYMENT STATUS OF THE PATIENT'S FATHER OR OTHER CARETAKER: ATTENDING SCHOOL 35 HOURS A WEEK OR MORE,phaseiii_fm07.csv,FM07,continuous
OCAS35HL,F07 II_12H   EMPLOYMENT STATUS OF THE PATIENT'S FATHER OR OTHER CARETAKER: ATTENDING SCHOOL LESS THAN 35 HOURS A WEEK,phaseiii_fm07.csv,FM07,continuous
OCVRWORK,F07 II_12I   EMPLOYMENT STATUS OF THE PATIENT'S FATHER OR OTHER CARETAKER: DOING VOLUNTEER WORK,phaseiii_fm07.csv,FM07,continuous
OCEMP5YR,F07 II_12K   EMPLOYMENT STATUS OF THE PATIENT'S FATHER OR OTHER CARETAKER: EMPLOYED IN LAST 5 YEARS,phaseiii_fm07.csv,FM07,continuous
PRIVTINS,F07 II_14A   WHAT TYPE OF MEDICAL INSURANCE: PRIVATE INSURANCE,phaseiii_fm07.csv,FM07,continuous
MEDICARE,F07 II_14B   WHAT TYPE OF MEDICAL INSURANCE: MEDICARE,phaseiii_fm07.csv,FM07,continuous
MEDICAID,F07 II_14C   WHAT TYPE OF MEDICAL INSURANCE:  MEDICAID,phaseiii_fm07.csv,FM07,continuous
STATEPRG,F07 II_14D   WHAT TYPE OF MEDICAL INSURANCE: STATE PROGRAM,phaseiii_fm07.csv,FM07,continuous
NOINSRNC,F07 II_14E   WHAT TYPE OF MEDICAL INSURANCE:  NO INSURANCE,phaseiii_fm07.csv,FM07,continuous
AMNGCARE,F07 II_14F   WHAT TYPE OF MEDICAL INSURANCE:  ANY MANAGED CARE,phaseiii_fm07.csv,FM07,continuous
VIS_DT_DAYS,F07 I_5      FORM COMPLETED DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm07.csv,FM07,continuous
RACEG,"Race (1 = Black, non-hispanic, 2 = Non-black/Hispanic/Multiple races)",phaseiii_fm07.csv,FM07,continuous
PRCARTKRG,"F07 II_7     WHO IS THE PATIENT'S PRIMARY CARETAKER? (regrouped: 1 = Mother, 2 = Other)",phaseiii_fm07.csv,FM07,continuous
PCSCHOOLG,"F07 II_8 HIGHEST LEVEL OF SCHOOL PRIMARY CARETAKER COMPLETED (regrouped: 4=5th-11th Grade;5=H.S. Diploma or Equiv;6=Some College-No Degree;7=Assoc. Degree,8=Bachelor's Degree;9=Master's, Prof School, or Doctorate Degree)",phaseiii_fm07.csv,FM07,continuous
PCWORKG,"F07 II_9 EMPLOYMENT STATUS OF THE PATIENT'S PRIMARY CARETAKER: DISABLED, RETIRED, or OTHER (1 = Yes, 2 = No, 3 = N/A)",phaseiii_fm07.csv,FM07,continuous
PCRTOCPNG,"F07 II_9L    WHAT IS/WAS THE PRIMARY CARETAKER'S MAIN OCCUPATION (regrouped: 1=Professional/technical,2=Manager/administrator,3=Sales worker,4=Clerical worker,5=Operative/Laborer/Farm Foreman/Other,9=Service worker)",phaseiii_fm07.csv,FM07,continuous
OTHCRTKRG,"F07 II_10    WHO IS THE PATIENT'S OTHER CARETAKER (regrouped: 1=Mother,3=Father,12=Grandparent(s),13=Other Relative,15=Unrelated person or No other caretaker,18=N/A)",phaseiii_fm07.csv,FM07,continuous
OCSCHOOLG,"F07 II_11 HIGHEST Lvl OF SCHOOL FATHER/OTH CARETAKER COMPLETED (regrouped: 4=None-11th Grade;5=H.S. Diploma or Equiv;6=Some College-No Degree;7=Assoc, Prof School, or Doctorate Degree;8=Bachelor's Deg;9=Master's Deg;12=N/A",phaseiii_fm07.csv,FM07,continuous
OCWORKG,"F07 II_12 EMPLOYMENT STATUS OF THE PATIENT'S FATHER OR OTHER CARETAKER: DISABLED, RETIRED, or OTHER (1 = Yes, 2 = No, 3 = N/A)",phaseiii_fm07.csv,FM07,continuous
OCRTOCPNG,"F07 II_12L   WHAT IS/WAS THE OTHER CARETAKER'S MAIN OCCUPATION (regrouped: 1=Professional/technical,2=Manager/administrator,3=Sales worker,4=Clerical worker,5=Operative/Laborer/Farm Foreman/Other,9=Service worker,11=N/A)",phaseiii_fm07.csv,FM07,continuous
FAMINCOMG,"F07 II_13  COUNTING ALL INCOME (regrouped: 1= < $10,000,2=$10,000-$19,999,3=$20,000-$29,999,4=$30,000-$39,999,5=$40,000-$49,999,6=$50,000-$59,999,7=$60,000-$79,999,9=$80,000-$124,999,12=$125,000-$150,000 or More,14=N/A)",phaseiii_fm07.csv,FM07,continuous
ID,Unique patient identifier (randomized),phaseiii_fm08.csv,FM08,continuous
FORM,F08 FORM     STUDY FORM NUMBER,phaseiii_fm08.csv,FM08,continuous
REV,F08 REV      NUMBER OF THE FORM REVISONS,phaseiii_fm08.csv,FM08,continuous
VISIT,F08 I_4VIS   SUBJECT CLINICAL VISIT NUMBER,phaseiii_fm08.csv,FM08,categorical
SEQNO,F08 I_4SEQ   SUBJECT VISIT SEQUENCE NUMBER,phaseiii_fm08.csv,FM08,continuous
GESTAGW,F08 II_1     GESTATIONAL AGE AT BIRTH WEEK,phaseiii_fm08.csv,FM08,continuous
NEWB_HT,F08 II_2A    NEONATAL ANTHROPOMETRY LENGTH,phaseiii_fm08.csv,FM08,continuous
NWBHT_ND,F08 II_2ANA  NEONATAL ANTHROPOMETRY LENGTH (NOT APPLICABLE),phaseiii_fm08.csv,FM08,continuous
NEWB_WT,F08 II_2B    NEONATAL ANTHROPOMETRY WEIGHT,phaseiii_fm08.csv,FM08,continuous
NWBWT_ND,F08 II_2BNA  NEONATAL ANTHROPOMETRY WEIGHT (NOT APPLICABLE),phaseiii_fm08.csv,FM08,continuous
NEWB_HC,F08 II_2C    NEONATAL ANTHROPOMETRY HEAD CIRCUMFERENCE,phaseiii_fm08.csv,FM08,continuous
NWBHC_ND,F08 II_2CNA  NEONATAL ANTHROPOMETRY HEAD CIRCUMFERENCE (NOT APPLICABLE),phaseiii_fm08.csv,FM08,continuous
A3MO_NA,F08 II_3ANA  2-4 MONTHS OF AGE DATE OF MEASUREMENT (NOT APPLICABLE),phaseiii_fm08.csv,FM08,continuous
A3MO_HT,F08 II_3B    2-4 MONTHS OF AGE LENGTH,phaseiii_fm08.csv,FM08,continuous
A3MOHTND,F08 II_3BNA  2-4 MONTHS OF AGE LENGTH (NOT APPLICABLE),phaseiii_fm08.csv,FM08,continuous
A3MO_WT,F08 II_3C    2-4 MONTHS OF AGE WEIGHT,phaseiii_fm08.csv,FM08,continuous
A3MOWTND,F08 II_3CNA  2-4 MONTHS OF AGE WEIGHT (NOT APPLICABLE),phaseiii_fm08.csv,FM08,continuous
A3MO_HC,F08 II_3D    2-4 MONTHS OF AGE  HEAD CIRCUMFERENCE,phaseiii_fm08.csv,FM08,continuous
A3MOHCND,F08 II_3DNA  2-4 MONTHS OF AGE  HEAD CIRCUMFERENCE (NOT APPLICABLE),phaseiii_fm08.csv,FM08,continuous
A6MO_NA,F08 II_4ANA  5-7 MONTHS OF AGE DATE OF MEASUREMENT (NOT APPLICABLE),phaseiii_fm08.csv,FM08,continuous
A6MO_HT,F08 II_4B    5-7 MONTHS OF AGE LENGTH,phaseiii_fm08.csv,FM08,continuous
A6MOHTND,F08 II_4BNA  5-7 MONTHS OF AGE LENGTH (NOT APPLICABLE),phaseiii_fm08.csv,FM08,continuous
A6MO_WT,F08 II_4C    5-7 MONTHS OF AGE WEIGHT,phaseiii_fm08.csv,FM08,continuous
A6MOWTND,F08 II_4CNA  5-7 MONTHS OF AGE WEIGHT (NOT APPLICABLE),phaseiii_fm08.csv,FM08,continuous
A6MO_HC,F08 II_4D    5-7 MONTHS OF AGE HEAD CIRCUMFERENCE,phaseiii_fm08.csv,FM08,continuous
A6MOHCND,F08 II_4DNA  5-7 MONTHS OF AGE HEAD CIRCUMFERENCE (NOT APPLICABLE),phaseiii_fm08.csv,FM08,continuous
A9MO_NA,F08 II_5ANA  8-10 MONTHS OF AGE DATE OF MEASUREMENT (NOT APPLICABLE),phaseiii_fm08.csv,FM08,continuous
A9MO_HT,F08 II_5B    8-10 MONTHS OF AGE LENGTH,phaseiii_fm08.csv,FM08,continuous
A9MOHTND,F08 II_5BNA  8-10 MONTHS OF AGE LENGTH (NOT APPLICABLE),phaseiii_fm08.csv,FM08,continuous
A9MO_WT,F08 II_5C    8-10 MONTHS OF AGE WEIGHT,phaseiii_fm08.csv,FM08,continuous
A9MOWTND,F08 II_5CNA  8-10 MONTHS OF AGE WEIGHT (NOT APPLICABLE),phaseiii_fm08.csv,FM08,continuous
A9MO_HC,F08 II_5D    8-10 MONTHS OF AGE HEAD CIRCUMFERENCE,phaseiii_fm08.csv,FM08,continuous
A9MOHCND,F08 II_5DNA  8-10 MONTHS OF AGE HEAD CIRCUMFERENCE (NOT APPLICABLE),phaseiii_fm08.csv,FM08,continuous
A12MO_NA,F08 II_6ANA  11-13 MONTHS OF AGE DATE OF MEASUREMENT (NOT APPLICABLE),phaseiii_fm08.csv,FM08,continuous
A12MO_HT,F08 II_6B    11-13 MONTHS OF AGE LENGTH,phaseiii_fm08.csv,FM08,continuous
A12MHTND,F08 II_6BNA  11-13 MONTHS OF AGE LENGTH (NOT APPLICABLE),phaseiii_fm08.csv,FM08,continuous
A12MO_WT,F08 II_6C    11-13 MONTHS OF AGE WEIGHT,phaseiii_fm08.csv,FM08,continuous
A12MWTND,F08 II_6CNA  11-13 MONTHS OF AGE WEIGHT (NOT APPLICABLE),phaseiii_fm08.csv,FM08,continuous
A12MO_HC,F08 II_6D    11-13 MONTHS OF AGE HEAD CIRCUMFERENCE,phaseiii_fm08.csv,FM08,continuous
A12MHCND,F08 II_6DNA  11-13 MONTHS OF AGE HEAD CIRCUMFERENCE (NOT APPLICABLE),phaseiii_fm08.csv,FM08,continuous
VIS_DT_DAYS,F08 I_5      FORM COMPLETED DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm08.csv,FM08,continuous
A3MO_DT_DAYS,F08 II_3ADT  2-4 MONTHS OF AGE DATE OF MEASUREMENT (recode: number of days after date of eligibility or ineligibility),phaseiii_fm08.csv,FM08,continuous
A6MO_DT_DAYS,F08 II_4ADT  5-7 MONTHS OF AGE DATE OF MEASUREMENT (recode: number of days after date of eligibility or ineligibility),phaseiii_fm08.csv,FM08,continuous
A9MO_DT_DAYS,F08 II_5ADT  8-10 MONTHS OF AGE DATE OF MEASUREMENT (recode: number of days after date of eligibility or ineligibility),phaseiii_fm08.csv,FM08,continuous
A12MO_DT_DAYS,F08 II_6ADT  11-13 MONTHS OF AGE DATE OF MEASUREMENT (recode: number of days after date of eligibility or ineligibility),phaseiii_fm08.csv,FM08,continuous
ID,Unique patient identifier (randomized),phaseiii_fm21.csv,FM21,continuous
FORM,F21 FORM     STUDY FORM NUMBER,phaseiii_fm21.csv,FM21,continuous
REV,F21 REV      NUMBER OF THE FORM REVISONS,phaseiii_fm21.csv,FM21,continuous
VISIT,F21 I_4VIS   SUBJECT CLINICAL VISIT NUMBER,phaseiii_fm21.csv,FM21,continuous
SEQNO,F21 I_4SEQ   SUBJECT VISIT SEQUENCE NUMBER,phaseiii_fm21.csv,FM21,continuous
TRNRND21,F21 II_1     HAS PATIENT BEEN TRANSFUSED SINCE RANDOMIZATION?,phaseiii_fm21.csv,FM21,continuous
HBF21,F21 II_2A    SPECIMEN LABEL: HEMATOLOGY/HBF (REQUIRED) (0.5 ML EDTA LAVENDER-TOP),phaseiii_fm21.csv,FM21,continuous
BIOCHEM,F21 II_2B    SPECIMEN LABEL: BIOCHEMISTRY (REQUIRED) (1.0 ML RED-TOP),phaseiii_fm21.csv,FM21,continuous
TXBOTNO,F21 III_1A   RECORD BOTTLE # OF STUDY TREATMENT DISPENSED TO PATIENT TODAY,phaseiii_fm21.csv,FM21,continuous
TXDOSEMG,F21 III_1B1  DAILY DOSE MG,phaseiii_fm21.csv,FM21,continuous
TXDOSEML,F21 III_1B2  DAILY DOSE ML,phaseiii_fm21.csv,FM21,continuous
HEIGHT1,F21 IV_1A    CHILD'S RECUMBENT LENGTH MEASUREMENT #1,phaseiii_fm21.csv,FM21,continuous
HEIGHT2,F21 IV_1B    CHILD'S RECUMBENT LENGTH MEASUREMENT #2,phaseiii_fm21.csv,FM21,continuous
HEIGHT3,F21 IV_1C    CHILD'S RECUMBENT LENGTH MEASUREMENT #3,phaseiii_fm21.csv,FM21,continuous
HEIGHT,F21          CHILD'S AVERAGE RECUMBENT LENGTH,phaseiii_fm21.csv,FM21,continuous
HAIRHGHT,F21 IV_1D    RATE HAIR STYLE INTERFERENCE ON CHILD'S LENGTH,phaseiii_fm21.csv,FM21,continuous
WEIGHT1,F21 IV_2A    CHILD'S WEIGHT MEASUREMENT #1,phaseiii_fm21.csv,FM21,continuous
WEIGHT2,F21 IV_2B    CHILD'S WEIGHT MEASUREMENT #2,phaseiii_fm21.csv,FM21,continuous
WEIGHT3,F21 IV_2C    CHILD'S WEIGHT MEASUREMENT #3,phaseiii_fm21.csv,FM21,continuous
WEIGHT,F21          CHILD'S AVERAGE WEIGHT,phaseiii_fm21.csv,FM21,continuous
HEADC1,F21 IV_3A    CHILD'S HEAD CIRCUMFERENCE MEASUREMENT #1,phaseiii_fm21.csv,FM21,continuous
HEADC2,F21 IV_3B    CHILD'S HEAD CIRCUMFERENCE MEASUREMENT #2,phaseiii_fm21.csv,FM21,continuous
HEADC3,F21 IV_3C    CHILD'S HEAD CIRCUMFERENCE MEASUREMENT #3,phaseiii_fm21.csv,FM21,continuous
HEADC,F21          CHILD'S AVERAGE HEAD CIRCUMFERENCE,phaseiii_fm21.csv,FM21,continuous
HAIR,F21 IV_3D    RATE HAIR STYLE INTERFERENCE ON CHILD'S HEAD CIRCUMFERENCE,phaseiii_fm21.csv,FM21,continuous
VIS_DT_DAYS,F21 I_5      SUBJECT CLINICAL VISIT START DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm21.csv,FM21,continuous
ID,Unique patient identifier (randomized),phaseiii_fm22.csv,FM22,continuous
FORM,F22 FORM     STUDY FORM NUMBER,phaseiii_fm22.csv,FM22,continuous
REV,F22 REV      NUMBER OF THE FORM REVISONS,phaseiii_fm22.csv,FM22,continuous
VISIT,F22 I_4VIS   SUBJECT CLINICAL VISIT NUMBER,phaseiii_fm22.csv,FM22,categorical
SEQNO,F22 I_4SEQ   SUBJECT VISIT SEQUENCE NUMBER,phaseiii_fm22.csv,FM22,continuous
PRDTPAHR,"F22 II_1AHR  PRE-DTPA TIME,  HOUR",phaseiii_fm22.csv,FM22,continuous
PRDTPAMN,"F22 II_1AMN  PRE-DTPA TIME,  MINUTES",phaseiii_fm22.csv,FM22,continuous
HULABEL,F22 II_1B    TUBE LABEL (2 ML IN EDTA),phaseiii_fm22.csv,FM22,continuous
STSAPRE,F22 II_1A    STANDARD SYRINGE ACTIVITY: PRE,phaseiii_fm22.csv,FM22,continuous
STSAPOST,F22 II_1B    STANDARD SYRINGE ACTIVITY: POST,phaseiii_fm22.csv,FM22,continuous
STSASTAC,F22 II_1C    STANDARD SYRINGE ACTIVITY: STANDARD ACTIVITY,phaseiii_fm22.csv,FM22,continuous
DSSAPRE,F22 II_2A    DOSE SYRINGE ACTIVITY: PRE,phaseiii_fm22.csv,FM22,continuous
DSSAPOST,F22 II_2B    DOSE SYRINGE ACTIVITY: POST,phaseiii_fm22.csv,FM22,continuous
DTPADOSE,F22 II_2C    DOSE SYRINGE ACTIVITY: DTPA DOSE ADMINISTERED,phaseiii_fm22.csv,FM22,continuous
DTPAHR,F22 II_2DHR  DOSE SYRINGE ACTIVITY: TIME DTPA ADMINISTERED HOUR,phaseiii_fm22.csv,FM22,continuous
DTPAMN,F22 II_2DMN  DOSE SYRINGE ACTIVITY: TIME DTPA ADMINISTERED MINUTES,phaseiii_fm22.csv,FM22,continuous
STDYHR,F22 II_3AHR  TIME STUDY TREATMENT ADMINISTERED HOUR,phaseiii_fm22.csv,FM22,continuous
STDYMN,F22 II_3AMN  TIME STUDY TREATMENT ADMINISTERED  MINUTES,phaseiii_fm22.csv,FM22,continuous
STDYCMPL,F22 II_3B     COMPLETE ADMINISTRATION OF STUDY TREATMENT,phaseiii_fm22.csv,FM22,continuous
STDY_SP,"F22 II_3B1   IF ADMINISTRATION OF STUDY TREATMENT NOT COMPLETED, SPECIFY",phaseiii_fm22.csv,FM22,continuous
ROOMFRST,F22 II_4A    ROOM (WATER) BACKGROUND FIRST COUNT:,phaseiii_fm22.csv,FM22,continuous
ROOMSEC,F22 II_4B    ROOM (WATER) BACKGROUND SECOND COUNT:,phaseiii_fm22.csv,FM22,continuous
ROOMSCND,F22 II_4BND  ROOM (WATER) BACKGROUND SECOND COUNT NOT DONE,phaseiii_fm22.csv,FM22,continuous
STNDFRST,F22 II_5A    STANDARD FIRST COUNT:,phaseiii_fm22.csv,FM22,continuous
STNDSEC,F22 II_5B    STANDARD SECOND  COUNT:,phaseiii_fm22.csv,FM22,continuous
STNDSCND,F22 II_5BND  STANDARD SECOND  COUNT  NOT DONE,phaseiii_fm22.csv,FM22,continuous
ONEHR,"F22 II_6AHR  ONE-HOUR TIME,  HOUR",phaseiii_fm22.csv,FM22,continuous
ONEMN,"F22 II_6AMN  ONE-HOUR TIME,  MINUTES",phaseiii_fm22.csv,FM22,continuous
ONEDTPA,F22 II_6B    ONE HOUR DTPA MEASUREMENT,phaseiii_fm22.csv,FM22,continuous
ONE_ND,F22 II_6BND  ONE HOUR DTPA MEASUREMENT NOT DONE,phaseiii_fm22.csv,FM22,continuous
ONEDTPA2,F22 II_6C    ONE HOUR SECOND DTPA MEASUREMENT,phaseiii_fm22.csv,FM22,continuous
ONE_ND2,F22 II_6CND  ONE HOUR SECOND DTPA MEASUREMENT NOT DONE,phaseiii_fm22.csv,FM22,continuous
ONEHULBL,F22 II_6D    ONE HOUR TUBE LABEL (3 ML IN EDTA):,phaseiii_fm22.csv,FM22,continuous
TWOHR,"F22 II_7AHR  TWO-HOUR TIME,  HOUR",phaseiii_fm22.csv,FM22,continuous
TWOMN,"F22 II_7AMN  TWO-HOUR TIME,  MINUTE",phaseiii_fm22.csv,FM22,continuous
TWODTPA,F22 II_7B    TWO HOUR DTPA MEASUREMENT,phaseiii_fm22.csv,FM22,continuous
TWO_ND,F22 II_7BND  TWO HOUR DTPA MEASUREMENT NOT DONE,phaseiii_fm22.csv,FM22,continuous
TWODTPA2,F22 II_7C    TWO HOUR SECOND DTPA MEASUREMENT,phaseiii_fm22.csv,FM22,continuous
TWO_ND2,F22 II_7CND  TWO HOUR SECOND DTPA MEASUREMENT NOT DONE,phaseiii_fm22.csv,FM22,continuous
TWOHULBL,F22 II_7D    TWO HOUR TUBE LABEL (3 ML IN EDTA):,phaseiii_fm22.csv,FM22,continuous
FORHR,"F22 II_8AHR  FOUR-HOUR TIME,   HOUR",phaseiii_fm22.csv,FM22,continuous
FORMN,"F22 II_8AMN  FOUR-HOUR TIME,  MINUTE",phaseiii_fm22.csv,FM22,continuous
FORDTPA,F22 II_8B    FOUR HOUR DTPA MEASUREMENT,phaseiii_fm22.csv,FM22,continuous
FOR_ND,F22 II_8BND  FOUR HOUR DTPA MEASUREMENT NOT DONE,phaseiii_fm22.csv,FM22,continuous
FORDTPA2,F22 II_8C    FOUR HOUR SECOND DTPA MEASUREMENT,phaseiii_fm22.csv,FM22,continuous
FOR_ND2,F22 II_8CND  FOUR HOUR SECOND DTPA MEASUREMENT NOT DONE,phaseiii_fm22.csv,FM22,continuous
FORHULBL,F22 II_8D    FOUR HOUR TUBE LABEL (3 ML IN EDTA):,phaseiii_fm22.csv,FM22,continuous
EITHR,"F22 II_10AHR EIGHT-HOUR TIME,  HOUR",phaseiii_fm22.csv,FM22,continuous
EITMN,"F22 II_10AMN EIGHT-HOUR TIME,  MINUTE",phaseiii_fm22.csv,FM22,continuous
EIT_ND,F22 II_10AND EIGHT-HOUR TIME (24-HR CLOCK) NOT DONE,phaseiii_fm22.csv,FM22,continuous
EITLBLND,F22 II_10BND EIGHT HOUR TUBE LABEL (2 ML IN EDTA) NOT DONE,phaseiii_fm22.csv,FM22,continuous
GFRDTP_A,F22 II_9A   GFR FROM DTPA ML/MIN,phaseiii_fm22.csv,FM22,continuous
GFRDTP_B,F22 II_9B   GFR FROM DTPA ML/MIN/M 2,phaseiii_fm22.csv,FM22,continuous
GFRDTP_C,F22 II_9C   GFR FROM DTPA ML/MIN/1.73M 2,phaseiii_fm22.csv,FM22,continuous
VIS_DT_DAYS,F22 I_5      SUBJECT CLINICAL VISIT START DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm22.csv,FM22,continuous
ID,Unique patient identifier (randomized),phaseiii_fm23.csv,FM23,continuous
FORM,F23 FORM     STUDY FORM NUMBER,phaseiii_fm23.csv,FM23,continuous
REV,F23 REV      NUMBER OF THE FORM REVISONS,phaseiii_fm23.csv,FM23,continuous
VISIT,F23 I_4VIS   SUBJECT CLINICAL VISIT NUMBER,phaseiii_fm23.csv,FM23,categorical
SEQNO,F23 I_4SEQ   SUBJECT VISIT SEQUENCE NUMBER,phaseiii_fm23.csv,FM23,continuous
TRHR,"F23 II_1A_HR TIME STUDY TREATMENT ADMINISTERED (24-HR CLOCK), HOUR",phaseiii_fm23.csv,FM23,continuous
TRMN,"F23 II_1A_MN TIME STUDY TREATMENT ADMINISTERED (24-HR CLOCK), MINUTE",phaseiii_fm23.csv,FM23,continuous
NEW_BOT,F23 II_1B    NEW BOTTLE OF STUDY TREATMENT RECONSTITUTED FOR THIS ADMINISTRATION?,phaseiii_fm23.csv,FM23,continuous
COMPLETE,F23 II_1C    COMPLETE ADMINISTRATION OF STUDY TREATMENT?,phaseiii_fm23.csv,FM23,continuous
THIRTYHR,F23 II_2A_HR 30-MINUTE TIME (24-HR CLOCK) BY HOUR,phaseiii_fm23.csv,FM23,continuous
THIRTYMN,F23 II_2A_MN 30-MINUTE TIME (24-HR CLOCK) BY MINUTE,phaseiii_fm23.csv,FM23,continuous
THIRTYLB,F23 II_2B    30-MINUTE TUBE LABEL (EDTA),phaseiii_fm23.csv,FM23,continuous
NINETYHR,F23 II_3A_HR 90-MINUTE TIME (24-HR CLOCK) HR,phaseiii_fm23.csv,FM23,continuous
NINETYMN,F23 II_3A_MN 90-MINUTE TIME (24-HR CLOCK) MN,phaseiii_fm23.csv,FM23,continuous
NINETYLB,F23 II_3B    90-MINUTE TUBE LABEL (EDTA),phaseiii_fm23.csv,FM23,continuous
VIS_DT_DAYS,F23 I_5      SUBJECT CLINICAL VISIT DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm23.csv,FM23,continuous
ID,Unique patient identifier (randomized),phaseiii_fm31.csv,FM31,continuous
FORM,F31 FORM     STUDY FORM NUMBER,phaseiii_fm31.csv,FM31,continuous
REV,F31 REV      NUMBER OF THE FORM REVISONS,phaseiii_fm31.csv,FM31,continuous
VISIT,F31 I_4VIS   SUBJECT CLINICAL VISIT NUMBER,phaseiii_fm31.csv,FM31,continuous
SEQNO,F31 I_4SEQ   SUBJECT VISIT SEQUENCE NUMBER,phaseiii_fm31.csv,FM31,continuous
SPLNMDCL,F31 II_1A    MIDCLAVICULAR LINE,phaseiii_fm31.csv,FM31,continuous
SPLNMCND,F31 II_1AND  MIDCLAVICULAR LINE MEASUREMENT NOT DONE,phaseiii_fm31.csv,FM31,continuous
SPLNINTC,F31 II_1B    ANTERIOR AXILLARY LINE,phaseiii_fm31.csv,FM31,continuous
SPLNICND,F31 II_1BND  ANTERIOR AXILLARY LINE MEASUREMENT NOT DONE,phaseiii_fm31.csv,FM31,continuous
TEMP,F31 II_2A    TEMPERATURE,phaseiii_fm31.csv,FM31,continuous
TEMPMEAS,F31 II_2AFC  TYPE OF TEMPERATURE DEGREES,phaseiii_fm31.csv,FM31,continuous
TEMPND,F31 II_2AND  TEMPERATURE MEASUREMENT NOT DONE,phaseiii_fm31.csv,FM31,continuous
PULSE,F31 II_2B    PULSE,phaseiii_fm31.csv,FM31,continuous
PULSEND,F31 II_2BND  PULSE MEASUREMENT NOT DONE,phaseiii_fm31.csv,FM31,continuous
RESP,F31 II_2C    RESPIRATION,phaseiii_fm31.csv,FM31,continuous
RESPND,F31 II_2CND  RESPIRATION MEASUREMENT NOT DONE,phaseiii_fm31.csv,FM31,continuous
HEIGHT1,F31 II_3A    CHILD'S RECUMBENT LENGTH MEASUREMENT #1,phaseiii_fm31.csv,FM31,continuous
HEIGHTND,F31 II_3AND  CHILD'S RECUMBENT LENGTH MEASUREMENT #1 NOT DONE,phaseiii_fm31.csv,FM31,continuous
HEIGHT2,F31 II_3B    CHILD'S RECUMBENT LENGTH MEASUREMENT #2,phaseiii_fm31.csv,FM31,continuous
HEIGHT3,F31 II_3C    CHILD'S RECUMBENT LENGTH MEASUREMENT #3,phaseiii_fm31.csv,FM31,categorical
HEIGHT,F31          CHILD'S AVERAGE RECUMBENT LENGTH,phaseiii_fm31.csv,FM31,continuous
HAIRHGHT,F31 II_3D    RATE HAIR STYLE INTERFERENCE ON CHILD'S LENGTH,phaseiii_fm31.csv,FM31,continuous
WEIGHT1,F31 II_4A    CHILD'S WEIGHT MEASUREMENT #1,phaseiii_fm31.csv,FM31,continuous
WEIGHTND,F31 II_4AND  CHILD'S WEIGHT MEASUREMENT #1 NOT DONE,phaseiii_fm31.csv,FM31,continuous
WEIGHT2,F31 II_4B    CHILD'S WEIGHT MEASUREMENT #2,phaseiii_fm31.csv,FM31,continuous
WEIGHT3,F31 II_4C    CHILD'S WEIGHT MEASUREMENT #3,phaseiii_fm31.csv,FM31,categorical
WEIGHT,F31          CHILD'S AVERAGE WEIGHT,phaseiii_fm31.csv,FM31,continuous
HEADC1,F31 II_5A    CHILD'S HEAD CIRCUMFERENCE MEASUREMENT #1,phaseiii_fm31.csv,FM31,continuous
HEADCND,F31 II_5AND  CHILD'S HEAD CIRCUMFERENCE MEASUREMENT #1 NOT DONE,phaseiii_fm31.csv,FM31,continuous
HEADC2,F31 II_5B    CHILD'S HEAD CIRCUMFERENCE MEASUREMENT #2,phaseiii_fm31.csv,FM31,continuous
HEADC3,F31 II_5C    CHILD'S HEAD CIRCUMFERENCE MEASUREMENT #3,phaseiii_fm31.csv,FM31,categorical
HEADC,F31          CHILD'S AVERAGE HEAD CIRCUMFERENCE,phaseiii_fm31.csv,FM31,continuous
HAIR,F31 II_5D    RATE HAIR STYLE INTERFERENCE ON CHILD'S HEAD CIRCUMFERENCE,phaseiii_fm31.csv,FM31,continuous
N_EVTS,F31 II_6     NUMBER OF REPORTABLE EVENTS AND/OR HOSPITALIZATIONS SINCE LAST COMPLETED STUDY VISIT,phaseiii_fm31.csv,FM31,continuous
FEVER31,F31 II_7A    FEVER MORE THAN 101.5 DEGREES F. (38.4 DEGREES C.),phaseiii_fm31.csv,FM31,continuous
VACCINE,F31 II_7B    ANY VACCINATIONS SINCE LAST VISIT,phaseiii_fm31.csv,FM31,continuous
PENCILN,F31 II_8A    DID THE CHILD HAVE PENICILLIN LAST NIGHT,phaseiii_fm31.csv,FM31,continuous
ANANTBTC,"F31 II_8A1   IF NO, DID THE CHILD TAKE ANOTHER ANTIBIOTIC",phaseiii_fm31.csv,FM31,continuous
ANANT_SP,F31 II_8A1A  SPECIFY ANTIBIOTICS USED,phaseiii_fm31.csv,FM31,continuous
PENDOSE,F31 II_8B    HOW MANY DOSES OF PENICILLIN OR SIMILAR ANTIBOTIC WERE MISSED IN THE LAST WEEK?,phaseiii_fm31.csv,FM31,continuous
PENNA,F31 II_8BNA  HOW MANY DOSES OF PENICILLIN OR SIMILAR ANTIBOTIC WERE MISSED IN THE LAST WEEK (NOT APPLICABLE),phaseiii_fm31.csv,FM31,continuous
WHCHVIS,"F31 II_9     FOR 3-MONTH, 9-MONTH, 15-MONTH OR 21-MONTH VISIT, HAS FORM 33 BEEN COMPLETED?",phaseiii_fm31.csv,FM31,continuous
RECORDRX,F31 III_1A   RECORD RX #,phaseiii_fm31.csv,FM31,continuous
RXNORET,F31 III_1ANR RECORD RX # NOT RETURNED,phaseiii_fm31.csv,FM31,continuous
VOLLFT,F31 III_1B   APPROXIMATELY HOW MUCH VOLUME IS LEFT?,phaseiii_fm31.csv,FM31,continuous
VOLNA,F31 III_1BNA VOLUME LEFT (NOT APPLICABLE),phaseiii_fm31.csv,FM31,continuous
IRRTRT,F31 III_1C   ANY IRREGULAR TREATMENT ADMINISTRATION SINCE LAST VISIT?,phaseiii_fm31.csv,FM31,continuous
BLOODCOL,F31 III_2    WERE BLOOD SPECIMENS COLLECTED FOR THIS VISIT?,phaseiii_fm31.csv,FM31,continuous
DIFBLDDW,F31 III_2A1  REASON BLOOD SPECIMENS NOT COLLECTED TODAY: DIFFICULTY WITH BLOOD DRAWING,phaseiii_fm31.csv,FM31,continuous
PATRFUSL,F31 III_2A2  REASON BLOOD SPECIMENS NOT COLLECTED TODAY: PATIENT/FAMILY REFUSAL,phaseiii_fm31.csv,FM31,continuous
OTHNOBLD,F31 III_2A3  REASON BLOOD SPECIMENS NOT COLLECTED TODAY: OTHER,phaseiii_fm31.csv,FM31,continuous
OTHBLDSP,F31 III_2A3ARSPECIFY THE OTHER REASONS WHY BLOOD SPECIMENS NOT COLLECTED,phaseiii_fm31.csv,FM31,continuous
HBF31,F31 III_2B1  SPECIMEN LABEL: HEMATOLOGY (0.5ML EDTA LAVENDER-TOP),phaseiii_fm31.csv,FM31,continuous
HBF31ND,F31 III_2B1NDSPECIMEN LABEL FOR HEMATOLOGY NOT DONE OR NOT APPLICABLE,phaseiii_fm31.csv,FM31,continuous
BIOCHEM,F31 III_2B2  SPECIMEN LABEL: BIOCHEMISTRY (1.0ML RED TOP),phaseiii_fm31.csv,FM31,continuous
BIOCHND,F31 III_2B2NDBIOCHEMISTRY (CHECK CHILD'S SCHEDULE) N/D N/A,phaseiii_fm31.csv,FM31,continuous
TXOK,F31 III_3A   IS THERE ANY REASON YOU WOULD NOT RECOMMEND STUDY TREATMENT TO THIS CHILD TODAY?,phaseiii_fm31.csv,FM31,continuous
TXBOTNO,"F31 III_3B1  IF TX OK, DISPENSE STUDY TREATMENT AND RECORD BOTTLE NUMBER",phaseiii_fm31.csv,FM31,continuous
TXDDOSMG,F31 III_3B2A DAILY DOSE MG,phaseiii_fm31.csv,FM31,continuous
TXDDOSML,F31 III_3B2B DAILY DOSE ML,phaseiii_fm31.csv,FM31,continuous
VOLDISP,F31 III_3B3  VOLUME DISPENSED,phaseiii_fm31.csv,FM31,continuous
TXNOTOK,F31 III_3C   CHECK HERE TO CONFIRM THAT STUDY TREATMENT WAS NOT DISPENSED,phaseiii_fm31.csv,FM31,continuous
GEN_CMNT,F31 IV_1C    GENERAL COMMENTS REGARDING TO THE FILLED OUT FORM,phaseiii_fm31.csv,FM31,continuous
VIS_DT_DAYS,F31 I_5      SUBJECT CLINICAL VISIT START DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm31.csv,FM31,continuous
ID,Unique patient identifier (randomized),phaseiii_fm32.csv,FM32,continuous
FORM,F32 FORM     STUDY FORM NUMBER,phaseiii_fm32.csv,FM32,continuous
REV,F32 REV      NUMBER OF THE FORM REVISONS,phaseiii_fm32.csv,FM32,continuous
VISIT,F32 I_4VIS   SUBJECT CLINICAL VISIT NUMBER,phaseiii_fm32.csv,FM32,categorical
SEQNO,F32 I_4SEQ   SUBJECT VISIT SEQUENCE NUMBER,phaseiii_fm32.csv,FM32,continuous
FORGOT,F32 II_1A    REASONS FOR MISSED VISIT: FORGOT APPOINTMENT,phaseiii_fm32.csv,FM32,continuous
SCHEDULE,F32 II_1B    REASONS FOR MISSED VISIT: SCHEDULING DIFFICULTIES,phaseiii_fm32.csv,FM32,continuous
TRANSPT,F32 II_1C    REASONS FOR MISSED VISIT: TRANSPORTATION DIFFICULTY,phaseiii_fm32.csv,FM32,continuous
ILLCHILD,F32 II_1D    REASONS FOR MISSED VISIT: CHILD WAS ILL WITH HOSPITALIZATION OR REPORTABLE EVENT,phaseiii_fm32.csv,FM32,continuous
NODOCTOR,F32 II_1E    CHILD WAS ILL - NO MEDICAL ATTENTION?,phaseiii_fm32.csv,FM32,continuous
NODOCSP,F32 II_1E1   CHILD WAS ILL - NO MEDICAL ATTENTION DETAILS,phaseiii_fm32.csv,FM32,categorical
ADVOCATE,F32 II_2     HAS PATIENT/FAMILY ADVOCATE BEEN IN TOUCH WITH THE FAMILY SINCE LAST VISIT?,phaseiii_fm32.csv,FM32,continuous
GEN_CMNT,F32 III_1C   GENERAL COMMENTS REGARDING TO THE FILLED OUT FORM,phaseiii_fm32.csv,FM32,continuous
VIS_DT_DAYS,F32 I_5      SUBJECT SCHEDULED VISIT DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm32.csv,FM32,continuous
ID,Unique patient identifier (randomized),phaseiii_fm33.csv,FM33,continuous
FORM,F33 FORM     STUDY FORM NUMBER,phaseiii_fm33.csv,FM33,continuous
REV,F33 REV      NUMBER OF THE FORM REVISONS,phaseiii_fm33.csv,FM33,continuous
VISIT,F33 I_4VIS   SUBJECT CLINICAL VISIT NUMBER,phaseiii_fm33.csv,FM33,categorical
SEQNO,F33 I_4SEQ   SUBJECT VISIT SEQUENCE NUMBER,phaseiii_fm33.csv,FM33,continuous
O2SAT,F33 II_1A    O2 SATURATION (PULSE OXYMETRY),phaseiii_fm33.csv,FM33,continuous
O2SATND,F33 II_1AND  O2 SATURATION (PULSE OXYMETRY) NOT DONE,phaseiii_fm33.csv,FM33,continuous
O2SATSM,F33 II_1B    SECOND MEASUREMENT FOR O2 SATURATION,phaseiii_fm33.csv,FM33,continuous
O2SATSND,F33 II_1BND  SECOND MEASUREMENT NOT DONE,phaseiii_fm33.csv,FM33,continuous
F80II2,"F33 II_2     IF NOT MEASURED, HAS FORM 80 BEEN SUBMITTED?",phaseiii_fm33.csv,FM33,continuous
GEN_CMNT,F33 III_1C   GENERAL COMMENTS REGARDING TO THE FILLED OUT FORM,phaseiii_fm33.csv,FM33,continuous
VIS_DT_DAYS,F33 I_5      SUBJECT CLINICAL VISIT START DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm33.csv,FM33,continuous
ID,Unique patient identifier (randomized),phaseiii_fm34.csv,FM34,continuous
FORM,F34 FORM     STUDY FORM NUMBER,phaseiii_fm34.csv,FM34,continuous
REV,F34 REV      NUMBER OF THE FORM REVISONS,phaseiii_fm34.csv,FM34,continuous
VISIT,F34 I_4VIS   SUBJECT CLINICAL VISIT NUMBER,phaseiii_fm34.csv,FM34,categorical
SEQNO,F34 I_4SEQ   SUBJECT VISIT SEQUENCE NUMBER,phaseiii_fm34.csv,FM34,continuous
SPC_PITC,F34 II_1     SPECIMEN LABEL: PITTED CELL COUNT COLLECTED AND PREPARED WITHIN 1 HOUR OF COLLECTION?,phaseiii_fm34.csv,FM34,continuous
SPCPITND,F34 II_1ND   PITTED CELL COUNT SPECIMEN NOT COLLECTED,phaseiii_fm34.csv,FM34,continuous
LIVRCM,F34 III_1CM  PALPABLE LIVER,phaseiii_fm34.csv,FM34,continuous
O2SAT,F34 III_2A   O2 SATURATION (PULSE OXYMETRY),phaseiii_fm34.csv,FM34,continuous
O2SATND,F34 III_2AND O2 SATURATION (PULSE OXYMETRY) NOT DONE,phaseiii_fm34.csv,FM34,continuous
O2SATSM,F34 III_2B   SECOND MEASUREMENT OF O2 SATURATION,phaseiii_fm34.csv,FM34,continuous
O2SATSND,F34 III_2BND SECOND MEASUREMENT NOT DONE,phaseiii_fm34.csv,FM34,continuous
SPPNCLND,F34 III_3ND  PENICILLIN COMPLIANCE SPECIMEN NOT COLLECTED,phaseiii_fm34.csv,FM34,continuous
BAYLEYS,F34 III_4    WAS FORM 40 - BAYLEY'S ADMINISTERED?,phaseiii_fm34.csv,FM34,continuous
VINELAND,F34 III_5    WAS FORM 41 - VINELAND ADMINISTERED TO PARENTS?,phaseiii_fm34.csv,FM34,continuous
NRLGQUES,F34 III_6    WAS FORM 43 - NEUROLOGICAL QUESTIONNAIRE ADMINISTERED?,phaseiii_fm34.csv,FM34,continuous
F80III7,F34 III_7    WAS FORM 80 SUBMITTED?,phaseiii_fm34.csv,FM34,continuous
VIS_DT_DAYS,F34 I_5      SUBJECT VISIT START DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm34.csv,FM34,continuous
ID,Unique patient identifier (randomized),phaseiii_fm35.csv,FM35,continuous
FORM,F35 FORM     STUDY FORM NUMBER,phaseiii_fm35.csv,FM35,continuous
REV,F35 REV      NUMBER OF THE FORM REVISONS,phaseiii_fm35.csv,FM35,continuous
VISIT,F35 I_4VIS   SUBJECT CLINICAL VISIT NUMBER,phaseiii_fm35.csv,FM35,categorical
SEQNO,F35 I_4SEQ   SUBJECT VISIT SEQUENCE NUMBER,phaseiii_fm35.csv,FM35,continuous
SPC_PITC,F35 II_1     SPECIMEN LABEL: PITTED CELL COUNT COLLECTED AND PREPARED WITHIN 1 HOUR OF COLLECTION?,phaseiii_fm35.csv,FM35,continuous
SPCPITND,F35 II_1ND   PITTED CELL COUNT SPECIMEN NOT COLLECTED,phaseiii_fm35.csv,FM35,continuous
LIVRCM,F35 III_1    PALPABLE LIVER,phaseiii_fm35.csv,FM35,continuous
LIVRCMND,F35 III_1ND  LIVER PALPABLE MEASUREMENT NOT DONE,phaseiii_fm35.csv,FM35,continuous
O2SAT,F35 III_2A   O2 SATURATION (PULSE OXYMETRY),phaseiii_fm35.csv,FM35,continuous
O2SATND,F35 III_2AND O2 SATURATION (PULSE OXYMETRY) NOT DONE,phaseiii_fm35.csv,FM35,continuous
O2SATSM,F35 III_2B   SECOND MEASUREMENT OF O2 SATURATION,phaseiii_fm35.csv,FM35,continuous
O2SATSND,F35 III_2BND SECOND MEASUREMENT NOT DONE,phaseiii_fm35.csv,FM35,continuous
SPC_PNCL,F35 III_3    WAS PENICILLIN COMPLIANCE SPECIMEN COLLECTED?,phaseiii_fm35.csv,FM35,continuous
SPPNCLND,F35 III_3ND  PENICILLIN COMPLIANCE SPECIMEN NOT COLLECTED,phaseiii_fm35.csv,FM35,continuous
BAYLEYS,F35 III_4    WAS FORM 40 - BAYLEY'S ADMINISTERED?,phaseiii_fm35.csv,FM35,continuous
VINELAND,F35 III_5    WAS FORM 41 - VINELAND ADMINISTERED TO PARENTS?,phaseiii_fm35.csv,FM35,continuous
NRLGQUES,F35 III_6    WAS FORM 43 - NEUROLOGICAL QUESTIONNAIRE ADMINISTERED?,phaseiii_fm35.csv,FM35,continuous
MRI,F35 III_7    WAS MRI DONE?,phaseiii_fm35.csv,FM35,continuous
SEDATION,F35 III_7A   SEDATION,phaseiii_fm35.csv,FM35,continuous
HRSNPO,F35 III_8    HOURS NPO?,phaseiii_fm35.csv,FM35,continuous
TCD,F35 III_3    WAS TCD PERFORMED?,phaseiii_fm35.csv,FM35,continuous
F80III8,F35 III_8    WAS FORM 80 SUBMITTED?,phaseiii_fm35.csv,FM35,continuous
GEN_CMNT,F35 IV_1C    GENERAL COMMENTS REGARDING TO THE FILLED OUT FORM,phaseiii_fm35.csv,FM35,continuous
VIS_DT_DAYS,F35 I_5      SUBJECT CLINICAL VISIT START DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm35.csv,FM35,continuous
ID,Unique patient identifier (randomized),phaseiii_fm36.csv,FM36,continuous
FORM,F36 FORM     STUDY FORM NUMBER,phaseiii_fm36.csv,FM36,continuous
REV,F36 REV      NUMBER OF THE FORM REVISONS,phaseiii_fm36.csv,FM36,continuous
VISIT,F36 I_4VIS   SUBJECT CLINICAL VISIT NUMBER,phaseiii_fm36.csv,FM36,categorical
SEQNO,F36 I_4SEQ   SUBJECT VISIT SEQUENCE NUMBER,phaseiii_fm36.csv,FM36,continuous
EOT_PLAN,F36 II_1A    END OF RANDOMIZED STUDY TREATMENT: PLANNED END OF RANDOMIZED TREATMENT AT 2-YEARS,phaseiii_fm36.csv,FM36,continuous
EOT_INAC,F36 II_1B    END OF RANDOMIZED STUDY TREATMENT: INACTIVE FOLLOW-UP STATUS,phaseiii_fm36.csv,FM36,continuous
EOT_RELO,F36 II_1C    END OF RANDOMIZED STUDY TREATMENT: PERMANENT RELOCATION TO AREA WITH NO BABY HUG CLINIC,phaseiii_fm36.csv,FM36,continuous
EOT_WCON,F36 II_1D    END OF RANDOMIZED STUDY TREATMENT: WITHDREW CONSENT,phaseiii_fm36.csv,FM36,continuous
EOT_KIDN,F36 II_1E    END OF RANDOMIZED STUDY TREATMENT: RENAL FAILURE OR CHRONIC DIALYSIS REQUIRING CESSATION OF STUDY TREATMENT,phaseiii_fm36.csv,FM36,continuous
EOT_MB,F36 II_1F    END OF RANDOMIZED STUDY TREATMENT: BONE MARROW STATUS REQUIRING CESSATION OF STUDY TREATMENT,phaseiii_fm36.csv,FM36,continuous
EOT_STRK,F36 II_1G    END OF RANDOMIZED STUDY TREATMENT: STROKE,phaseiii_fm36.csv,FM36,continuous
EOT_CHTR,F36 II_1H    END OF RANDOMIZED STUDY TREATMENT: PLACEMENT ON CHRONIC TRANSFUSION PROGRAM,phaseiii_fm36.csv,FM36,continuous
EOT_BMT,F36 II_1I    END OF RANDOMIZED STUDY TREATMENT: BONE MARROW TRANSPLANTATION,phaseiii_fm36.csv,FM36,continuous
EOT_DTH,F36 II_1J    END OF RANDOMIZED STUDY TREATMENT: DEATH,phaseiii_fm36.csv,FM36,continuous
EOT_OTHR,F36 II_1K    END OF RANDOMIZED STUDY TREATMENT: OTHER CONDITION REQUIRING END OF STUDY TREATMENT,phaseiii_fm36.csv,FM36,continuous
F80II2,F36 II_2     FORM 80 SUBMITTED?,phaseiii_fm36.csv,FM36,continuous
SPC_HEM,F36 III_1A   SPECIMEN LABEL: HEMATOLOGY (0.5 ML EDTA LAVENDER TOP),phaseiii_fm36.csv,FM36,continuous
SPCHEMND,F36 III_1AND SPECIMEN FOR HEMATOLOGY NOT COLLECTED,phaseiii_fm36.csv,FM36,continuous
SPC_BIOC,F36 III_1B   SPECIMEN LABEL: BIOCHEMISTRY COLLECTED JUST PRIOR TO URINE OSMOLALITY SPECIMEN (1.0 ML RED TOP),phaseiii_fm36.csv,FM36,continuous
SPCBIOND,F36 III_1BND BIOCHEMISTRY SPECIMEN NOT COLLECTED,phaseiii_fm36.csv,FM36,continuous
SPC_PITC,F36 III_1C   SPECIMEN LABEL: PITTED CELL COUNT COLLECTED AND PREPARED WITHIN 1 HOUR OF COLLECTION(0.1 ML EDTA LAVENDER TOP),phaseiii_fm36.csv,FM36,continuous
SPCPITND,F36 III_1CND PITTED CELL COUNT SPECIMEN NOT COLLECTED,phaseiii_fm36.csv,FM36,continuous
SPC_GYTO,F36 III_1D   SPECIMEN LABEL: CYTOGENETICS (4.0 ML NA HEPARIN GREEN TOP),phaseiii_fm36.csv,FM36,continuous
SPCGYTND,F36 III_1DND SPECIMEN FOR CYTOGENETICS NOT COLLECTED,phaseiii_fm36.csv,FM36,continuous
SPC_DNA,F36 III_1E   SPECIMEN LABEL: DNA (3.0 ML EDTA LAVENDER TOP),phaseiii_fm36.csv,FM36,continuous
SPCDNAND,F36 III_1END SPECIMEN FOR DNA (3.0 ML EDTA LAVENDER TOP) NOT COLLECTED,phaseiii_fm36.csv,FM36,continuous
SPC_IMMN,F36 III_1F   SPECIMEN LABEL: IMMUNOLOGY (RECORD LABELS ON FORM 42),phaseiii_fm36.csv,FM36,continuous
F80III2,F36 III_2    FORM 80 SUBMITTED?,phaseiii_fm36.csv,FM36,continuous
LIVRCM,F36 IV_1A    PALPABLE LIVER CM,phaseiii_fm36.csv,FM36,continuous
LIVRCMND,F36 IV_1AND  PALPABLE LIVER NOT DONE,phaseiii_fm36.csv,FM36,continuous
SPLNMDCL,F36 IV_1B1   MIDCLAVICULAR LINE CM,phaseiii_fm36.csv,FM36,continuous
SPLNMCND,F36 IV_1B1ND MIDCLAVICULAR LINE NOT DONE,phaseiii_fm36.csv,FM36,continuous
SPLNINTC,F36 IV_1B2   ANTERIOR AXILLARY LINE CM,phaseiii_fm36.csv,FM36,continuous
SPLNICND,F36 IV_1B2ND ANTERIOR AXILLARY LINE NOT DONE,phaseiii_fm36.csv,FM36,continuous
REDCELLS,F36 IV_2A    URINALYSIS: DEGREE OF RED CELLS,phaseiii_fm36.csv,FM36,continuous
WHTCELLS,F36 IV_2B    URINALYSIS: DEGREE OF WHITE CELLS,phaseiii_fm36.csv,FM36,continuous
URN_PH,F36 IV_2C    URINALYSIS: URINE PH VALUE,phaseiii_fm36.csv,FM36,continuous
URN_PHND,F36 IV_2CND  URINALYSIS  PH NOT DONE,phaseiii_fm36.csv,FM36,continuous
URNPR,F36 IV_2D    URINALYSIS: DEGREE OF PROTEIN,phaseiii_fm36.csv,FM36,continuous
URNHB,F36 IV_2E    URINALYSIS: DEGREE OF HEMOGLOBIN,phaseiii_fm36.csv,FM36,continuous
URINSG,F36 IV_2F    URINALYSIS: URINE SPECIFIC GRAVITY,phaseiii_fm36.csv,FM36,continuous
URINSGND,F36 IV_2FND  URINALYSIS: SPECIFIC GRAVITY NOT DONE,phaseiii_fm36.csv,FM36,continuous
O2SAT,F36 IV_3A    O2 SATURATION,phaseiii_fm36.csv,FM36,continuous
O2SATND,F36 IV_3AND  O2 SATURATION NOT DONE,phaseiii_fm36.csv,FM36,continuous
O2SATSM,F36 IV_3B    SECOND MEASUREMENT OF O2 SATURATION,phaseiii_fm36.csv,FM36,continuous
O2SATSND,F36 IV_3BND  SECOND MEASUREMENT NOT DONE,phaseiii_fm36.csv,FM36,continuous
SPC_PNCL,F36 IV_4     WAS PENICILLIN COMPLIANCE SPECIMEN COLLECTED,phaseiii_fm36.csv,FM36,continuous
SPPNCLND,F36 IV_4ND   PENICILLIN COMPLIANCE SPECIMEN COLLECTED NOT DONE,phaseiii_fm36.csv,FM36,continuous
BAYLEYS,F36 IV_5     WAS FORM 40 - BAYLEY'S ADMINISTERED?,phaseiii_fm36.csv,FM36,continuous
VINELAND,F36 IV_6     WAS FORM 41 - VINELAND ADMINISTERED TO PARENTS?,phaseiii_fm36.csv,FM36,continuous
NRLGQUES,F36 IV_7     WAS FORM 43 - NEUROLOGICAL QUESTIONNAIRE ADMINISTERED?,phaseiii_fm36.csv,FM36,continuous
URN_NPO,F36 IV_8A    HOW MANY HOURS NPO?,phaseiii_fm36.csv,FM36,continuous
URINOS,F36 IV_8B    SPECIMEN LABEL: URINE OSMOLALITY COLLECTED JUST AFTER BIOCHEMISTRY SPECIMEN,phaseiii_fm36.csv,FM36,continuous
URINOSND,F36 IV_8BND  URINE OSMOLALITY SPECIMEN NOT COLLECTED,phaseiii_fm36.csv,FM36,continuous
MRI,F36 IV_9A    WAS MRI DONE?,phaseiii_fm36.csv,FM36,continuous
MRINP,"F36 IV_9A1   IF NO, REASON NOT PERFORMED",phaseiii_fm36.csv,FM36,continuous
MRINP_SP,"F36 IV_9A1A  IF NO, REASON NOT PERFORMED, SPECIFY",phaseiii_fm36.csv,FM36,continuous
MRA,F36 IV_9B    WAS MRA DONE?,phaseiii_fm36.csv,FM36,continuous
MRANP,"F36 IV_9B1   IF NO, REASON NOT PERFORMED",phaseiii_fm36.csv,FM36,continuous
MRANP_SP,"F36 IV_9B1A  IF NO, REASON NOT PERFORMED, SPECIFY",phaseiii_fm36.csv,FM36,continuous
MRS,F36 IV_9C    WAS MRS DONE?,phaseiii_fm36.csv,FM36,continuous
MRSNP,"F36 IV_9C1   IF NO, REASON NOT PERFORMED",phaseiii_fm36.csv,FM36,continuous
MRSNP_SP,"F36 IV_9C1A  IF NO, REASON NOT PERFORMED, SPECIFY",phaseiii_fm36.csv,FM36,continuous
SEDATION,F36 IV_9D    SEDATION,phaseiii_fm36.csv,FM36,continuous
MRI_NPO,F36 IV_9E    HOW MANY HOURS NPO,phaseiii_fm36.csv,FM36,continuous
LVSPSCAN,F36 IV_10    WAS LIVER-SPLEEN SCAN PERFORMED,phaseiii_fm36.csv,FM36,continuous
LVSPSCNP,"F36 IV_10A   IF NO, REASON NOT PERFORMED",phaseiii_fm36.csv,FM36,continuous
LVSNP_SP,F36 IV_10A1  SPECIFY THE OTHER REASON NOT PERFORMED,phaseiii_fm36.csv,FM36,continuous
EOT_ABDS,F36 IV_11A   WAS ABDOMINAL SONOGRAM PERFORMED,phaseiii_fm36.csv,FM36,continuous
EOTABDNP,"F36 IV_11A1  IF NO, REASON NOT PERFORMED",phaseiii_fm36.csv,FM36,continuous
ABDNP_SP,F36 IV_11A1A SPECIFY THE OTHER REASON NOT PERFORMED,phaseiii_fm36.csv,FM36,continuous
ABD_NPO,F36 IV_11B   HOW MANY HOURS NPO,phaseiii_fm36.csv,FM36,continuous
EOT_TCD,F36 IV_12    WAS TRANSCRANIAL DOPPLER ATTEMPTED,phaseiii_fm36.csv,FM36,continuous
EOTTCDNP,"F36 IV_12A   IF NO, REASON NOT ATTEMPTED",phaseiii_fm36.csv,FM36,continuous
TCDNP_SP,F36 IV_12A1  SPECIFY THE OTHER REASON NOT ATTEMPTED,phaseiii_fm36.csv,FM36,continuous
F80IV13,F36 IV_13    FORM 80 SUBMITTED,phaseiii_fm36.csv,FM36,continuous
TRSTDTND,"F36 V_1ND    DATE STARTED, N/D",phaseiii_fm36.csv,FM36,continuous
PRDTRAHR,F36 V_1AHR   PRE-DTPA TIME HOUR,phaseiii_fm36.csv,FM36,continuous
PRDTRAMN,F36 V_1AMN   PRE-DTPA TIME MINUTES,phaseiii_fm36.csv,FM36,continuous
DTPAHR,F36 V_1BHR   DTPA ADMINISTERED HOUR,phaseiii_fm36.csv,FM36,continuous
DTPAMN,F36 V_1BMN   DTPA ADMINISTERED MINUTES,phaseiii_fm36.csv,FM36,continuous
DTPAND,F36 V_1BND   DTPA ADMINISTERED  N/D,phaseiii_fm36.csv,FM36,continuous
DTPADOSE,F36 V_1C     DOSE,phaseiii_fm36.csv,FM36,continuous
DTDOSEND,F36 V_1CND   DOSE N/D,phaseiii_fm36.csv,FM36,continuous
ONEHR,F36 V_2AHR   ONE-HOUR TIME HOUR,phaseiii_fm36.csv,FM36,continuous
ONEMN,F36 V_2AMN   ONE-HOUR TIME MINUTES,phaseiii_fm36.csv,FM36,continuous
ONEDTPA,F36 V_2B     DTPA MEASUREMENT,phaseiii_fm36.csv,FM36,continuous
ONE_ND,F36 V_2BND   DTPA MEASUREMENT N/D,phaseiii_fm36.csv,FM36,continuous
ONEDTPA2,F36 V_2C     SECOND DTPA MEASUREMENT,phaseiii_fm36.csv,FM36,continuous
ONE_ND2,F36 V_2CND   SECOND DTPA MEASUREMENT N/D,phaseiii_fm36.csv,FM36,continuous
ONEHULBL,F36 V_2D     TUBE LABEL (3 ML IN EDTA),phaseiii_fm36.csv,FM36,continuous
TWOHR,F36 V_3AHR   TWO-HOUR TIME HOUR,phaseiii_fm36.csv,FM36,continuous
TWOMN,F36 V_3AMN   TWO-HOUR TIME MINUTES,phaseiii_fm36.csv,FM36,continuous
TWODTPA,F36 V_3B     DTPA MEASUREMENT,phaseiii_fm36.csv,FM36,continuous
TWO_ND,F36 V_3BND   DTPA MEASUREMENT N/D,phaseiii_fm36.csv,FM36,continuous
TWODTPA2,F36 V_3C     SECOND DTPA MEASUREMENT,phaseiii_fm36.csv,FM36,continuous
TWO_ND2,F36 V_3CND   SECOND DTPA MEASUREMENT N/D,phaseiii_fm36.csv,FM36,continuous
TWOHULBL,F36 V_3D     TUBE LABEL (3 ML IN EDTA),phaseiii_fm36.csv,FM36,continuous
FORHR,F36 V_4AHR   FOUR-HOUR TIME  HOUR,phaseiii_fm36.csv,FM36,continuous
FORMN,F36 V_4AMN   FOUR-HOUR TIME  MINUTES,phaseiii_fm36.csv,FM36,continuous
FORDTPA,F36 V_4B     DTPA MEASUREMENT,phaseiii_fm36.csv,FM36,continuous
FOR_ND,F36 V_4BND   DTPA MEASUREMENT N/D,phaseiii_fm36.csv,FM36,continuous
FORDTPA2,F36 V_4C     SECOND DTPA MEASUREMENT,phaseiii_fm36.csv,FM36,continuous
FOR_ND2,F36 V_4CND   SECOND DTPA MEASUREMENT N/D,phaseiii_fm36.csv,FM36,continuous
FORHULBL,F36 V_4D     TUBE LABEL (3 ML IN EDTA),phaseiii_fm36.csv,FM36,continuous
GFRDTP_A,F36 V_5A     GFR FROM DTPA ML/MIN,phaseiii_fm36.csv,FM36,continuous
GFRA_ND,F36 V_5AND   GFR FROM DTPA ML/MIN ND,phaseiii_fm36.csv,FM36,continuous
GFRDTP_B,F36 V_5B     GFR FROM DTPA ML/MIN/M2,phaseiii_fm36.csv,FM36,continuous
GFRB_ND,F36 V_5BND   GFR FROM DTPA ML/MIN/M2 ND,phaseiii_fm36.csv,FM36,continuous
GFRDTP_C,F36 V_5C     GFR FROM DTPA ML/MIN/1.73M2,phaseiii_fm36.csv,FM36,continuous
GFRC_ND,F36 V_5CND   GFR FROM DTPA ML/MIN/1.73M2 ND,phaseiii_fm36.csv,FM36,continuous
F80V7,F36 V_6      FORM 80 SUBMITTED,phaseiii_fm36.csv,FM36,continuous
TEMP,F36 V_1A    TEMPERATURE,phaseiii_fm36.csv,FM36,continuous
TEMPMEAS,F36 V_1ADE  TYPE OF TEMPERATURE DEGREES F/C,phaseiii_fm36.csv,FM36,continuous
TEMPND,F36 V_1AND  TEMPERATURE NOT MEASURED,phaseiii_fm36.csv,FM36,continuous
PULSE,F36 V_1B    PULSE,phaseiii_fm36.csv,FM36,continuous
PULSEND,F36 V_1BND  PULSE NOT MEASURED,phaseiii_fm36.csv,FM36,continuous
RESP,F36 V_1C    RESPIRATION,phaseiii_fm36.csv,FM36,continuous
RESPND,F36 V_1CND  RESPIRATION NOT MEASURED,phaseiii_fm36.csv,FM36,continuous
HEIGHT1,F36 V_2A    CHILD'S RECUMBENT LENGTH MEASUREMENT #1,phaseiii_fm36.csv,FM36,continuous
HEIGHTND,F36 V_2AND  CHILD'S RECUMBENT LENGTH MEASUREMENT #1 NOT DONE,phaseiii_fm36.csv,FM36,continuous
HEIGHT2,F36 V_2B    CHILD'S RECUMBENT LENGTH MEASUREMENT #2,phaseiii_fm36.csv,FM36,continuous
HEIGHT3,F36 V_2C    CHILD'S RECUMBENT LENGTH MEASUREMENT #3,phaseiii_fm36.csv,FM36,categorical
HEIGHT,F36          CHILD'S AVERAGE OF RECUMBENT LENGTH,phaseiii_fm36.csv,FM36,continuous
HAIRHGHT,F36 V_2D    RATE HAIR STYLE INTERFERENCE ON CHILD'S LENGTH,phaseiii_fm36.csv,FM36,continuous
WEIGHT1,F36 VI_3A    CHILD'S WEIGHT MEASUREMENT # 1,phaseiii_fm36.csv,FM36,continuous
WEIGHTND,F36 VI_3AND  CHILD'S WEIGHT MEASUREMENT # 1 NOT DONE,phaseiii_fm36.csv,FM36,continuous
WEIGHT2,F36 VI_3B    CHILD'S WEIGHT MEASUREMENT # 2,phaseiii_fm36.csv,FM36,continuous
WEIGHT3,F36 VI_3C    CHILD'S WEIGHT MEASUREMENT # 3,phaseiii_fm36.csv,FM36,categorical
WEIGHT,F36          CHILD'S AVERAGE WEIGHT,phaseiii_fm36.csv,FM36,continuous
HEADC1,F36 V_4A    CHILD'S HEAD CIRCUMFERENCE MEASUREMENT #1,phaseiii_fm36.csv,FM36,continuous
HEADCND,F36 V_4AND  CHILD'S HEAD CIRCUMFERENCE MEASUREMENT #1 NOT DONE,phaseiii_fm36.csv,FM36,continuous
HEADC2,F36 V_4B    CHILD'S HEAD CIRCUMFERENCE MEASUREMENT #2,phaseiii_fm36.csv,FM36,continuous
HEADC3,F36 V_4C    CHILD'S HEAD CIRCUMFERENCE MEASUREMENT #3,phaseiii_fm36.csv,FM36,categorical
HEADC,F36          CHILD'S AVERAGE OF HEAD CIRCUMFERENCE,phaseiii_fm36.csv,FM36,continuous
HAIR,F36 V_4D    RATE HAIR STYLE INTERFERENCE ON CHILD'S HEAD CIRCUMFERENCE,phaseiii_fm36.csv,FM36,continuous
N_EVTS,F36 V_6     NUMBER OF REPORTABLE EVENTS,phaseiii_fm36.csv,FM36,continuous
V_EVTSNA,F36 V_6NA   NUMBER OF REPORTABLE EVENTS NOT APPLICABLE,phaseiii_fm36.csv,FM36,continuous
FEVER31,F36 V_7A    FEVER MORE THAN 101.5 DEGREES F. (38.4 DEGREES C.),phaseiii_fm36.csv,FM36,continuous
VACCINE,F36 V_7B    ANY VACCINATIONS SINCE LAST VISIT?,phaseiii_fm36.csv,FM36,continuous
PENCILN,F36 V_8A    DID THE CHILD TAKE THEIR NIGHT-TIME DOSE OF TWICE DAILY  PROPHYLATIC PENICILLIN LAST NIGHT?,phaseiii_fm36.csv,FM36,continuous
PENDOSE,F36 V_8B    HOW MANY DOSES OF PENICILLIN OR SIMILAR ANTIBIOTIC WERE MISSED IN THE LAST WEEK?,phaseiii_fm36.csv,FM36,continuous
PENNA,F36 V_8BNA  DOSES OF PENICILLIN SIMILAR ANTIBIOTIC MISSED IN THE LAST WEEK ( NOT APPLICABLE),phaseiii_fm36.csv,FM36,continuous
RECORDRX,F36 V_9A    RECORD RX #,phaseiii_fm36.csv,FM36,continuous
RXNORET,F36 V_9ANA  RECORD RX # NOT RETURNED,phaseiii_fm36.csv,FM36,continuous
VOLLFT,F36 V_9B    APPROXIMATELY HOW MUCH VOLUME IS LEFT?,phaseiii_fm36.csv,FM36,continuous
VOLNA,F36 V_9BNA  VOLUME LEFT(NOT APPLICABLE),phaseiii_fm36.csv,FM36,continuous
IRRTRT,F36 V_9C    ANY IRREGULAR TREATMENT ADMINISTRATION SINCE LAST VISIT?,phaseiii_fm36.csv,FM36,continuous
F80VI9,F36 VI_9     FORM 80 SUBMITTED?,phaseiii_fm36.csv,FM36,continuous
GEN_CMNT,F36 VII_1C   GENERAL COMMENTS REGARDING TO THE FILLED OUT FORM,phaseiii_fm36.csv,FM36,continuous
ANTIB,"F36 V_8A1    IF NO, DID THE CHILD TAKE ANOTHER ANTIBIOTIC?",phaseiii_fm36.csv,FM36,continuous
ANTIB_SP,F36 V_8A1A   SPECIFY,phaseiii_fm36.csv,FM36,continuous
FORM22,F36 IV_11    WAS FORM 22 - DTPA/GFR PERFORMED,phaseiii_fm36.csv,FM36,continuous
NEW_BTTL,"F36 IV_11A   IF YES, NEW STUDY TREATMENT BOTTLE USED",phaseiii_fm36.csv,FM36,continuous
TXBOTNO,"F36 IV_11A1  IF YES, RECORD BOTTLE NUMBER USED",phaseiii_fm36.csv,FM36,continuous
VIS_DT_DAYS,F36 I_5      SUBJECT CLINICAL VISIT START DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm36.csv,FM36,continuous
TRSTRTDT_DAYS,F36 V_1      DATE STARTED (recode: number of days after date of eligibility or ineligibility),phaseiii_fm36.csv,FM36,continuous
ANM_DT_DAYS,F36 V_5      ANTHROPOMETRY MEASUREMENT DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm36.csv,FM36,continuous
URIN_DT_DAYS,F36 IV_2G    URINALYSIS: DATE PERFORMED (recode: number of days after date of eligibility or ineligibility),phaseiii_fm36.csv,FM36,continuous
ID,Unique patient identifier (randomized),phaseiii_fm37.csv,FM37,continuous
FORM,F37 FORM     STUDY FORM NUMBER,phaseiii_fm37.csv,FM37,continuous
REV,F37 REV      NUMBER OF THE FORM REVISONS,phaseiii_fm37.csv,FM37,continuous
VISIT,F37 I_4VIS   SUBJECT CLINICAL VISIT NUMBER,phaseiii_fm37.csv,FM37,categorical
SEQNO,F37 I_4SEQ   SUBJECT VISIT SEQUENCE NUMBER,phaseiii_fm37.csv,FM37,continuous
UNSCHVIS,F37 II_1A    ARE THESE LAB RESULTS FOR AN UNSCHEDULED VISIT THAT RESULTED IN A TOXICITY OR ALERT?,phaseiii_fm37.csv,FM37,continuous
LABEL,F37 II_1B    LABEL NUMBER PUT ON LAB SPECIMENS,phaseiii_fm37.csv,FM37,continuous
WBC,F37 II_2A    WHITE BLOOD CELL COUNT (WBC),phaseiii_fm37.csv,FM37,continuous
RBC,F37 II_2B    RED BLOOD CELL COUNT (RBC),phaseiii_fm37.csv,FM37,continuous
HB,F37 II_2C    HEMOGLOBIN,phaseiii_fm37.csv,FM37,continuous
PCV,F37 II_2D    HEMATOCRIT,phaseiii_fm37.csv,FM37,continuous
PLAT,F37 II_2E    PLATELET COUNT,phaseiii_fm37.csv,FM37,continuous
DIFFTYPE,F37 II_3A    DIFFERENTIAL TYPE,phaseiii_fm37.csv,FM37,continuous
NEUT_CT,F37 II_3B    ABSOLUTE NEUTROPHIL COUNT (ANC),phaseiii_fm37.csv,FM37,continuous
NEUT_PT,F37 II_3C    NEUTROPHILS (% OF WBC),phaseiii_fm37.csv,FM37,continuous
LYMPH_CT,F37          LYMPHOCYTE COUNT,phaseiii_fm37.csv,FM37,continuous
LYMPH_PT,F37 II_3D    LYMPHOCYTES (% OF WBC),phaseiii_fm37.csv,FM37,continuous
MONO_CT,F37          MONOOCYTE COUNT,phaseiii_fm37.csv,FM37,continuous
MONO_PT,F37 II_3E    MONOCYTES (% OF WBC),phaseiii_fm37.csv,FM37,continuous
NRBC,F37 II_3F    NUCLEATED RED BLOOD CELLS (NRBC),phaseiii_fm37.csv,FM37,continuous
CWBC,"F37 II_3F1   IF NOT 0, CORRECTED WBC COUNT",phaseiii_fm37.csv,FM37,continuous
RETIC_PT,F37 II_3G    RETICULOCYTES (% OF RBC),phaseiii_fm37.csv,FM37,continuous
RETIC_CT,F37 II_3H    RETICULOCYTE COUNT,phaseiii_fm37.csv,FM37,continuous
MCV,F37 II_3I    MCV,phaseiii_fm37.csv,FM37,continuous
GEN_CMNT,F37 III_1C   GENERAL COMMENTS REGARDING TO THE FILLED OUT FORM,phaseiii_fm37.csv,FM37,continuous
VIS_DT_DAYS,F37 I_5      SUBJECT CLINICAL VISIT DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm37.csv,FM37,continuous
ID,Unique patient identifier (randomized),phaseiii_fm38.csv,FM38,continuous
FORM,F38 FORM     STUDY FORM NUMBER,phaseiii_fm38.csv,FM38,continuous
REV,F38 REV      NUMBER OF THE FORM REVISONS,phaseiii_fm38.csv,FM38,continuous
VISIT,F38 I_4VIS   SUBJECT CLINICAL VISIT NUMBER,phaseiii_fm38.csv,FM38,categorical
SEQNO,F38 I_4SEQ   SUBJECT VISIT SEQUENCE NUMBER,phaseiii_fm38.csv,FM38,continuous
CONCUR,F38 II_1     IS THIS STUDY RESTART VISIT CONCURRENT WITH A ROUTINE STUDY VISIT?,phaseiii_fm38.csv,FM38,continuous
TXBOTNO,F38 II_1A    RECORD BOTTLE NUMBER DISPENSED,phaseiii_fm38.csv,FM38,continuous
TXDDOSMG,F38 II_1B1   DAILY DOSE MG (USE TREATMENT RECOMMENDATION SENT AFTER HOLD WAS LIFTED),phaseiii_fm38.csv,FM38,continuous
TXDDOSML,F38 II_1B2   DAILY DOSE ML (USE TREATMENT RECOMMENDATION SENT AFTER HOLD WAS LIFTED),phaseiii_fm38.csv,FM38,continuous
VOLDISP,F38 II_1C    VOLUME DISPENSED,phaseiii_fm38.csv,FM38,continuous
GEN_CMNT,F38 III_1C   GENERAL COMMENTS REGARDING TO THE FILLED OUT FORM,phaseiii_fm38.csv,FM38,continuous
VIS_DT_DAYS,F38 I_5      SUBJECT CLINICAL VISIT RESTART DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm38.csv,FM38,continuous
ID,Unique patient identifier (randomized),phaseiii_fm39.csv,FM39,continuous
FORM,F39 FORM     STUDY FORM NUMBER,phaseiii_fm39.csv,FM39,continuous
REV,F39 REV      NUMBER OF THE FORM REVISONS,phaseiii_fm39.csv,FM39,continuous
VISIT,F39 I_4VIS   SUBJECT CLINICAL VISIT NUMBER,phaseiii_fm39.csv,FM39,continuous
SEQNO,F39 I_4SEQ   SUBJECT VISIT SEQUENCE NUMBER,phaseiii_fm39.csv,FM39,continuous
RECORDRX,F39 II_1A    RECORD RX #,phaseiii_fm39.csv,FM39,continuous
RXNORET,F39 II_1ANR  RECORD RX # NOT RETURNED,phaseiii_fm39.csv,FM39,continuous
VOLLFT,F39 II_1B    APPROXIMATELY HOW MUCH VOLUME IS LEFT?,phaseiii_fm39.csv,FM39,continuous
VOLNA,F39 II_1BNA  VOLUME LEFT (NOT APPLICABLE),phaseiii_fm39.csv,FM39,continuous
TXBOTNO,F39 II_2A    NEW BOTTLE NUMBER DISPENSED,phaseiii_fm39.csv,FM39,continuous
TXDDOSMG,F39 II_2B1   DAILY DOSE MG,phaseiii_fm39.csv,FM39,continuous
TXDDOSML,F39 II_2B2   DAILY DOSE ML,phaseiii_fm39.csv,FM39,continuous
VOLDISP,F39 II_2C    VOLUME DISPENSED,phaseiii_fm39.csv,FM39,continuous
BOTRN,F39 II_2D    REASON NEW BOTTLE DISPENSED,phaseiii_fm39.csv,FM39,continuous
BOTRN_SP,F39 II_2DA   SPECFY THE OTHER REASONS WHY NEW BOTTLE DISPENSED,phaseiii_fm39.csv,FM39,continuous
GEN_CMNT,F39 III_1C   GENERAL COMMENTS REGARDING TO THE FILLED OUT FORM,phaseiii_fm39.csv,FM39,continuous
VIS_DT_DAYS,F39 I_5      DRUG DISPENSING DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm39.csv,FM39,continuous
ID,Unique patient identifier (randomized),phaseiii_fm40.csv,FM40,continuous
FORM,F40 FORM     STUDY FORM NUMBER,phaseiii_fm40.csv,FM40,continuous
REV,F40 REV      NUMBER OF THE FORM REVISONS,phaseiii_fm40.csv,FM40,continuous
VISIT,F40 I_4VIS   SUBJECT CLINICAL VISIT NUMBER,phaseiii_fm40.csv,FM40,categorical
SEQNO,F40 I_4SEQ   SUBJECT VISIT SEQUENCE NUMBER,phaseiii_fm40.csv,FM40,continuous
ADJ_MO,F40 II_1A    ADJUSTMENT FOR PREMATURITY: MONTH,phaseiii_fm40.csv,FM40,continuous
ADJ_DAYS,F40 II_1B    ADJUSTMENT FOR PREMATURITY: DAYS,phaseiii_fm40.csv,FM40,continuous
MLCHAGYR,"F40 III_AYR  MENTAL SCALE CHRONOLOGICAL AGE, YEARS",phaseiii_fm40.csv,FM40,continuous
MLCHAGMN,"F40 III_AMO  MENTAL SCALE CHRONOLOGICAL AGE,  MONTHS",phaseiii_fm40.csv,FM40,continuous
MLPMAGYR,"F40 III_BYR  MENTAL SCALE IF PREMATURE, CORRECTED AGE,  YEARS",phaseiii_fm40.csv,FM40,continuous
MLPMAGMN,"F40 III_BMO  MENTAL SCALE IF PREMATURE, CORRECTED AGE,  MONTHS",phaseiii_fm40.csv,FM40,continuous
MLSTROW,F40 III_C1   MENTAL SCALE STARTING ROW,phaseiii_fm40.csv,FM40,continuous
MLENDROW,F40 III_C2   MENTAL SCALE ENDING ROW,phaseiii_fm40.csv,FM40,continuous
MENRAW,F40 III_179  MENTAL SCALE RAW SCORE,phaseiii_fm40.csv,FM40,continuous
MENMDI,F40 III_180  MENTAL SCALE MDI SCORE,phaseiii_fm40.csv,FM40,continuous
MEN95CIL,F40 III_181A MENTAL SCALE 95% CI LOW BOUND,phaseiii_fm40.csv,FM40,continuous
MEN95CIH,F40 III_181B MENTAL SCALE 95% CI HIGH BOUND,phaseiii_fm40.csv,FM40,continuous
MRCHAGYR,"F40 IV_AYR   MOTOR SCALE CHRONOLOGICAL AGE,  YEARS",phaseiii_fm40.csv,FM40,continuous
MRCHAGMN,"F40 IV_AMO   MOTOR SCALE CHRONOLOGICAL AGE, MONTHS",phaseiii_fm40.csv,FM40,continuous
MRPMAGYR,"F40 IV_BYR   MOTOR SCALE IF PREMATURE, CORRECTED AGE,  YEARS",phaseiii_fm40.csv,FM40,continuous
MRPMAGMN,"F40 IV_BMO   MOTOR SCALE IF PREMATURE, CORRECTED AGE,  MONTHS",phaseiii_fm40.csv,FM40,continuous
MRSTROW,F40 IV_C1    MOTOR SCALE STARTING ROW,phaseiii_fm40.csv,FM40,continuous
MRENDROW,F40 IV_C2    MOTOR SCALE ENDING ROW,phaseiii_fm40.csv,FM40,continuous
MOTRAW,F40 IV_112   MOTOR SCALE RAW SCORE,phaseiii_fm40.csv,FM40,continuous
MOTPDI,F40 IV_113   MOTOR SCALE PDI SCORE,phaseiii_fm40.csv,FM40,continuous
MOT95CIL,F40 IV_114A  MOTOR SCALE 95% CI LOW BOUND,phaseiii_fm40.csv,FM40,continuous
MOT95CIH,F40 IV_114B  MOTOR SCALE 95% CI HIGH BOUND,phaseiii_fm40.csv,FM40,continuous
BRCHAGYR,"F40 V_AYR    BEHAVIOR RATING SCALE CHRONOLOGICAL AGE,  YEARS",phaseiii_fm40.csv,FM40,continuous
BRCHAGMN,"F40 V_AMO    BEHAVIOR RATING SCALE CHRONOLOGICAL AGE,  MONTHS",phaseiii_fm40.csv,FM40,continuous
BRPMAGYR,"F40 V_BYR    BEHAVIOR RATING SCALE IF PREMATURE, CORRECTED AGE,  YEARS",phaseiii_fm40.csv,FM40,continuous
BRPMAGMN,"F40 V_BMO    BEHAVIOR RATING SCALE IF PREMATURE, CORRECTED AGE,  MONTHS",phaseiii_fm40.csv,FM40,continuous
BEHRAW,F40 V_31     BEHAVIOR RATING SCALE RAW SCORE,phaseiii_fm40.csv,FM40,continuous
BEHPCTL,F40 V_32     BEHAVIOR RATING SCALE PERCENTILE,phaseiii_fm40.csv,FM40,continuous
GEN_CMNT,F40 VL_1C    GENERAL COMMENTS REGARDING TO THE FILLED OUT FORM,phaseiii_fm40.csv,FM40,continuous
VIS_DT_DAYS,F40 I_5      VISIT DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm40.csv,FM40,continuous
CARE40G,"F40 II_2     CAREGIVER'S RELATIONSHIP TO CHILD (regrouped: 1 = Mother, 2 = Father, 3 = Grandparent, 4 = Other)",phaseiii_fm40.csv,FM40,continuous
ID,Unique patient identifier (randomized),phaseiii_fm41.csv,FM41,continuous
FORM,F41 FORM     STUDY FORM NUMBER,phaseiii_fm41.csv,FM41,continuous
REV,F41 REV      NUMBER OF THE FORM REVISONS,phaseiii_fm41.csv,FM41,continuous
VISIT,F41 I_4VIS   SUBJECT CLINICAL VISIT NUMBER,phaseiii_fm41.csv,FM41,categorical
SEQNO,F41 I_4SEQ   SUBJECT VISIT SEQUENCE NUMBER,phaseiii_fm41.csv,FM41,continuous
CHRAGEYR,"F41 II_1YR   CHRONOLOGICAL AGE, YEARS",phaseiii_fm41.csv,FM41,continuous
CHRAGEMN,F41 II_1MN   CHRONOLOGICAL AGE: MONTHS,phaseiii_fm41.csv,FM41,continuous
CDSTROW,F41 III_A1   COMMUNICATIONS DOMAIN STARTING ROW,phaseiii_fm41.csv,FM41,continuous
CDENDROW,F41 III_A2   COMMUNICATIONS DOMAIN ENDING ROW,phaseiii_fm41.csv,FM41,continuous
COMRAW,F41 III_B68  COMMUNICATIONS DOMAIN RAW SCORE,phaseiii_fm41.csv,FM41,continuous
COMSTRD,F41 III_B69  COMMUNICATIONS DOMAIN STANDARD SCORE,phaseiii_fm41.csv,FM41,continuous
COM95CL,F41 III_B70  COMMUNICATIONS DOMAIN 95% CONFIDENCE LEVEL,phaseiii_fm41.csv,FM41,continuous
COMPCTL,F41 III_B71  COMMUNICATIONS DOMAIN PERCENTILE RANK,phaseiii_fm41.csv,FM41,continuous
DDSTROW,F41 IV_A1    DAILY LIVING SKILLS STARTING ROWS,phaseiii_fm41.csv,FM41,continuous
DDENDROW,F41 IV_A2    DAILY LIVING SKILLS ENDING ROWS,phaseiii_fm41.csv,FM41,continuous
DLSRAW,F41 IV_B93   DAILY LIVING SKILLS DOMAIN RAW SCORE,phaseiii_fm41.csv,FM41,continuous
DLSSTRD,F41 IV_B94   DAILY LIVING SKILLS STANDARD SCORE,phaseiii_fm41.csv,FM41,continuous
DLS95CL,F41 IV_B95   DAILY LIVING SKILLS 95% CONFIDENCE LEVEL,phaseiii_fm41.csv,FM41,continuous
DLSPCTL,F41 IV_B96   DAILY LIVING SKILLS PERCENTILE RANK,phaseiii_fm41.csv,FM41,continuous
SDSTROW,F41 V_A1     SOCIALIZATION DOMAIN STARTING ROW,phaseiii_fm41.csv,FM41,continuous
SDENDROW,F41 V_A2     SOCIALIZATION DOMAIN ENDING ROW,phaseiii_fm41.csv,FM41,continuous
SOCRAW,F41 V_B67    SOCIALIZATION DOMAIN RAW SCORE,phaseiii_fm41.csv,FM41,continuous
SOCSTRD,F41 V_B68    SOCIALIZATION DOMAIN STANDARD SCORE,phaseiii_fm41.csv,FM41,continuous
SOC95CL,F41 V_B69    SOCIALIZATION DOMAIN 95% CONFIDENCE LEVEL,phaseiii_fm41.csv,FM41,continuous
SOCPCTL,F41 V_B70    SOCIALIZATION DOMAIN PERCENTILE RANK,phaseiii_fm41.csv,FM41,continuous
MSSTROW,F41 V1_A1    MOTOR SKILLS STARTING ROW,phaseiii_fm41.csv,FM41,continuous
MSENDROW,F41 V1_A2    MOTOR SKILLS  ENDING ROW,phaseiii_fm41.csv,FM41,continuous
MTSKRAW,F41 VI_B37   MOTOR SKILLS DOMAIN RAW SCORE,phaseiii_fm41.csv,FM41,continuous
MTSKSTRD,F41 VI_B38   MOTOR SKILLS STANDARD SCORE,phaseiii_fm41.csv,FM41,continuous
MTSK95CL,F41 VI_B39   MOTOR SKILLS 95% CONFIDENCE LEVEL,phaseiii_fm41.csv,FM41,continuous
MTSKPCTL,F41 VI_B40   MOTOR SKILLS PERCENTILE RANK,phaseiii_fm41.csv,FM41,continuous
GEN_CMNT,F41 VLL_1C   GENERAL COMMENTS REGARDING TO THE FILLED OUT FORM,phaseiii_fm41.csv,FM41,continuous
VIS_DT_DAYS,F41 I_5      VISIT DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm41.csv,FM41,continuous
CARE41G,"F41 II_2     CAREGIVER'S RELATIONSHIP TO CHILD (regrouped: 1 = Mother, 2 = Father, 3 = Grandparent, 4 = Other)",phaseiii_fm41.csv,FM41,continuous
ID,Unique patient identifier (randomized),phaseiii_fm42.csv,FM42,continuous
FORM,F42 FORM     STUDY FORM NUMBER,phaseiii_fm42.csv,FM42,continuous
REV,F42 REV      NUMBER OF THE FORM REVISONS,phaseiii_fm42.csv,FM42,continuous
VISIT,F42 I_4VIS   SUBJECT CLINICAL VISIT NUMBER,phaseiii_fm42.csv,FM42,categorical
SEQNO,F42 I_4SEQ   SUBJECT VISIT SEQUENCE NUMBER,phaseiii_fm42.csv,FM42,continuous
HB2WSEQ,F42 II_2     HEP B 0-2 WEEKS VACCINATION SEQUENCE IN SERIES,phaseiii_fm42.csv,FM42,continuous
HB2WND,F42 II_2AND  HEP B  0-2 WEEKS VACCINATION NOT DONE,phaseiii_fm42.csv,FM42,continuous
DT6WSEQ,F42 II_3A    6-WEEKS TO 2-MONTHS OF AGE VACCINATIONS DTP/DTAP  SEQUENCE IN SERIES,phaseiii_fm42.csv,FM42,continuous
DT6WND,F42 II_3AND  6-WEEKS TO 2-MONTHS OF AGE VACCINATIONS DTP/DTAP  NOT DONE,phaseiii_fm42.csv,FM42,continuous
HO6WSEQ,F42 II_3B    6-WEEKS TO 2-MONTHS OF AGE VACCINATIONS HBOC/HIB SEQUENCE IN SERIES,phaseiii_fm42.csv,FM42,continuous
HO6WND,F42 II_3BND  6-WEEKS TO 2-MONTHS OF AGE VACCINATIONS HBOC/HIB NOT DONE,phaseiii_fm42.csv,FM42,continuous
OP6WSEQ,F42 II_3C    6-WEEKS TO 2-MONTHS OF AGE VACCINATIONS OPV/IPV SEQUENCE IN SERIES,phaseiii_fm42.csv,FM42,continuous
OP6WND,F42 II_3CND  6-WEEKS TO 2-MONTHS OF AGE VACCINATIONS OPV/IPV NOT DONE,phaseiii_fm42.csv,FM42,continuous
PN6WSEQ,F42 II_3D    6-WEEKS TO 2-MONTHS OF AGE VACCINATIONS PNEUMO (PCV7) SEQUENCE IN SERIES,phaseiii_fm42.csv,FM42,continuous
PN6WND,F42 II_3DND  6-WEEKS TO 2-MONTHS OF AGE VACCINATIONS PNEUMO (PCV7) NOT DONE,phaseiii_fm42.csv,FM42,continuous
HB6WSEQ,F42 II_3E    6-WEEKS TO 2-MONTHS OF AGE VACCINATIONS HEP B SEQUENCE IN SERIES,phaseiii_fm42.csv,FM42,continuous
HB6WND,F42 II_3END  6-WEEKS TO 2-MONTHS OF AGE VACCINATIONS HEP B NOT DONE,phaseiii_fm42.csv,FM42,continuous
DT4MSEQ,F42 II_4A    4-MONTHS OF AGE VACCINATIONS DTP/DTAP SEQUENCE IN SERIES,phaseiii_fm42.csv,FM42,continuous
DT4MND,F42 II_4AND  4-MONTHS OF AGE VACCINATIONS DTP/DTAP NOT DONE,phaseiii_fm42.csv,FM42,continuous
HO4MSEQ,F42 II_4B    4-MONTHS OF AGE VACCINATIONS HBOC/HIB SEQUENCE IN SERIES,phaseiii_fm42.csv,FM42,continuous
HO4MND,F42 II_4BND  4-MONTHS OF AGE VACCINATIONS HBOC/HIB NOT DONE,phaseiii_fm42.csv,FM42,continuous
OP4MSEQ,F42 II_4C    4-MONTHS OF AGE VACCINATIONS OPV/IPV SEQUENCE IN SERIES,phaseiii_fm42.csv,FM42,continuous
OP4MND,F42 II_4CND  4-MONTHS OF AGE VACCINATIONS OPV/IPV NOT DONE,phaseiii_fm42.csv,FM42,continuous
PN4MSEQ,F42 II_4D    4-MONTHS OF AGE VACCINATIONS PNEUMO (PCV 7) SEQUENCE IN SERIES,phaseiii_fm42.csv,FM42,continuous
PN4MND,F42 II_4DND  4-MONTHS OF AGE VACCINATIONS PNEUMO (PCV 7) NOT DONE,phaseiii_fm42.csv,FM42,continuous
DT6MSEQ,F42 II_5A    6-MONTHS OF AGE VACCINATIONS DTP/DTAP SEQUENCE IN SERIES,phaseiii_fm42.csv,FM42,continuous
DT6MND,F42 II_5AND  6-MONTHS OF AGE VACCINATIONS DTP/DTAP NOT DONE,phaseiii_fm42.csv,FM42,continuous
HO6MSEQ,F42 II_5B    6-MONTHS OF AGE VACCINATIONS HBOC/HIB SEQUENCE IN SERIES,phaseiii_fm42.csv,FM42,continuous
HO6MND,F42 II_5BND  6-MONTHS OF AGE VACCINATIONS HBOC/HIB NOT DONE,phaseiii_fm42.csv,FM42,continuous
PN6MSEQ,F42 II_5C    6-MONTHS OF AGE VACCINATIONS PNEUMO (PCV 7) SEQUENCE IN SERIES,phaseiii_fm42.csv,FM42,continuous
PN6MND,F42 II_5CND  6-MONTHS OF AGE VACCINATIONS PNEUMO (PCV 7) NOT DONE,phaseiii_fm42.csv,FM42,continuous
DT12MSEQ,F42 II_6A    6-18 MONTHS OF AGE VACCINATIONS DTP/DTAP SEQUENCE IN SERIES,phaseiii_fm42.csv,FM42,continuous
DT12MND,F42 II_6AND  6-18 MONTHS OF AGE VACCINATIONS DTP/DTAP NOT DONE,phaseiii_fm42.csv,FM42,continuous
HO12MSEQ,F42 II_6B    6-18 MONTHS OF AGE VACCINATIONS HBOC/HIB SEQUENCE IN SERIES,phaseiii_fm42.csv,FM42,continuous
HO12MND,F42 II_6BND  6-18 MONTHS OF AGE VACCINATIONS HBOC/HIB NOT DONE,phaseiii_fm42.csv,FM42,continuous
OP12MSEQ,F42 II_6C    6-18 MONTHS OF AGE VACCINATIONS SEQUENCE IN SERIES,phaseiii_fm42.csv,FM42,continuous
OP12MND,F42 II_6CND  6-18 MONTHS OF AGE VACCINATIONS IPV NOT DONE,phaseiii_fm42.csv,FM42,continuous
PN12MSEQ,F42 II_6D    6-18 MONTHS OF AGE VACCINATIONS PNEUMO (PCV 7) SEQUENCE IN SERIES,phaseiii_fm42.csv,FM42,continuous
PN12MND,F42 II_6DND  6-18 MONTHS OF AGE VACCINATIONS PNEUMO (PCV 7) NOT DONE,phaseiii_fm42.csv,FM42,continuous
HB12MSQ1,F42 II_6E    6-18 MONTHS OF AGE VACCINATIONS HEP B,phaseiii_fm42.csv,FM42,continuous
HB12MND1,F42 II_6END  6-18 MONTHS OF AGE VACCINATIONS HEP B NOT DONE,phaseiii_fm42.csv,FM42,continuous
MM12MSEQ,F42 II_6F    6-18 MONTHS OF AGE VACCINATIONS MMR SEQUENCE IN SERIES,phaseiii_fm42.csv,FM42,continuous
MM12MND,F42 II_6FND  6-18 MONTHS OF AGE VACCINATIONS MMR NOT DONE,phaseiii_fm42.csv,FM42,continuous
VR12MSEQ,F42 II_6G    6-18 MONTHS OF AGE VACCINATIONS VARICELLA SEQUENCE IN SERIES,phaseiii_fm42.csv,FM42,continuous
VR12MND,F42 II_6GND  6-18 MONTHS OF AGE VACCINATIONS VARICELLA NOT DONE,phaseiii_fm42.csv,FM42,continuous
OPBLND,F42 II_8AND  SERUM OPSONOPHAGOCYTIC + PNEUMOCOCAL ANTIBODY NOT DONE,phaseiii_fm42.csv,FM42,continuous
OPBLLBL,F42 II_8B    STUDY ENTRY (PRE-TREATMENT): TUBE LABEL (3.0 CC IN RED TUBE),phaseiii_fm42.csv,FM42,continuous
CD4BLND,F42 II_8CND  STUDY ENTRY (PRE-TREATMENT): NAIVE AND MEMORY CD4/CD8 NOT DONE,phaseiii_fm42.csv,FM42,continuous
CD4BLLBL,F42 II_8D    STUDY ENTRY (PRE-TREATMENT): TUBE LABEL (0.5 CC IN PURPLE TUBE),phaseiii_fm42.csv,FM42,continuous
MMA12MND,F42 II_9AND  2-6 WEEKS AFTER MMR: ANTIBODY TO MMR NOT DONE,phaseiii_fm42.csv,FM42,continuous
MMA12MLB,F42 II_9B    2-6 WEEKS AFTER MMR: TUBE LABEL (1.2 CC IN RED TUBE),phaseiii_fm42.csv,FM42,continuous
PCAB2YND,F42 II_10AND 23-MONTH-OF-AGE BLOOD SAMPLES: ANTIBODY RESPONSE TO PNEUMO 23 NOT DONE,phaseiii_fm42.csv,FM42,continuous
PCAB2YLB,F42 II_10B   23-MONTH-OF-AGE BLOOD SAMPLES: TUBE LABEL (3.0 CC IN RED TUBE),phaseiii_fm42.csv,FM42,continuous
MMA2YND,F42 II_10CND 23-MONTH-OF-AGE BLOOD SAMPLES: ANTIBODY RESPONSE TO MMR NOT DONE,phaseiii_fm42.csv,FM42,continuous
MMA2YLBL,F42 II_10D   23-MONTH-OF-AGE BLOOD SAMPLES: TUBE LABEL (1.2 CC IN RED TUBE),phaseiii_fm42.csv,FM42,continuous
CD42YND,F42 II_10END 23-MONTH-OF-AGE BLOOD SAMPLES: NAIVE AND MEMORY CD4/CD8 NOT DONE,phaseiii_fm42.csv,FM42,continuous
CD42YLBL,F42 II_10F   23-MONTH-OF-AGE BLOOD SAMPLES: TUBE LABEL (0.5 CC IN PURPLE TUBE),phaseiii_fm42.csv,FM42,continuous
PN2YSEQ,F42 II_11A   24-MONTH OF AGE VACCINATION PNEUMO 23 (23 PS) SEQUENCE IN SERIES,phaseiii_fm42.csv,FM42,continuous
PN2YND,F42 II_11AND 24-MONTH OF AGE VACCINATION PNEUMO 23 (23 PS) NOT DONE,phaseiii_fm42.csv,FM42,continuous
OC2YND,F42 II_12AND 2-8 WEEKS AFTER 24-MONTH OF AGE VACCINATIONS: SERUM OPSONOPHAGOCYTIC + PNEUMOCOCAL ANTIBODY NOT DONE,phaseiii_fm42.csv,FM42,continuous
OC2YLBL,F42 II_12B   2-8 WEEKS AFTER 24-MONTH OF AGE VACCINATIONS: TUBE LABEL (3.0 CC IN RED TUBE),phaseiii_fm42.csv,FM42,continuous
OCAEOSND,F42 II_13AND STUDY EXIT: SERUM OPSONOPHAGOCYTIC + PNEUMOCOCCAL ANTIBODY NOT DONE,phaseiii_fm42.csv,FM42,continuous
OCAEOSLB,F42 II_13B   STUDY EXIT: TUBE LABEL (3.0 CC IN RED TUBE),phaseiii_fm42.csv,FM42,continuous
MMAEOSND,F42 II_13CND STUDY EXIT: ANTIBODY RESPONSE TO MMR NOT DONE,phaseiii_fm42.csv,FM42,continuous
MMAEOSLB,F42 II_13D   STUDY EXIT: TUBE LABEL (1.2 CC IN RED TUBE),phaseiii_fm42.csv,FM42,continuous
CD4EDSND,F42 II_13END STUDY EXIT: NAIVE AND MEMORY CD4/CD8 CELLS NOT DONE,phaseiii_fm42.csv,FM42,continuous
CD4EDSLB,F42 II_13F   STUDY EXIT: TUBE LABEL (0.5 CC IN PURPLE TUBE),phaseiii_fm42.csv,FM42,continuous
GEN_CMNT,F42 III_1C   GENERAL COMMENTS REGARDING TO THE FILLED OUT FORM,phaseiii_fm42.csv,FM42,continuous
VIS_DT_DAYS,F42 I_5      VISIT DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm42.csv,FM42,continuous
HB2WDT_DAYS,F42 II_2ADT  HEP B 0-2 WEEKS VACCINATION DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm42.csv,FM42,continuous
DT6WDT_DAYS,F42 II_3ADT  6-WEEKS TO 2-MONTHS OF AGE VACCINATIONS DTP/DTAP DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm42.csv,FM42,continuous
HO6WDT_DAYS,F42 II_3BDT  6-WEEKS TO 2-MONTHS OF AGE VACCINATIONS HBOC/HIB DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm42.csv,FM42,continuous
OP6WDT_DAYS,F42 II_3CDT  6-WEEKS TO 2-MONTHS OF AGE VACCINATIONS OPV/IPV DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm42.csv,FM42,continuous
PN6WDT_DAYS,F42 II_3DDT  6-WEEKS TO 2-MONTHS OF AGE VACCINATIONS PNEUMO (PCV7) DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm42.csv,FM42,continuous
HB6WDT_DAYS,F42 II_3EDT  6-WEEKS TO 2-MONTHS OF AGE VACCINATIONS HEP B DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm42.csv,FM42,continuous
DT4MDT_DAYS,F42 II_4ADT  4-MONTHS OF AGE VACCINATIONS DTP/DTAP DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm42.csv,FM42,continuous
HO4MDT_DAYS,F42 II_4BDT  4-MONTHS OF AGE VACCINATIONS HBOC/HIB DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm42.csv,FM42,continuous
OP4MDT_DAYS,F42 II_4CDT  4-MONTHS OF AGE VACCINATIONS OPV/IPV DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm42.csv,FM42,continuous
PN4MDT_DAYS,F42 II_4DDT  4-MONTHS OF AGE VACCINATIONS PNEUMO (PCV 7) DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm42.csv,FM42,continuous
DT6MDT_DAYS,F42 II_5ADT  6-MONTHS OF AGE VACCINATIONS DTP/DTAP DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm42.csv,FM42,continuous
HO6MDT_DAYS,F42 II_5BDT  6-MONTHS OF AGE VACCINATIONS HBOC/HIB DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm42.csv,FM42,continuous
PN6MDT_DAYS,F42 II_5CDT  6-MONTHS OF AGE VACCINATIONS PNEUMO (PCV 7) DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm42.csv,FM42,continuous
DT12MDT_DAYS,F42 II_6ADT  6-18 MONTHS OF AGE VACCINATIONS DTP/DTAP DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm42.csv,FM42,continuous
HO12MDT_DAYS,F42 II_6BDT  6-18 MONTHS OF AGE VACCINATIONS HBOC/HIB DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm42.csv,FM42,continuous
OP12MDT_DAYS,F42 II_6CDT  6-18 MONTHS OF AGE VACCINATIONS IPV DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm42.csv,FM42,continuous
PN12MDT_DAYS,F42 II_6DDT  6-18 MONTHS OF AGE VACCINATIONS PNEUMO (PCV 7) DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm42.csv,FM42,continuous
HB12MDT1_DAYS,F42 II_6EDT  6-18 MONTHS OF AGE VACCINATIONS HEP B DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm42.csv,FM42,continuous
MM12MDT_DAYS,F42 II_6FDT  6-18 MONTHS OF AGE VACCINATIONS MMR DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm42.csv,FM42,continuous
VR12MDT_DAYS,F42 II_6GDT  6-18 MONTHS OF AGE VACCINATIONS VARICELLA DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm42.csv,FM42,continuous
INFLU1_DAYS,"F42 II_7A    DATE OF YEARLY INFLUENZA VACCINES, A (recode: number of days after date of eligibility or ineligibility)",phaseiii_fm42.csv,FM42,continuous
INFLU2_DAYS,"F42 II_7B    DATE OF YEARLY INFLUENZA VACCINES, B (recode: number of days after date of eligibility or ineligibility)",phaseiii_fm42.csv,FM42,continuous
INFLU3_DAYS,"F42 II_7C    DATE OF YEARLY INFLUENZA VACCINES, C (recode: number of days after date of eligibility or ineligibility)",phaseiii_fm42.csv,FM42,continuous
INFLU4_DAYS,"F42 II_7D    DATE OF YEARLY INFLUENZA VACCINES, D (recode: number of days after date of eligibility or ineligibility)",phaseiii_fm42.csv,FM42,continuous
OPBLDT_DAYS,F42 II_8ADT  STUDY ENTRY (PRE-TREATMENT): SERUM OPSONOPHAGOCYTIC + PNEUMOCOCAL ANTIBODY DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm42.csv,FM42,continuous
CD4BLDT_DAYS,F42 II_8CDT  STUDY ENTRY (PRE-TREATMENT): NAIVE AND MEMORY CD4/CD8 DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm42.csv,FM42,continuous
MMA12MDT_DAYS,F42 II_9ADT  2-6 WEEKS AFTER MMR: ANTIBODY TO MMR DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm42.csv,FM42,continuous
PCAB2YDT_DAYS,F42 II_10ADT 23-MONTH-OF-AGE BLOOD SAMPLES: ANTIBODY RESPONSE TO PNEUMO 23 DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm42.csv,FM42,continuous
MMA2YDT_DAYS,F42 II_10CDT 23-MONTH-OF-AGE BLOOD SAMPLES: ANTIBODY RESPONSE TO MMR DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm42.csv,FM42,continuous
CD42YDT_DAYS,F42 II_10EDT 23-MONTH-OF-AGE BLOOD SAMPLES: NAIVE AND MEMORY CD4/CD8 DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm42.csv,FM42,continuous
PN2YDT_DAYS,F42 II_11ADT 24-MONTH OF AGE VACCINATION PNEUMO 23 (23 PS) DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm42.csv,FM42,continuous
OC2YDT_DAYS,F42 II_12ADT 2-8 WEEKS AFTER 24-MONTH OF AGE VACCINATIONS: SERUM OPSONOPHAGOCYTIC + PNEUMOCOCAL ANTIBODY DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm42.csv,FM42,continuous
OCAEOSDT_DAYS,F42 II_13ADT STUDY EXIT: SERUM OPSONOPHAGOCYTIC + PNEUMOCOCCAL ANTIBODY DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm42.csv,FM42,continuous
MMAEOSDT_DAYS,F42 II_13CDT STUDY EXIT: ANTIBODY RESPONSE TO MMR DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm42.csv,FM42,continuous
CD4EDSDT_DAYS,F42 II_13EDT STUDY EXIT: NAIVE AND MEMORY CD4/CD8 CELLS DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm42.csv,FM42,continuous
ID,Unique patient identifier (randomized),phaseiii_fm43.csv,FM43,continuous
FORM,F43 FORM     STUDY FORM NUMBER,phaseiii_fm43.csv,FM43,continuous
REV,F43 REV      NUMBER OF THE FORM REVISONS,phaseiii_fm43.csv,FM43,continuous
VISIT,F43 I_4VIS   SUBJECT CLINICAL VISIT NUMBER,phaseiii_fm43.csv,FM43,categorical
SEQNO,F43 I_4SEQ   SUBJECT VISIT SEQUENCE NUMBER,phaseiii_fm43.csv,FM43,continuous
HANDED,F43 II_1     WHICH HAND DOES YOUR CHILD PREFER TO?,phaseiii_fm43.csv,FM43,continuous
SWALLOW,F43 II_2     HOW WOULD YOU DESCRIBE YOUR CHILD'S ABILITY TO SWALLOW?,phaseiii_fm43.csv,FM43,continuous
WALKCLMB,F43 II_3     HOW WOULD YOU DESCRIBE YOUR CHILD'S ABILITY TO WALK AND CLIMB STAIRS?,phaseiii_fm43.csv,FM43,continuous
DIAPNITE,F43 II_4A    DESCRIBE YOUR CHILD'S TOILETING: ROUTINELY WEARS DIAPERS AT NIGHT,phaseiii_fm43.csv,FM43,continuous
WETSNITE,F43 II_4B    DESCRIBE YOUR CHILD'S TOILETING: WETS AT NIGHT,phaseiii_fm43.csv,FM43,continuous
DIAP_DAY,F43 II_4C    DESCRIBE YOUR CHILD'S TOILETING: ROUTINELY WEARS DIAPERS IN DAYTIME,phaseiii_fm43.csv,FM43,continuous
WET_ACC,"F43 II_4C1   IF NOT WEARING DIAPERS IN DAYTIME, CURRENTLY EXPERIENCING WETTING ACCIDENTS",phaseiii_fm43.csv,FM43,continuous
TINGNUMB,"F43 II_5     DOES YOUR CHILD HAVE TINGLING, NUMBNESS, PINS AND NEEDLES, ELECTRIC SHOCK OR A BURNING SENSATION IN HIS/HER HANDS OR FEET?",phaseiii_fm43.csv,FM43,continuous
SEIZURE,F43 II_6     HAS YOUR CHILD EVER HAD A SEIZURE OR CONVULSION?,phaseiii_fm43.csv,FM43,continuous
SENSLOSS,F43 III_1    DOES THE CHILD HAVE SENSORY LOSS OR SENSORY DIMINISHMENT?,phaseiii_fm43.csv,FM43,continuous
DESCLOSR,"F43 III_1AR  WHICH BEST DESCRIBES THE CHANGE,  RIGHT",phaseiii_fm43.csv,FM43,continuous
DESCLOSL,"F43 III_1AL  WHICH BEST DESCRIBES THE CHANGE,  LEFT",phaseiii_fm43.csv,FM43,continuous
LOSSSTRG,F43 III_2    DOES THE CHILD HAVE LOSS OR DIMINISHMENT OF MOTOR FUNCTION?,phaseiii_fm43.csv,FM43,continuous
LOSSSTRU,F43 III_2A1  LOSS OF STREHGTH: RIGHT UPPER,phaseiii_fm43.csv,FM43,continuous
LOSSSTLU,F43 III_2A2  LOSS OF STREHGTH: LEFT UPPER,phaseiii_fm43.csv,FM43,continuous
LOSSSTRL,F43 III_2A3  LOSS OF STREHGTH: RIGHT LOWER,phaseiii_fm43.csv,FM43,continuous
LOSSSTLL,F43 III_2A4  LOSS OF STREHGTH: LEFT LOWER,phaseiii_fm43.csv,FM43,continuous
LOSSGMTR,F43 III_2A5  NONFOCAL IMPAIRMENT OF GROSS MOTOR DEVELOPMENT,phaseiii_fm43.csv,FM43,continuous
LOSSFMTR,F43 III_2A6  NONFOCAL IMPAIRMENT OF FINE MOTOR SKILLS,phaseiii_fm43.csv,FM43,continuous
LOSSTONE,F43 III_2B   WHICH BEST DESCRIBES THE CHANGE IN TONE?,phaseiii_fm43.csv,FM43,continuous
RFLXBICR,"F43 IV_1R    A BICEPS REFLEX,  RIGHT",phaseiii_fm43.csv,FM43,continuous
RFLXBICL,"F43 IV_1L    A BICEPS REFLEX,  LEFT",phaseiii_fm43.csv,FM43,continuous
RFLXKJR,"F43 IV_2R    KNEE JERK,  RIGHT",phaseiii_fm43.csv,FM43,continuous
RFLXKJL,"F43 IV_2L    KNEE JERK,  LEFT",phaseiii_fm43.csv,FM43,continuous
RFLXAJR,"F43 IV_3R    ANKLE JERK,  RIGHT",phaseiii_fm43.csv,FM43,continuous
RFLXAJL,"F43 IV_3L    ANKLE JERK,  LEFT",phaseiii_fm43.csv,FM43,continuous
RFLXACR,"F43 IV_4R    ANKLE CLONUS,  RIGHT",phaseiii_fm43.csv,FM43,continuous
RFLXACL,"F43 IV_4L    ANKLES CLONUS,  LEFT",phaseiii_fm43.csv,FM43,continuous
RFLXARR,"F43 IV_5R    CROSSED ADDUCTOR RESPONSE, RIGHT",phaseiii_fm43.csv,FM43,continuous
RFLXARL,"F43 IV_5L    CROSSED ADDUCTOR RESPONSE,  LEFT",phaseiii_fm43.csv,FM43,continuous
RFLXUPTR,"F43 IV_6R    UPGOING TOE,  RIGHT",phaseiii_fm43.csv,FM43,continuous
RFLXUPTL,"F43 IV_6L    UPGOING TOE,  LEFT",phaseiii_fm43.csv,FM43,continuous
WALKINDE,F43 V_1      DOES THE CHILD ORDINARILY WALK INDEPENDENTLY?,phaseiii_fm43.csv,FM43,continuous
CRWL9IN,F43 V_1A1    CRAWLS ON FOUR LIMBS FOR 9 INCHES OR MORE,phaseiii_fm43.csv,FM43,continuous
PULL2STD,F43 V_1A2    PULLS-TO-STAND,phaseiii_fm43.csv,FM43,continuous
STND3SEC,F43 V_1A3    STANDS ALONE FOR AT LEAST 3 SECONDS,phaseiii_fm43.csv,FM43,continuous
STND30S,F43 V_1A4    STANDS ALONE FOR AT LEAST 30 SECONDS,phaseiii_fm43.csv,FM43,continuous
STEP3SPT,F43 V_1A5    TAKES AT LEAST 3 STEPS WITH SUPPORT,phaseiii_fm43.csv,FM43,continuous
STEP3HOL,F43 V_1A6    TAKES AT LEAST 3 STEPS HOLDING ONTO FURNITURE,phaseiii_fm43.csv,FM43,continuous
STEP3ALN,F43 V_1A7    TAKES AT LEAST 3 STEPS WITHOUT SUPPORT,phaseiii_fm43.csv,FM43,continuous
STDUPALN,F43 V_1A8    GETS UP OFF FLOOR TO STANDING WITHOUT HELP,phaseiii_fm43.csv,FM43,continuous
WALK6FT,F43 V_1A9    WALKS INDEPENDENTLY FOR AT LEAST 6 FEET,phaseiii_fm43.csv,FM43,continuous
KNEEFLXR,"F43 V_1B1R   KNEE FLEXION,  RIGHT",phaseiii_fm43.csv,FM43,continuous
KNEEFLXL,"F43 V_1B1L   KNEE FLEXION,  LEFT",phaseiii_fm43.csv,FM43,continuous
KNEHYPER,"F43 V_1B2R   KNEE HYPEREXTENSION,  RIGHT",phaseiii_fm43.csv,FM43,continuous
KNEHYPEL,"F43 V_1B2L   KNEE HYPEREXTENSION, LEFT",phaseiii_fm43.csv,FM43,continuous
TOEWALKR,"F43 V_1B3R   TOE WALKING,  RIGHT",phaseiii_fm43.csv,FM43,continuous
TOEWALKL,"F43 V_1B3L   TOE WALKING,  LEFT",phaseiii_fm43.csv,FM43,continuous
CIRCGTR,"F43 V_1B4R   CIRCUMDUCTING GAIT,  RIGHT",phaseiii_fm43.csv,FM43,continuous
CIRCGTL,"F43 V_1B4L   CIRCUMDUCTING GAIT,  LEFT",phaseiii_fm43.csv,FM43,continuous
DECRSWNR,"F43 V_1B5R   DECREASING ARM SWING,  RIGHT",phaseiii_fm43.csv,FM43,continuous
DECRSWNL,"F43 V_1B5L   DECREASING ARM SWING,  LEFT",phaseiii_fm43.csv,FM43,continuous
CORARMPR,"F43 V_1B6R   CORTICAL ARM POSTURE,  RIGHT",phaseiii_fm43.csv,FM43,continuous
CORARMPL,"F43 V_1B6L   CORTICAL ARM POSTURE,  LEFT",phaseiii_fm43.csv,FM43,continuous
HYPOTOND,F43 VI_1AD   TONE HYPOTONIA DISTRIBUTION,phaseiii_fm43.csv,FM43,continuous
HYPOTONS,F43 VI_1AS   TONE HYPOTONIA SEVERITY,phaseiii_fm43.csv,FM43,continuous
HYPRTOND,F43 VI_1BD   TONE HYPERTONIA DISTRIBUTION,phaseiii_fm43.csv,FM43,continuous
HYPRTONS,F43 VI_1BS   TONE HYPERTONIA SEVERITY,phaseiii_fm43.csv,FM43,continuous
DIAGNOS,F43 VI_2     ARE ANY OF THE DIAGNOSES LISTED BELOW PRESENT TODAY?,phaseiii_fm43.csv,FM43,continuous
DIAGN_A,F43 VI_2ADS  DIAGNOSIS  A,phaseiii_fm43.csv,FM43,continuous
DIAGN_AS,F43 VI_2ASI  DIAGNOSIS  A SIDE,phaseiii_fm43.csv,FM43,continuous
DIAGNASP,"F43 VI_2ASP  DIAGNOSIS A,  SPECIFY",phaseiii_fm43.csv,FM43,continuous
DIAGN_B,F43 VI_2BDS  DIAGNOSIS B,phaseiii_fm43.csv,FM43,continuous
DIAGN_BS,F43 VI_2BSI  DIAGNOSIS B SIDE,phaseiii_fm43.csv,FM43,continuous
DIAGNBSP,"F43 VI_2BSP  DIAGNOSIS B,  SPECIFY",phaseiii_fm43.csv,FM43,continuous
DIAGN_C,F43 VI_2CDS  DIAGNOSIS C,phaseiii_fm43.csv,FM43,continuous
DIAGN_CS,F43 VI_2CSI  DIAGNOSIS C SIDE,phaseiii_fm43.csv,FM43,continuous
DIAGNCSP,"F43 VI_2CSP  DIAGNOSIS C,  SPECIFY",phaseiii_fm43.csv,FM43,continuous
NEURSTA1,"F43 VII_1    FROM A NEUROLOGICAL STANDPOINT, WHAT DO YOU THINK THE STATUS OF THE PATIENT IS SINCE LAST ASSESSMENT?",phaseiii_fm43.csv,FM43,continuous
NEURSTA2,"F43 VII_2    FROM A NEUROLOGICAL STANDPOINT, WHAT DO YOU THINK THE STATUS OF THE PATIENT IS SINCE INITITAL BASELINE ASSESSMENT?",phaseiii_fm43.csv,FM43,continuous
NEW_STRK,F43 VII_3A   SUMMARY FINDINGS NEW STROKE,phaseiii_fm43.csv,FM43,continuous
NEW_TIA,F43 VII_3B   SUMMARY FINDINGS NEW TIA,phaseiii_fm43.csv,FM43,continuous
F80VII4,F43 VII_4    FORM 80 SUBMITTED?,phaseiii_fm43.csv,FM43,continuous
GEN_CMNT,F43 VII_1C   GENERAL COMMENTS REGARDING TO THE FILLED OUT FORM,phaseiii_fm43.csv,FM43,continuous
VIS_DT_DAYS,F43 I_5      TESTING DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm43.csv,FM43,continuous
ID,Unique patient identifier (randomized),phaseiii_fm44.csv,FM44,continuous
FORM,F44 FORM     STUDY FORM NUMBER,phaseiii_fm44.csv,FM44,continuous
REV,F44 REV      NUMBER OF THE FORM REVISONS,phaseiii_fm44.csv,FM44,continuous
VISIT,F44 I_4VIS   SUBJECT CLINICAL VISIT NUMBER,phaseiii_fm44.csv,FM44,categorical
SEQNO,F44 I_4SEQ   SUBJECT VISIT SEQUENCE NUMBER,phaseiii_fm44.csv,FM44,continuous
CAMTYPE,F44 II_1     CAMERA MANUFACTURER,phaseiii_fm44.csv,FM44,categorical
CAMMODEL,F44 II-2     CAMERA MODEL,phaseiii_fm44.csv,FM44,categorical
COLLIMAT,F44 II_3     COLLIMATOR,phaseiii_fm44.csv,FM44,categorical
SUPCOLLD,F44 II_4     SUPPLIER OF TC-SULFUR COLLOID,phaseiii_fm44.csv,FM44,categorical
DOSINJ44,F44 II_5     DOSE INJECTED,phaseiii_fm44.csv,FM44,continuous
INJ44HR,"F44 II_6HR   TIME OF INJECTION (24-HOUR CLOCK), HOUR",phaseiii_fm44.csv,FM44,continuous
INJ44MN,"F44 II_6MN   TIME OF INJECTION (24-HOUR CLOCK), MINUTE",phaseiii_fm44.csv,FM44,continuous
IMSTRHR,"F44 II_7HR   TIME IMAGING STARTED, HOUR",phaseiii_fm44.csv,FM44,continuous
IMSTRMN,"F44 II_7MN   TIME IMAGING STARTED, MINUTE",phaseiii_fm44.csv,FM44,continuous
IMCOMHR,"F44 II_8HR   TIME IMAGING COMPLETED, HOUR",phaseiii_fm44.csv,FM44,continuous
IMCOMMN,"F44 II_8MN   TIME IMAGING COMPLETED, MINUTE",phaseiii_fm44.csv,FM44,continuous
CAMANGLE,F44 II_9     CAMERA ANGLE,phaseiii_fm44.csv,FM44,continuous
ANTPOSMN,"F44 II_10MN  TRUE POSTERIOR IMAGING TIME (MIN:SEC), MINUTE",phaseiii_fm44.csv,FM44,continuous
ANTPOSSC,"F44 II_10SC  TRUE POSTERIOR IMAGING TIME (MIN:SEC), SECOND",phaseiii_fm44.csv,FM44,continuous
OBLIMCNT,F44 II_11    RIGHT POSTERIOR OBLIQUE IMAGE COUNTS:,phaseiii_fm44.csv,FM44,continuous
LSSCNLBL,F44 II_12    FILM LABEL,phaseiii_fm44.csv,FM44,continuous
AOI400K,F44 II_13A   400 K IMAGE ADEQUATE?,phaseiii_fm44.csv,FM44,continuous
AOITIMED,F44 II_13B   TIMED IMAGE ADEQUATE?,phaseiii_fm44.csv,FM44,continuous
KASPLTOT,F44 III_1A1A 400K IMAGE: ANTERIOR VIEW SPLEEN TOTAL COUNTS,phaseiii_fm44.csv,FM44,continuous
KASPLPIX,F44 III_1A1B 400K IMAGE: ANTERIOR VIEW SPLEEN # PIXELS IN ROI,phaseiii_fm44.csv,FM44,continuous
KASPLCNT,F44 III_1A1C 400K IMAGE: ANTERIOR VIEW SPLEEN COUNTS/PIXEL,phaseiii_fm44.csv,FM44,continuous
KALIVTOT,F44 III_1A2A 400K IMAGE: ANTERIOR VIEW LIVER TOTAL COUNTS,phaseiii_fm44.csv,FM44,continuous
KALIVPIX,F44 III_1A2B 400K IMAGE: ANTERIOR VIEW LIVER # PIXELS IN ROI,phaseiii_fm44.csv,FM44,continuous
KALIVCNT,F44 III_1A2C 400K IMAGE: ANTERIOR VIEW LIVER COUNTS/PIXEL,phaseiii_fm44.csv,FM44,continuous
KPSPLTOT,F44 III_1B1A 400K IMAGE: POSTERIOR VIEW SPLEEN TOTAL COUNTS,phaseiii_fm44.csv,FM44,continuous
KPSPLPIX,F44 III_1B1B 400K IMAGE: POSTERIOR VIEW SPLEEN # PIXELS IN ROI,phaseiii_fm44.csv,FM44,continuous
KPSPLCNT,F44 III_1B1C 400K IMAGE: POSTERIOR VIEW SPLEEN COUNTS/PIXEL,phaseiii_fm44.csv,FM44,continuous
KPLIVTOT,F44 III_1B2A 400K IMAGE: POSTERIOR VIEW LIVER TOTAL COUNTS,phaseiii_fm44.csv,FM44,continuous
KPLIVPIX,F44 III_1B2B 400K IMAGE: POSTERIOR VIEW LIVER # PIXELS IN ROI,phaseiii_fm44.csv,FM44,continuous
KPLIVCNT,F44 III_1B2C 400K IMAGE: POSTERIOR VIEW LIVER COUNTS/PIXEL,phaseiii_fm44.csv,FM44,continuous
KSLRTTOT,F44 III_1C1  400K IMAGE: SPLEEN/LIVER RATIO TOTAL COUNTS,phaseiii_fm44.csv,FM44,continuous
KSLRTCNT,F44 III_1C2  400K IMAGE: SPLEEN/LIVER RATIO COUNTS/PIXEL,phaseiii_fm44.csv,FM44,continuous
TASPLTOT,F44 III_2A1A TIMED IMAGE: LEFT ANTERIOR OBLIQUE VIEW SPLEEN TOTAL COUNTS,phaseiii_fm44.csv,FM44,continuous
TASPLPIX,F44 III_2A1B TIMED IMAGE: LEFT ANTERIOR OBLIQUE VIEW SPLEEN # PIXELS IN ROI,phaseiii_fm44.csv,FM44,continuous
TASPLCNT,F44 III_2A1C TIMED IMAGE: LEFT ANTERIOR OBLIQUE VIEW SPLEEN COUNTS/PIXEL,phaseiii_fm44.csv,FM44,continuous
TALIVTOT,F44 III_2A2A TIMED IMAGE: LEFT ANTERIOR OBLIQUE VIEW LIVER TOTAL COUNTS,phaseiii_fm44.csv,FM44,continuous
TALIVPIX,F44 III_2A2B TIMED IMAGE: LEFT ANTERIOR OBLIQUE VIEW LIVER # PIXELS IN ROI,phaseiii_fm44.csv,FM44,continuous
TALIVCNT,F44 III_2A2C TIMED IMAGE: LEFT ANTERIOR OBLIQUE VIEW LIVER COUNTS/PIXEL,phaseiii_fm44.csv,FM44,continuous
TPSPLTOT,F44 III_2B1A TIMED IMAGE: RIGHT ANTERIOR OBLIQUE VIEW SPLEEN TOTAL COUNTS,phaseiii_fm44.csv,FM44,continuous
TPSPLPIX,F44 III_2B1B TIMED IMAGE: RIGHT ANTERIOR OBLIQUE VIEW SPLEEN # PIXELS IN ROI,phaseiii_fm44.csv,FM44,continuous
TPSPLCNT,F44 III_2B1C TIMED IMAGE: RIGHT  ANTERIOR OBLIQUE VIEW SPLEEN COUNTS/PIXEL,phaseiii_fm44.csv,FM44,continuous
TPLIVTOT,F44 III_2B2A TIMED IMAGE: RIGHT ANTERIOR OBLIQUE VIEW LIVER TOTAL COUNTS,phaseiii_fm44.csv,FM44,continuous
TPLIVPIX,F44 III_2B2B TIMED IMAGE: RIGHT ANTERIOR OBLIQUE VIEW LIVER # PIXELS IN ROI,phaseiii_fm44.csv,FM44,continuous
TPLIVCNT,F44 III_2B2C TIMED IMAGE: RIGHT ANTERIOR OBLIQUE VIEW LIVER COUNTS/PIXEL,phaseiii_fm44.csv,FM44,continuous
TSLRTTOT,F44 III_2C1  TIMED IMAGE: SPLEEN/LIVER RATIO TOTAL COUNTS,phaseiii_fm44.csv,FM44,continuous
TSLRTCNT,F44 III_2C2  TIMED IMAGE: SPLEEN/LIVER RATIO COUNTS/PIXEL,phaseiii_fm44.csv,FM44,continuous
GEN_CMNT,F44 IV_1C    GENERAL COMMENTS REGARDING TO THE FILLED OUT FORM,phaseiii_fm44.csv,FM44,continuous
VIS_DT_DAYS,F44 I_V      PROCEDURE DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm44.csv,FM44,continuous
ID,Unique patient identifier (randomized),phaseiii_fm45.csv,FM45,continuous
FORM,F45 FORM     STUDY FORM NUMBER,phaseiii_fm45.csv,FM45,continuous
REV,F45 REV      NUMBER OF THE FORM REVISONS,phaseiii_fm45.csv,FM45,continuous
VISIT,F45 I_4VIS   SUBJECT CLINICAL VISIT NUMBER,phaseiii_fm45.csv,FM45,categorical
SEQNO,F45 I_4SEQ   SUBJECT VISIT SEQUENCE NUMBER,phaseiii_fm45.csv,FM45,continuous
ABDSEQPT,F45 II_1     EQUIPMENT,phaseiii_fm45.csv,FM45,categorical
ABDSTRNS,F45 II_2     TRANSDUCER,phaseiii_fm45.csv,FM45,categorical
STATUS45,"F45 II_4     QUALITY OF STUDY, FORM 45",phaseiii_fm45.csv,FM45,continuous
SONO_LBL,F45 II_5     FILM LABEL,phaseiii_fm45.csv,FM45,continuous
GEN_CMNT,F45 IV_1C    GENERAL COMMENTS REGARDING TO THE FILLED OUT FORM,phaseiii_fm45.csv,FM45,continuous
VIS_DT_DAYS,F45 I_5      PROCEDURE DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm45.csv,FM45,continuous
ID,Unique patient identifier (randomized),phaseiii_fm46.csv,FM46,continuous
FORM,F46 FORM     STUDY FORM NUMBER,phaseiii_fm46.csv,FM46,continuous
REV,F46 REV      NUMBER OF THE FORM REVISONS,phaseiii_fm46.csv,FM46,continuous
VISIT,F46 I_4VIS   SUBJECT CLINICAL VISIT NUMBER,phaseiii_fm46.csv,FM46,categorical
SEQNO,F46 I_4SEQ   SUBJECT VISIT SEQUENCE NUMBER,phaseiii_fm46.csv,FM46,continuous
TCDMNUM,F46 II_2     TCD MACHINE SERIAL NUMBER,phaseiii_fm46.csv,FM46,categorical
PTNTPOS,F46 II_3     PATIENT'S POSITION DURING EXAM,phaseiii_fm46.csv,FM46,continuous
POS_SP,"F46 II_3A    PATIENT'S POSITION DURING EXAM,  SPECIFY",phaseiii_fm46.csv,FM46,continuous
PTNTCALM,"F46 III_1A   PATIENT'S COOPERATIVENESS DURING THE EXAM,  CALM",phaseiii_fm46.csv,FM46,continuous
PTNTCACT,"F46 III_1B   PATIENT'S COOPERATIVENESS DURING THE EXAM,  VERY ACTIVE",phaseiii_fm46.csv,FM46,continuous
PTNTCRY,"F46 III_1C   PATIENT'S COOPERATIVENESS DURING THE EXAM, CRYING/SCREAMING",phaseiii_fm46.csv,FM46,continuous
COMPEXAM,F46 III_2    COMPLETENESS OF EXAM,phaseiii_fm46.csv,FM46,continuous
INCEXAM,F46 III_2A   REASON FOR INCOMPLETE EXAM,phaseiii_fm46.csv,FM46,continuous
INCEX_SP,"F46 III_2A1  REASON FOR INCOMPLETE EXAM,  SPECIFY",phaseiii_fm46.csv,FM46,continuous
TCD_LBL,F46 III_2B   TCD LABEL,phaseiii_fm46.csv,FM46,continuous
GEN_CMNT,F46 IV_1C    GENERAL COMMENTS REGARDING TO THE FILLED OUT FORM,phaseiii_fm46.csv,FM46,continuous
VIS_DT_DAYS,F46 I_5      PROCEDURE DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm46.csv,FM46,continuous
ID,Unique patient identifier (randomized),phaseiii_fm47.csv,FM47,continuous
FORM,F47 FORM     STUDY FORM NUMBER,phaseiii_fm47.csv,FM47,continuous
REV,F47 REV      NUMBER OF THE FORM REVISONS,phaseiii_fm47.csv,FM47,continuous
VISIT,F47 I_4VIS   SUBJECT CLINICAL VISIT NUMBER,phaseiii_fm47.csv,FM47,categorical
SEQNO,F47 I_4SEQ   SUBJECT VISIT SEQUENCE NUMBER,phaseiii_fm47.csv,FM47,continuous
MRI,F47 II_1     MRI INTERPRETABLE?,phaseiii_fm47.csv,FM47,continuous
MRI_LBL,F47 II_2     MRI FILM LABEL,phaseiii_fm47.csv,FM47,continuous
MRA,F47 II_3     MRA INTERPRETABLE?,phaseiii_fm47.csv,FM47,continuous
STENOSIS,F47 II_3A    GREATER THAN 50% STENOSIS?,phaseiii_fm47.csv,FM47,continuous
MRA_LBL,F47 II_4     MRA FILM LABEL,phaseiii_fm47.csv,FM47,continuous
GEN_CMNT,F47 III_1C   GENERAL COMMENTS REGARDING TO THE FILLED OUT FORM,phaseiii_fm47.csv,FM47,continuous
VIS_DT_DAYS,F47 I_5      FILM DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm47.csv,FM47,continuous
ID,Unique patient identifier (randomized),phaseiii_fm51.csv,FM51,continuous
FORM,F51 FORM     STUDY FORM NUMBER,phaseiii_fm51.csv,FM51,continuous
REV,F51 REV      NUMBER OF THE FORM REVISONS,phaseiii_fm51.csv,FM51,continuous
VISIT,F51 I_4VIS   WEEK OF VISIT,phaseiii_fm51.csv,FM51,categorical
REASON,F51 II_1     PLEASE INDICATE WHY THIS FORM IS BEING SUBMITTED.,phaseiii_fm51.csv,FM51,continuous
SUPPLE,F51 III_1A   DID THE PATIENT RECEIVE SUPPLEMENTS?,phaseiii_fm51.csv,FM51,continuous
ANTIBIOT,F51 III_2A   DID THE PATIENT RECEIVE ANTIBIOTICS?,phaseiii_fm51.csv,FM51,continuous
ANALGES,F51 III_3A   DID THE PATIENT RECEIVE ANALGESICS?,phaseiii_fm51.csv,FM51,continuous
PULMONAR,F51 III_4A   DID THE PATIENT RECEIVE PULMONARY MEDICATIONS?,phaseiii_fm51.csv,FM51,continuous
TOPICALS,F51 III_5A   WAS THE PATIENT USING TOPICAL MEDICATIONS?,phaseiii_fm51.csv,FM51,continuous
OTHER,F51 III_6A   WAS THE PATIENT USING ANY OTHER MEDICATIONS?,phaseiii_fm51.csv,FM51,continuous
GEN_CMNT,F51          GENERAL COMMENTS REGARDING TO THE FILLED OUT FORM,phaseiii_fm51.csv,FM51,continuous
VIS_DT_DAYS,F51 I_5      CONCOMITANT MEDICATIONS COLLECTION START DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm51.csv,FM51,continuous
EVENT_DT_DAYS,F51 II_2     DATE OF CORRESPONDING EVENT (recode: number of days after date of eligibility or ineligibility),phaseiii_fm51.csv,FM51,continuous
ID,Unique patient identifier (randomized),phaseiii_fm51a.csv,FM51A,continuous
FORM,F51AFORM     STUDY FORM NUMBER,phaseiii_fm51a.csv,FM51A,categorical
REV,F51AREV      NUMBER OF THE FORM REVISONS,phaseiii_fm51a.csv,FM51A,continuous
VISIT,F51AI_4VIS   WEEK OF VISIT,phaseiii_fm51a.csv,FM51A,categorical
SEQNO,F51ASEQNO    SEQUENCE NUMBER OF THE VISIT,phaseiii_fm51a.csv,FM51A,continuous
ADD_MED,F51AINTERNAL ADDITIONAL MEDICATION,phaseiii_fm51a.csv,FM51A,continuous
MED_TYPE,F51AINTERNAL MEDICATION TYPE (THIS FIELD IS AUTO-POPULATED),phaseiii_fm51a.csv,FM51A,continuous
MED_CD,F51AINTERNAL MEDICATION CODE (THIS FIELD IS AUTO-POPULATED),phaseiii_fm51a.csv,FM51A,continuous
MED_NAME,F51A         MEDICATION NAME (THIS FIELD IS AUTO-POPULATED),phaseiii_fm51a.csv,FM51A,categorical
NOT_RECD,F51A(A)      NOT RECEIVED,phaseiii_fm51a.csv,FM51A,continuous
W3DPK,F51A(B)      WITHIN 3 DAYS OF PK COLLECTION,phaseiii_fm51a.csv,FM51A,continuous
W7DPK,F51A(C)      WITHIN 7 DAYS OF SAE ONSET,phaseiii_fm51a.csv,FM51A,continuous
CLOS_SAE,F51A(D)      UNTIL CLOSE OF SAE,phaseiii_fm51a.csv,FM51A,continuous
GEN_CMNT,F51AIV_1C    GENERAL COMMENTS REGARDING TO THE FILLED OUT FORM,phaseiii_fm51a.csv,FM51A,continuous
MAIN,F51AINTERNAL ANSWER TO THE LEADING QUESTION (THIS FIELD IS AUTO-POPULATED),phaseiii_fm51a.csv,FM51A,continuous
VIS_DT_DAYS,F51A         CONCOMITANT MEDICATIONS COLLECTION START DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm51a.csv,FM51A,continuous
ID,Unique patient identifier (randomized),phaseiii_fm52.csv,FM52,continuous
FORM,F52 FORM     STUDY FORM NUMBER,phaseiii_fm52.csv,FM52,continuous
REV,F52 REV      NUMBER OF THE FORM REVISONS,phaseiii_fm52.csv,FM52,continuous
VISIT,F52 I_4VIS   VISIT NUMBER,phaseiii_fm52.csv,FM52,continuous
SEQNO,F52 I_4SEQ   SEQUENCE NUMBER OF THE VISIT,phaseiii_fm52.csv,FM52,continuous
TR_TYPE,F52 II_1     TRANSFUSION TYPE,phaseiii_fm52.csv,FM52,continuous
TRVOLPR2,F52 II_2B    VOLUME OF PACKED RED CELLS TRANSFUSED,phaseiii_fm52.csv,FM52,continuous
TR_SP,F52 II_5     REASON FOR TRANSFUSION,phaseiii_fm52.csv,FM52,continuous
GEN_CMNT,F52 III_1C   GENERAL COMMENTS REGARDING TO THE FILLED OUT FORM,phaseiii_fm52.csv,FM52,continuous
VIS_DT_DAYS,F52 I_5      TRANSFUSION DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm52.csv,FM52,continuous
TSTRT_DT_DAYS,F52 II_3     TRANSFUSION START DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm52.csv,FM52,continuous
TSTOP_DT_DAYS,F52 II_4     TRANSFUSION STOP DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm52.csv,FM52,continuous
ID,Unique patient identifier (randomized),phaseiii_fm64.csv,FM64,continuous
FORM,F64 FORM     STUDY FORM NUMBER,phaseiii_fm64.csv,FM64,continuous
REV,F64 REV      NUMBER OF THE FORM REVISONS,phaseiii_fm64.csv,FM64,continuous
VISIT,F64 I_4VIS   VISIT NUMBER,phaseiii_fm64.csv,FM64,continuous
SEQNO,F64 I_4SEQ   SEQUENCE NUMBER OF THE VISIT,phaseiii_fm64.csv,FM64,continuous
STOPBY,F64 II_1     STOP ORDER INITIATED BY,phaseiii_fm64.csv,FM64,continuous
TPSTOPTX,F64 II_2     TYPE OF STOP ORDER,phaseiii_fm64.csv,FM64,continuous
CCSTOPTX,F64 II_3     IS CLINICAL CENTER STAFF DIRECTED TO CONTACT THE PATIENT'S CAREGIVER AND INSTRUCT HIM/HER TO STOP TAK STDY MED TO THE PATIENT?,phaseiii_fm64.csv,FM64,continuous
CCCONTPT,F64 III_1    DID THE CLINICAL CENTER STAFF CONTACT THE PATIENT'S CAREGIVER?,phaseiii_fm64.csv,FM64,continuous
CONTHR,"F64 III_1BHR STOP ORDER TIME,  HOUR",phaseiii_fm64.csv,FM64,continuous
CONTMN,"F64 III_1BMN STOP ORDER TIME,  MINUTES",phaseiii_fm64.csv,FM64,continuous
ATTMCONT,F64 III_2A   HOW MANY ATTEMPTS WERE MADE TO CONTACT THE PATIENT?,phaseiii_fm64.csv,FM64,continuous
ENDCONHR,"F64 III_2B2HRCONTACT ATTEMPTS ENDED,  HOUR",phaseiii_fm64.csv,FM64,continuous
ENDCONMN,"F64 III_2B2MNCONTACT ATTEMPTS ENDED,  MINUTES",phaseiii_fm64.csv,FM64,continuous
PTAGR,F64 III_3    DID PATIENT'S CAREGIVER AGREE TO STOP TAKING ALL STUDY TREATMENTS?,phaseiii_fm64.csv,FM64,continuous
PTAGRTRN,F64 III_4    DID PATIENT'S CAREGIVER AGREE TO RETURN ALL UNUSED STUDY MEDICATION AT NEXT CLINIC VISIT?,phaseiii_fm64.csv,FM64,continuous
GEN_CMNT,F64 IV_1C    GENERAL COMMENTS REGARDING TO THE FILLED OUT FORM,phaseiii_fm64.csv,FM64,continuous
VIS_DT_DAYS,F64 I_5      DATE OF ORDER (recode: number of days after date of eligibility or ineligibility),phaseiii_fm64.csv,FM64,continuous
CCCONTDT_DAYS,F64 III_1ADT STOP ORDER DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm64.csv,FM64,continuous
ENDCONDT_DAYS,F64 III_2B1DTDATE AND TIME CONTACT ATTEMPTS ENDED (recode: number of days after date of eligibility or ineligibility),phaseiii_fm64.csv,FM64,continuous
ID,Unique patient identifier (randomized),phaseiii_fm65.csv,FM65,continuous
FORM,F65 FORM     STUDY FORM NUMBER,phaseiii_fm65.csv,FM65,continuous
REV,F65 REV      NUMBER OF THE FORM REVISONS,phaseiii_fm65.csv,FM65,continuous
VISIT,F65 I_4VIS   VISIT NUMBER,phaseiii_fm65.csv,FM65,continuous
SEQNO,F65 I_4SEQ   SEQUENCE NUMBER OF THE VISIT,phaseiii_fm65.csv,FM65,continuous
RESTRTTY,F65 II_1     TYPE OF RESTART,phaseiii_fm65.csv,FM65,continuous
PATUNSTN,F65 II_2     DID PATIENT'S CAREGIVER RECEIVE AND UNDERSTAND INSTRUCTION?,phaseiii_fm65.csv,FM65,continuous
GEN_CMNT,F65 III_1C   GENERAL COMMENTS REGARDING TO THE FILLED OUT FORM,phaseiii_fm65.csv,FM65,continuous
VIS_DT_DAYS,F65 I_5      DATE OF ORDER (recode: number of days after date of eligibility or ineligibility),phaseiii_fm65.csv,FM65,continuous
ID,Unique patient identifier (randomized),phaseiii_fm66.csv,FM66,continuous
FORM,F66 FORM     STUDY FORM NUMBER,phaseiii_fm66.csv,FM66,continuous
REV,F66 REV      NUMBER OF THE FORM REVISONS,phaseiii_fm66.csv,FM66,continuous
VISIT,F66 I_4VIS   VISIT NUMBER,phaseiii_fm66.csv,FM66,continuous
SEQNO,F66 I_4SEQ   SEQUENCE NUMBER OF THE VISIT,phaseiii_fm66.csv,FM66,continuous
MEDEMERG,F66 II_3A    MEDICAL EMERGENCY,phaseiii_fm66.csv,FM66,continuous
NONMEDEM,F66 II_3B    NON-MEDICAL EMERGENCY,phaseiii_fm66.csv,FM66,continuous
OVERDOSE,F66 II_3C    POSSIBLE OR REAL STUDY TREATMENT OVERDOSE,phaseiii_fm66.csv,FM66,continuous
DOSOTHER,F66 II_3D    OTHER REASONS FOR DOSING IRREGULARITY OCCURRENCE,phaseiii_fm66.csv,FM66,continuous
DOS_SP,"F66 II_3D_1  IF OTHER, SPECIFY THE REASONS",phaseiii_fm66.csv,FM66,continuous
UNBLIND,F66 III_1    WAS THE PATIENT UNBLINDED?,phaseiii_fm66.csv,FM66,continuous
INDPRINV,F66 III_4A   PRINCIPAL INVESTIGATOR,phaseiii_fm66.csv,FM66,continuous
INDCOORD,F66 III_4B   CLINIC COORDINATOR,phaseiii_fm66.csv,FM66,continuous
INDPTNT,F66 III_4C   PATIENT/FAMILY,phaseiii_fm66.csv,FM66,continuous
INDOTHER,F66 III_4D   OTHER INDIVIDUALS INFORMED OF THE ASSIGNED STUDY TREATMENT,phaseiii_fm66.csv,FM66,continuous
GEN_CMNT,F66 IV_1C    GENERAL COMMENTS REGARDING TO THE FILLED OUT FORM,phaseiii_fm66.csv,FM66,continuous
VIS_DT_DAYS,F66 I_5      DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm66.csv,FM66,continuous
ID,Unique patient identifier (randomized),phaseiii_fm80.csv,FM80,continuous
FORM,F80 FORM     STUDY FORM NUMBER,phaseiii_fm80.csv,FM80,continuous
REV,F80 REV      NUMBER OF THE FORM REVISONS,phaseiii_fm80.csv,FM80,continuous
VISIT,F80 I_4VIS   VISIT NUMBER,phaseiii_fm80.csv,FM80,categorical
SEQNO,F80 I_4SEQ   SEQUENCE NUMBER OF THE VISIT,phaseiii_fm80.csv,FM80,continuous
FORM2,F80          FORM,phaseiii_fm80.csv,FM80,continuous
REV2,F80          REV,phaseiii_fm80.csv,FM80,continuous
PAGE,F80          PAGE,phaseiii_fm80.csv,FM80,continuous
GEN_CMNT,F80          GENERAL COMMENTS REGARDING TO THE FILLED OUT FORM,phaseiii_fm80.csv,FM80,continuous
VIS_DT_DAYS,F80 I_5      DATE OF REFERENCED FORM (recode: number of days after date of eligibility or ineligibility),phaseiii_fm80.csv,FM80,continuous
ID,Unique patient identifier (randomized),phaseiii_fm81.csv,FM81,continuous
FORM,F81 FORM     STUDY FORM NUMBER,phaseiii_fm81.csv,FM81,continuous
REV,F81 REV      NUMBER OF THE FORM REVISONS,phaseiii_fm81.csv,FM81,continuous
VISIT,F81 I_4VIS   VISIT NUMBER,phaseiii_fm81.csv,FM81,categorical
SEQNO,F81 I_4SEQ   SEQUENCE NUMBER OF THE VISIT,phaseiii_fm81.csv,FM81,continuous
MRI_LBL,F81 II_3     FILM LABEL,phaseiii_fm81.csv,FM81,continuous
QUAL81,F81 II_4     SCAN QUALITY,phaseiii_fm81.csv,FM81,continuous
VOLUM81,F81 II_5     VOLUMETRICS,phaseiii_fm81.csv,FM81,continuous
STATUS81,"F81 II_6     CURRENT READING STATUS, FORM 81",phaseiii_fm81.csv,FM81,continuous
F80II5A,"F81 II_6A    IF CURRENT READING STATUS IS (2) OR (3), FORM 80 SUBMITTED?",phaseiii_fm81.csv,FM81,continuous
ATROPHY,F81 II_7     GENERAL APPEARANCE,phaseiii_fm81.csv,FM81,continuous
ATR_GENL,F81 II_7A    IS THE ATROPHY GENERAL?,phaseiii_fm81.csv,FM81,continuous
ATRGSULC,F81 II_7A1   GENERAL: SULCAL,phaseiii_fm81.csv,FM81,continuous
ATRGVENT,F81 II_7A2   GENERAL: VENTRICULAR,phaseiii_fm81.csv,FM81,continuous
ATR_SEV,F81 II_7A3   GENERAL: LEVEL OF SEVERITY,phaseiii_fm81.csv,FM81,continuous
ATR_FOCL,F81 II_7B    FOCAL,phaseiii_fm81.csv,FM81,continuous
ATRFSULC,F81 II_7B1   FOCAL: SULCAL,phaseiii_fm81.csv,FM81,continuous
ATRFVENT,F81 II_7B2   FOCAL: VENTRICULAR,phaseiii_fm81.csv,FM81,continuous
FOCAL_SP,F81 II_7B3SP FOCAL: SPECIFY AREA,phaseiii_fm81.csv,FM81,continuous
FINDINGS,F81 III_1    DISCREET FINDINGS,phaseiii_fm81.csv,FM81,continuous
LSNA_SID,F81 III_1ASIDLESION SIDE A,phaseiii_fm81.csv,FM81,categorical
LSNA_TYP,F81 III_1ATYPLESION TYPE A,phaseiii_fm81.csv,FM81,categorical
LSNA_SIZ,F81 III_1ASIZLESION SIZE A,phaseiii_fm81.csv,FM81,continuous
LSNA_LC1,F81 III_1A1  LESION LOCATION A1,phaseiii_fm81.csv,FM81,continuous
LSNA_LC2,F81 III_1A2  LESION LOCATION A2,phaseiii_fm81.csv,FM81,continuous
LSNA_LC3,F81 III_1A3  LESION LOCATION A3,phaseiii_fm81.csv,FM81,continuous
LSNA_LC4,F81 III_1A4  LESION LOCATION A4,phaseiii_fm81.csv,FM81,continuous
LSNB_SID,F81 III_1BSIDLESION SIDE B,phaseiii_fm81.csv,FM81,categorical
LSNB_TYP,F81 III_1BTYPLESION TYPE B,phaseiii_fm81.csv,FM81,categorical
LSNB_SIZ,F81 III_1BSIZLESION SIZE B,phaseiii_fm81.csv,FM81,continuous
LSNB_LC1,F81 III_1B1  LESION LOCATION B1,phaseiii_fm81.csv,FM81,continuous
LSNB_LC2,F81 III_1B2  LESION LOCATION B2,phaseiii_fm81.csv,FM81,continuous
LSNB_LC3,F81 III_1B3  LESION LOCATION B3,phaseiii_fm81.csv,FM81,continuous
LSNB_LC4,F81 III_1B4  LESION LOCATION B4,phaseiii_fm81.csv,FM81,continuous
LSNC_SID,F81 III_1CSIDLESION SIDE C,phaseiii_fm81.csv,FM81,categorical
LSNC_TYP,F81 III_1CTYPLESION TYPE C,phaseiii_fm81.csv,FM81,categorical
LSNC_SIZ,F81 III_1CSIZLESION SIZE C,phaseiii_fm81.csv,FM81,continuous
LSNC_LC1,F81 III_1C1  LESION LOCATION C1,phaseiii_fm81.csv,FM81,continuous
LSNC_LC2,F81 III_1C2  LESION LOCATION C2,phaseiii_fm81.csv,FM81,continuous
LSNC_LC3,F81 III_1C3  LESION LOCATION C3,phaseiii_fm81.csv,FM81,continuous
LSNC_LC4,F81 III_1C4  LESION LOCATION C4,phaseiii_fm81.csv,FM81,continuous
LSND_SID,F81 III_1DSIDLESION SIDE D,phaseiii_fm81.csv,FM81,categorical
LSND_TYP,F81 III_1DTYPLESION TYPE D,phaseiii_fm81.csv,FM81,categorical
LSND_SIZ,F81 III_1DSIZLESION  SIZE D,phaseiii_fm81.csv,FM81,continuous
LSND_LC1,F81 III_1D1  LESION LOCATION D1,phaseiii_fm81.csv,FM81,continuous
LSND_LC2,F81 III_1D2  LESION LOCATION D2,phaseiii_fm81.csv,FM81,continuous
LSND_LC3,F81 III_1D3  LESION LOCATION D3,phaseiii_fm81.csv,FM81,continuous
LSND_LC4,F81 III_1D4  LESION LOCATION D4,phaseiii_fm81.csv,FM81,continuous
LSNE_SID,F81 III_1ESIDLESION SIDE E,phaseiii_fm81.csv,FM81,categorical
LSNE_TYP,F81 III_1ETYPLESION TYPE E,phaseiii_fm81.csv,FM81,continuous
LSNE_SIZ,F81 III_1ESIZLESION SIZE E,phaseiii_fm81.csv,FM81,continuous
LSNE_LC1,F81 III_1E1  LESION LOCATION E1,phaseiii_fm81.csv,FM81,continuous
LSNE_LC2,F81 III_1E2  LESION LOCATION E2,phaseiii_fm81.csv,FM81,continuous
LSNE_LC3,F81 III_1E3  LESION LOCATION E3,phaseiii_fm81.csv,FM81,continuous
LSNE_LC4,F81 III_1E4  LESION LOCATION E4,phaseiii_fm81.csv,FM81,continuous
VRIICC_R,"F81 III_2AR  VASCULAR REGION OF INFARCT: ICC,  RIGHT",phaseiii_fm81.csv,FM81,continuous
VRIICC_L,"F81 III_2AL  VASCULAR REGION OF INFARCT: ICC,  LEFT",phaseiii_fm81.csv,FM81,continuous
VRIICS_R,"F81 III_2BR  VASCULAR REGION OF INFARCT: ICS,  RIGHT",phaseiii_fm81.csv,FM81,continuous
VRIICS_L,"F81 III_2BL  VASCULAR REGION OF INFARCT: ICS,  LEFT",phaseiii_fm81.csv,FM81,continuous
VRIMCA_R,"F81 III_2CR  VASCULAR REGION OF INFARCT: MCA, RIGHT",phaseiii_fm81.csv,FM81,continuous
VRIMCA_L,"F81 III_2CL  VASCULAR REGION OF INFARCT: MCA, LEFT",phaseiii_fm81.csv,FM81,continuous
VRIACA_R,"F81 III_2DR  VASCULAR REGION OF INFARCT: ACA,  RIGHT",phaseiii_fm81.csv,FM81,continuous
VRIACA_L,"F81 III_2DL  VASCULAR REGION OF INFARCT: ACA,  LEFT",phaseiii_fm81.csv,FM81,continuous
VRIPCA_R,"F81 III_2ER  VASCULAR REGION OF INFARCT: PCA,  RIGHT",phaseiii_fm81.csv,FM81,continuous
VRIPCA_L,"F81 III_2EL  VASCULAR REGION OF INFARCT: PCA,  LEFT",phaseiii_fm81.csv,FM81,continuous
VRIBSL,F81 III_2F   VASCULAR REGION OF INFARCT: BASILAR,phaseiii_fm81.csv,FM81,continuous
VRIABZ,F81 III_2G   VASCULAR REGION OF INFARCT: ANTERIOR BORDER ZONE,phaseiii_fm81.csv,FM81,continuous
VRIPBZ,F81 III_2H   VASCULAR REGION OF INFARCT: POSTERIOR BORDER ZONE,phaseiii_fm81.csv,FM81,continuous
VRICSB,F81 III_2I   VASCULAR REGION OF INFARCT: CENTRUM SEMIOVALE BORDER ZONE,phaseiii_fm81.csv,FM81,continuous
VRISTR,F81 III_2J   VASCULAR REGION OF INFARCT: STRIATUM (LENTICULOSTRIATES),phaseiii_fm81.csv,FM81,continuous
BONY_CHG,F81 III_4    BONY CHANGES,phaseiii_fm81.csv,FM81,continuous
F80III4A,"F81 III_4A   IF BONE CHANGES IS FOCAL ABNORMALITY, FORM 80 SUBMITTED?",phaseiii_fm81.csv,FM81,continuous
OTHLESN,F81 III_5    OTHER LESIONS,phaseiii_fm81.csv,FM81,continuous
DWIFAVAI,F81 III_6    ARE DWI FILMS AVAILABLE FOR THIS REVIEW?,phaseiii_fm81.csv,FM81,continuous
F80III6A,"F81 III_6A   IF YES, FORM 80 SUBMITTED",phaseiii_fm81.csv,FM81,continuous
GEN_CMNT,F81 IV_1C    GENERAL COMMENTS REGARDING TO THE FILLED OUT FORM,phaseiii_fm81.csv,FM81,continuous
VIS_DT_DAYS,F81 I_5      FILM DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm81.csv,FM81,continuous
RDR81_DT_DAYS,F81 II_2DT   DATE READ (recode: number of days after date of eligibility or ineligibility),phaseiii_fm81.csv,FM81,continuous
ID,Unique patient identifier (randomized),phaseiii_fm82.csv,FM82,continuous
FORM,F82 FORM     STUDY FORM NUMBER,phaseiii_fm82.csv,FM82,continuous
REV,F82 REV      NUMBER OF THE FORM REVISONS,phaseiii_fm82.csv,FM82,continuous
VISIT,F82 I_4VIS   VISIT NUMBER,phaseiii_fm82.csv,FM82,categorical
SEQNO,F82 I_4SEQ   SEQUENCE NUMBER OF THE VISIT,phaseiii_fm82.csv,FM82,continuous
MRA_LBL,F82 II_3     FILM LABEL,phaseiii_fm82.csv,FM82,continuous
QUAL82,F82 II_4     SCAN QUALITY,phaseiii_fm82.csv,FM82,continuous
STATUS82,F82 II_5     CURRENT STATUS OF THIS READING,phaseiii_fm82.csv,FM82,continuous
ORRICA,F82 III_1A   RIGHT ICA OVERALL RATING,phaseiii_fm82.csv,FM82,continuous
ABRICA,F82 III_1B   RIGHT ICA  DESCRIPTION OF ABNORMALITY,phaseiii_fm82.csv,FM82,continuous
LSSRICA,F82 III_1C   RIGHT ICA  LENGTH OF STENOTIC SEGMENT,phaseiii_fm82.csv,FM82,continuous
INVSEGR1,F82 III_1D1  RIGHT ICA  INVOLVED SEGMENTS ONE,phaseiii_fm82.csv,FM82,continuous
INVSEGR2,F82 III_1D2  RIGHT ICA  INVOLVED SEGMENTS TWO,phaseiii_fm82.csv,FM82,continuous
INVSEGR3,F82 III_1D3  RIGHT ICA  INVOLVED SEGMENTS THREE,phaseiii_fm82.csv,FM82,continuous
INVSEGR4,F82 III_1D4  RIGHT ICA  INVOLVED SEGMENTS FOUR,phaseiii_fm82.csv,FM82,continuous
ORRMCA,F82 III_2A   RIGHT MCA OVERALL RATING,phaseiii_fm82.csv,FM82,continuous
ABRMCA,F82 III_2B   RIGHT MCA DESCRIPTION OF ABNORMALITY,phaseiii_fm82.csv,FM82,continuous
LSSRMCA,F82 III_2C   RIGHT MCA LENGHT OF STENOTIC SEGMENT,phaseiii_fm82.csv,FM82,continuous
ORRACA,F82 III_3A   RIGHT ACA OVERALL RATING,phaseiii_fm82.csv,FM82,continuous
ABRACA,F82 III_3B   RIGHT ACA DESCRIPTION OF ABNORMALITY,phaseiii_fm82.csv,FM82,continuous
LSSRACA,F82 III_3C   RIGHT ACA LENGTH OF STENOTIC SEGMENT,phaseiii_fm82.csv,FM82,continuous
ORLICA,F82 III_4A   LEFT ICA OVERALL RATING,phaseiii_fm82.csv,FM82,continuous
ABLICA,F82 III_4B   LEFT ICA DESCRIPTION OF ABNORMALITY,phaseiii_fm82.csv,FM82,continuous
LSSLICA,F82 III_4C   LEFT ICA LENGHT OF STENOTIC SEGMENT,phaseiii_fm82.csv,FM82,continuous
INVSEGL1,F82 III_4D1  LEFT ICA INVOLVED SEGMENT ONE,phaseiii_fm82.csv,FM82,continuous
INVSEGL2,F82 III_4D2  LEFT ICA INVOLVED SEGMENT TWO,phaseiii_fm82.csv,FM82,continuous
INVSEGL3,F82 III_4D3  LEFT ICA INVOLVED SEGMENT THREE,phaseiii_fm82.csv,FM82,continuous
INVSEGL4,F82 III_4D4  LEFT ICA INVOLVED SEGMENT FOUR,phaseiii_fm82.csv,FM82,continuous
ORLMCA,F82 III_5A   LEFT MCA OVERALL RATING,phaseiii_fm82.csv,FM82,continuous
ABLMCA,F82 III_5B   LEFT MCA DESCRIPTION OF ABNORMALITY,phaseiii_fm82.csv,FM82,continuous
LSSLMCA,F82 III_5C   LEFT MCA LENGTH OF STENOTIC SEGMENT,phaseiii_fm82.csv,FM82,continuous
ORLACA,F82 III_6A   LEFT ACA OVERALL RATING,phaseiii_fm82.csv,FM82,continuous
ABLACA,F82 III_6B   LEFT ACA DESCRIPTION OF ABNORMALITY,phaseiii_fm82.csv,FM82,continuous
LSSLACA,F82 III_6C   LEFT ACA LENGTH OF STENOTIC SEGMENT,phaseiii_fm82.csv,FM82,continuous
ORBASIL,F82 III_7A   BASILAR OVERALL RATING,phaseiii_fm82.csv,FM82,continuous
LSSBASIL,F82 III_7C   BASILAR LENGHT OF STENOTIC SEGMENT,phaseiii_fm82.csv,FM82,continuous
ORMRA,F82 III_8A   OVERALL MRA OVERALL RATING,phaseiii_fm82.csv,FM82,continuous
ABMRA,F82 III_8B   OVERALL MRA DESCRIPTION OF ABNORMALITY,phaseiii_fm82.csv,FM82,continuous
LSSMRA,F82 III_8C   OVERALL MRA LENGHT OF STENOTIC SEGMENT,phaseiii_fm82.csv,FM82,continuous
INVSEG1,F82 III_8D1  OVERALL MRA INVOLVED SEGMENT ONE,phaseiii_fm82.csv,FM82,continuous
INVSEG2,F82 III_8D2  OVERALL MRA INVOLVED SEGMENT TWO,phaseiii_fm82.csv,FM82,continuous
INVSEG3,F82 III_8D3  OVERALL MRA INVOLVED SEGMENT THREE,phaseiii_fm82.csv,FM82,continuous
INVSEG4,F82 III_8D4  OVERALL MRA INVOLVED SEGMENT FOUR,phaseiii_fm82.csv,FM82,continuous
BLDVSLS,F82 III_9    COLLATERAL BLOOD VESSELS (MARK ONE):,phaseiii_fm82.csv,FM82,continuous
FM80III7,"F82 III_10   IF NARRATIVE PROVIDED, COMPLETE FORM 80",phaseiii_fm82.csv,FM82,continuous
GEN_CMNT,F82 IV_1C    GENERAL COMMENTS REGARDING TO THE FILLED OUT FORM,phaseiii_fm82.csv,FM82,continuous
VIS_DT_DAYS,F82 I_5      FILM DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm82.csv,FM82,continuous
RDR82_DT_DAYS,F82 II_2     DATE READ (recode: number of days after date of eligibility or ineligibility),phaseiii_fm82.csv,FM82,continuous
ID,Unique patient identifier (randomized),phaseiii_fm84.csv,FM84,continuous
FORM,F84 FORM     STUDY FORM NUMBER,phaseiii_fm84.csv,FM84,continuous
REV,F84 REV      NUMBER OF THE FORM REVISONS,phaseiii_fm84.csv,FM84,continuous
VISIT,F84 I_4VIS   VISIT NUMBER,phaseiii_fm84.csv,FM84,categorical
SEQNO,F84 I_4SEQ   SEQUENCE NUMBER OF THE VISIT,phaseiii_fm84.csv,FM84,continuous
LSSCNLBL,F84 II-3     FILM LABEL NUMBER,phaseiii_fm84.csv,FM84,continuous
QUAL84,F84 II_4     CURRENT STATUS OF THIS READING,phaseiii_fm84.csv,FM84,continuous
F80II3A,"F84 II_4A    IF ITEM 4 IS (2), SUBMIT FORM 80",phaseiii_fm84.csv,FM84,continuous
SPLUPT84,F84 III_1    SPLENIC UPTAKE,phaseiii_fm84.csv,FM84,continuous
GEN_CMNT,F84 IV_1C    GENERAL COMMENTS REGARDING TO THE FILLED OUT FORM,phaseiii_fm84.csv,FM84,continuous
VIS_DT_DAYS,F84 I_5      PROCEDURE DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm84.csv,FM84,continuous
RD84_DT_DAYS,F84 II_2     DATE OF READING (recode: number of days after date of eligibility or ineligibility),phaseiii_fm84.csv,FM84,continuous
ID,Unique patient identifier (randomized),phaseiii_fm85.csv,FM85,continuous
FORM,F85 FORM     STUDY FORM NUMBER,phaseiii_fm85.csv,FM85,continuous
REV,F85 REV      NUMBER OF THE FORM REVISONS,phaseiii_fm85.csv,FM85,continuous
VISIT,F85 I_4VIS   VISIT NUMBER,phaseiii_fm85.csv,FM85,categorical
SEQNO,F85 I_4SEQ   SEQUENCE NUMBER OF THE VISIT,phaseiii_fm85.csv,FM85,continuous
STATUS85,F85 II_3     CURRENT STATUS OF THIS READING,phaseiii_fm85.csv,FM85,continuous
F80II3A,"F85 II_3A    IF STATUS85 IS (2) OR (3), SUBMIT FORM 80",phaseiii_fm85.csv,FM85,continuous
GALBLA85,F85 III_1    GALLBLADDER,phaseiii_fm85.csv,FM85,continuous
GBWALL85,F85 III_1A   GALLBLADDER: WALL,phaseiii_fm85.csv,FM85,continuous
GBCDV85,F85 III_1B   GALLBLADDER: COLOR DOPPLER VASCULARITY,phaseiii_fm85.csv,FM85,continuous
GBNSTN85,F85 III_1C1  GALLBLADDER: NUMBER OF STONES,phaseiii_fm85.csv,FM85,continuous
GBMSTN85,F85 III_1C2  GALLBLADDER: MULTIPLE STONES NOT COUNTABLE,phaseiii_fm85.csv,FM85,continuous
GBLGST85,F85 III_1D   GALLBLADDER: LARGEST STONE,phaseiii_fm85.csv,FM85,continuous
GBLGSTNA,F85 III_1DNA GALLBLADDER: LARGEST STONE ( NOT APPLICABLE),phaseiii_fm85.csv,FM85,continuous
GBSFM85,F85 III_1E   GALLBLADDER: STONES FREELY MOBILE,phaseiii_fm85.csv,FM85,continuous
GBCBD85,F85 III_1F1  GALLBLADDER: COMMON BILE DUCT,phaseiii_fm85.csv,FM85,continuous
GBPAND85,F85 III_1F2  GALLBLADDER: PANCREATIC DUCT,phaseiii_fm85.csv,FM85,continuous
GBIHEP85,F85 III_1F3  GALLBLADDER: INTRAHEPATIC DUCTS,phaseiii_fm85.csv,FM85,continuous
GBSLDG85,F85 III_1G   GALLBLADDER: SLUDGE,phaseiii_fm85.csv,FM85,continuous
GBPRFL85,F85 III_1H   GALLBLADDER: PERICHOLECYSTIC FLUID,phaseiii_fm85.csv,FM85,continuous
SPLEEN85,F85 III_2    SPLEEN PRESENCE,phaseiii_fm85.csv,FM85,continuous
ACCSPL85,F85 III_2A   SPLEEN: ACCESSORY SPLEEN(S),phaseiii_fm85.csv,FM85,continuous
SPLCLN85,F85 III_2B   SPLEEN: CEPHALOCAUDAD LENGTH,phaseiii_fm85.csv,FM85,continuous
SPLTRN85,F85 III_2C   SPLEEN: TRANSVERSE,phaseiii_fm85.csv,FM85,continuous
SPLANP85,F85 III_2D   SPLEEN: ANTERIOR - POSTERIOR,phaseiii_fm85.csv,FM85,continuous
SPLVOL85,F85 III_2E   SPLEEN: ESTIMATED TOTAL SPLEEN VOLUME,phaseiii_fm85.csv,FM85,continuous
SPLVOLND,F85 III_2END SPLEEN: TOTAL SPLEEN VOLUME NOT DONE,phaseiii_fm85.csv,FM85,continuous
SPLHOM85,F85 III_2F   SPLEEN: HOMOGENEITY,phaseiii_fm85.csv,FM85,continuous
F80III2F,"F85 III_2F1  SPLEEN: IF INHOMOGENEOUS, SUBMIT FORM 80",phaseiii_fm85.csv,FM85,continuous
RKIDN85,F85 III_3    RIGHT KIDNEY,phaseiii_fm85.csv,FM85,continuous
RKVOL85,F85 III_3A   RIGHT KIDNEY: ESTIMATED VOLUME,phaseiii_fm85.csv,FM85,continuous
RKRPAR85,F85 III_3B   RIGHT KIDNEY: RENAL PARENCHYMA,phaseiii_fm85.csv,FM85,continuous
RKRPEX85,"F85 III_3B1  IF ABNORMAL, EXPLAIN:",phaseiii_fm85.csv,FM85,continuous
RKECHO85,F85 III_3C   RIGHT KIDNEY: ECHOGENICITY,phaseiii_fm85.csv,FM85,continuous
RKECEX85,"F85 III_3C1  IF ABNORMAL, EXPLAIN:",phaseiii_fm85.csv,FM85,continuous
LKID85,F85 III_4    LEFT KIDNEY,phaseiii_fm85.csv,FM85,continuous
LKVOL85,F85 III_4A   LEFT KIDNEY: ESTIMATED VOLUME,phaseiii_fm85.csv,FM85,continuous
LKRPAR85,F85 III_4B   LEFT KIDNEY: RENAL PARENCHYMA,phaseiii_fm85.csv,FM85,continuous
LKRPEX85,"F85 III_4B1  LEFT KIDNEY: IF ABNORMAL, EXPLAIN:",phaseiii_fm85.csv,FM85,continuous
LKECHO85,F85 III_4C   LEFT KIDNEY: ECHOGENICITY,phaseiii_fm85.csv,FM85,continuous
LKECEX85,"F85 III_4C1  LEFT KIDNEY: IF ABNORMAL, EXPLAIN:",phaseiii_fm85.csv,FM85,continuous
LVRENL85,F85 III_5    LIVER ENLARGED,phaseiii_fm85.csv,FM85,continuous
ABDABN85,F85 III_6    ANY OTHER ABDOMINAL ABNORMALITIES,phaseiii_fm85.csv,FM85,continuous
F80III5A,"F85 III_6A   IF YES, SUBMIT FORM 80",phaseiii_fm85.csv,FM85,continuous
GEN_CMNT,F85 IV_1C    GENERAL COMMENTS REGARDING TO THE FILLED OUT FORM,phaseiii_fm85.csv,FM85,continuous
SPLVLCAL,F85          SPLEEN: CALCULATED TOTAL SPLEEN VOLUME,phaseiii_fm85.csv,FM85,continuous
VIS_DT_DAYS,F85 I_5      PROCEDURE DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fm85.csv,FM85,continuous
RDR85_DT_DAYS,F85 II_2     DATE OF READING (recode: number of days after date of eligibility or ineligibility),phaseiii_fm85.csv,FM85,continuous
ID,Unique patient identifier (randomized),phaseiii_fmcomment.csv,FMCOMMENT,continuous
FORM,FORM NUMBER,phaseiii_fmcomment.csv,FMCOMMENT,continuous
REV,FORM REVISION NUMBER,phaseiii_fmcomment.csv,FMCOMMENT,continuous
VISIT,VISIT NUMBER,phaseiii_fmcomment.csv,FMCOMMENT,categorical
SEQNO,FORM SEQUENCE NUMBER,phaseiii_fmcomment.csv,FMCOMMENT,continuous
COL_NAME,COMMENT FIELD,phaseiii_fmcomment.csv,FMCOMMENT,categorical
VIS_DT_DAYS,VISIT DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_fmcomment.csv,FMCOMMENT,continuous
ID,Unique patient identifier (randomized),phaseiii_immunology_mmr.csv,IMMUNOLOGY_MMR,continuous
MMA12MLB,TUBE LABEL: BASELINE,phaseiii_immunology_mmr.csv,IMMUNOLOGY_MMR,continuous
BOX_NUM,BOX NUMBER,phaseiii_immunology_mmr.csv,IMMUNOLOGY_MMR,continuous
MEASLES_12M,MEASLES ANTIBODY INDEX: BASELINE,phaseiii_immunology_mmr.csv,IMMUNOLOGY_MMR,continuous
MUMPS_12M,MUMPS ANTIBODY INDEX: BASELINE,phaseiii_immunology_mmr.csv,IMMUNOLOGY_MMR,continuous
RUBELLA_12M,RUBELLA ANTIBODY INDEX: BASELINE,phaseiii_immunology_mmr.csv,IMMUNOLOGY_MMR,categorical
MMA2YLBL,TUBE LABEL: AT AGE OF TWO YEARS,phaseiii_immunology_mmr.csv,IMMUNOLOGY_MMR,continuous
MEASLES_2Y,MEASLES ANTIBODY INDEX: AT AGE OF 24 MONTHS,phaseiii_immunology_mmr.csv,IMMUNOLOGY_MMR,categorical
MUMPS_2Y,MUMPS ANTIBODY INDEX: AT AGE OF 24 MONTHS,phaseiii_immunology_mmr.csv,IMMUNOLOGY_MMR,continuous
RUBELLA_2Y,RUBELLA ANTIBODY INDEX: AT AGE OF 24 MONTHS,phaseiii_immunology_mmr.csv,IMMUNOLOGY_MMR,categorical
MMAEOSLB,TUBE LABEL: EXIT,phaseiii_immunology_mmr.csv,IMMUNOLOGY_MMR,continuous
MEASLES_EOS,MEASLES ANTIBODY INDEX: EXIT,phaseiii_immunology_mmr.csv,IMMUNOLOGY_MMR,categorical
MUMPS_EOS,MUMPS ANTIBODY INDEX: EXIT,phaseiii_immunology_mmr.csv,IMMUNOLOGY_MMR,continuous
RUBELLA_EOS,RUBELLA ANTIBODY INDEX: EXIT,phaseiii_immunology_mmr.csv,IMMUNOLOGY_MMR,categorical
MMA12MDT_DAYS,DATE OF ANTIBODY TO MMR AT BASELINE (recode: number of days after date of eligibility or ineligibility),phaseiii_immunology_mmr.csv,IMMUNOLOGY_MMR,continuous
MMA2YDT_DAYS,DATE OF ANTIBODY RESPONSE TO MMR AT AGE OF TWO YEARS (recode: number of days after date of eligibility or ineligibility),phaseiii_immunology_mmr.csv,IMMUNOLOGY_MMR,continuous
MMAEOSDT_DAYS,DATE OF ANTIBODY RESPONSE TO MMR AT STUDY EXIT (recode: number of days after date of eligibility or ineligibility),phaseiii_immunology_mmr.csv,IMMUNOLOGY_MMR,continuous
ID,Unique patient identifier (randomized),phaseiii_inventory.csv,INVENTORY,continuous
ELIGSTAT,STATUS OF ELIGIBILITY (1 = ELIGIBLE; 2 = INELIGIBLE),phaseiii_inventory.csv,INVENTORY,continuous
TRT_GRP,TREATMENT GROUP (1 = HU; 2 = Placebo),phaseiii_inventory.csv,INVENTORY,continuous
MTD,MAXIMUM TOLERANCE DOSE (mg),phaseiii_inventory.csv,INVENTORY,continuous
MTD_VIS,VISIT OF REACHING MAXIMUM TOLERANCE DOSE,phaseiii_inventory.csv,INVENTORY,continuous
KIT,DRUG KIT NUMBER,phaseiii_inventory.csv,INVENTORY,categorical
MTD_VIS_ACT,ACTUAL VISIT OF REACHING MAXIMUM TOLERANCE DOSE,phaseiii_inventory.csv,INVENTORY,continuous
SEQNO,SUBJECT SEQUENCE NUMBER,phaseiii_inventory.csv,INVENTORY,continuous
TRT_AGE,AGE AT TREATMENT INITIATION (MONTH),phaseiii_inventory.csv,INVENTORY,continuous
SIBLING_RAND,RANDOMIZED ID OF SIBLINGS,phaseiii_inventory.csv,INVENTORY,continuous
MATCH_ID_RAND,RANDOMIZED ID OF MATCHED SUBJECT,phaseiii_inventory.csv,INVENTORY,continuous
SCRN_DT_DAYS,DATE OF SCREENING (recode: number of days after date of eligibility or ineligibility),phaseiii_inventory.csv,INVENTORY,continuous
TRT_DT_DAYS,DATE OF TREATMENT INITIATION (recode: number of days after date of eligibility or ineligibility),phaseiii_inventory.csv,INVENTORY,continuous
DEATH_DT_DAYS,DATE OF DEATH (recode: number of days after date of eligibility or ineligibility),phaseiii_inventory.csv,INVENTORY,continuous
EXIT_DT_DAYS,DATE OF EXIT (recode: number of days after date of eligibility or ineligibility),phaseiii_inventory.csv,INVENTORY,continuous
ID,Unique patient identifier (randomized),phaseiii_labs.csv,LABS,continuous
FORM,FORM NUMBER,phaseiii_labs.csv,LABS,continuous
VISIT,VISIT NUMBER,phaseiii_labs.csv,LABS,categorical
LABEL,SAMPLE LABEL,phaseiii_labs.csv,LABS,continuous
LAB,LABORATORY TYPE,phaseiii_labs.csv,LABS,categorical
HB,HEMOGLOBIN (HB) (g/dL),phaseiii_labs.csv,LABS,categorical
PCV,PACKED CELL VOLUME (%),phaseiii_labs.csv,LABS,categorical
HBF,FETAL HEMOGLOBIN (HBF) (%),phaseiii_labs.csv,LABS,categorical
MCV,MEAN CORPUSCULAR VOLUME (MCV) (fL),phaseiii_labs.csv,LABS,categorical
PLAT,PLATELET COUNT (K/mm^3),phaseiii_labs.csv,LABS,categorical
NEUT_PT,NEUTROPHILS (% OF WBC),phaseiii_labs.csv,LABS,categorical
LYMPH_PT,LYMPHOCYTES (%OF WBC),phaseiii_labs.csv,LABS,categorical
RETIC_PT,RETICULOCYTES (%OF RBC),phaseiii_labs.csv,LABS,categorical
NEUT_CT,NEUTROPHIL COUNT (K/mm^3),phaseiii_labs.csv,LABS,categorical
LYMPH_CT,LYMPHOCYTE COUNT,phaseiii_labs.csv,LABS,categorical
RETIC_CT,RETICULOCYTE COUNT (K/mm^3),phaseiii_labs.csv,LABS,categorical
WBC,WHITE BLOOD CELL COUNT (K/mm^3),phaseiii_labs.csv,LABS,categorical
RBC,RED BLOOD CELL COUNT (M/mm^3),phaseiii_labs.csv,LABS,categorical
MCH,MEAN CORPUSCULAR HB (PG),phaseiii_labs.csv,LABS,categorical
MCHC,MEAN CORPUSCULAR HB CONCENTRATION (g/dL),phaseiii_labs.csv,LABS,categorical
NRBC,NUCLEATED RED BLOOD CELLS (% of WBC),phaseiii_labs.csv,LABS,categorical
CWBC,CORRECTED WBC (K/mm^3),phaseiii_labs.csv,LABS,categorical
F_CELL,FETAL CELLS BY CYTOFLOW (%),phaseiii_labs.csv,LABS,categorical
MONO_CT,MONOCYTE COUNT,phaseiii_labs.csv,LABS,categorical
MONO_PT,MONOCYTE (%),phaseiii_labs.csv,LABS,categorical
CREAT,SERUM CREATININE (mg/dL),phaseiii_labs.csv,LABS,categorical
T_BILI,TOTAL BILIRUBIN (mg/dL),phaseiii_labs.csv,LABS,categorical
UREA_N,UREA N (mg/dL),phaseiii_labs.csv,LABS,categorical
ALT,ALANINE TRANSAMINASE (ALT) (/dL),phaseiii_labs.csv,LABS,categorical
FERRITIN,FERRITIN (ng/mL),phaseiii_labs.csv,LABS,categorical
D_BILI,DIRECT BILIRUBIN (mg/dL),phaseiii_labs.csv,LABS,categorical
CA,CALCIUM (mg/dL),phaseiii_labs.csv,LABS,categorical
PO4,INORGANIC PHOSPHOROUS (mg/dL),phaseiii_labs.csv,LABS,categorical
MG,MAGNESIUM (mg/dL),phaseiii_labs.csv,LABS,categorical
CREAT_H,CREATININE BY HPLC (mg/dL),phaseiii_labs.csv,LABS,categorical
PIT_CELL,PITTED CELLS (%),phaseiii_labs.csv,LABS,continuous
PENICIL,PENICILLIN (1 = YES; 2 = NO),phaseiii_labs.csv,LABS,continuous
HBA_PCT,GEL ELECTROPHORESIS %HBA,phaseiii_labs.csv,LABS,categorical
HBA2_PCT,GEL ELECTROPHORESIS %HBA2,phaseiii_labs.csv,LABS,categorical
HBS_PCT,GEL ELECTROPHORESIS %HBS,phaseiii_labs.csv,LABS,categorical
HBF_PCT,GE L ELECTROPHORESIS %HBF,phaseiii_labs.csv,LABS,categorical
HBOTHR,GEL ELECTROPHHORESIS % OTHER,phaseiii_labs.csv,LABS,categorical
S_OSMO,SERUM OSMOLALITY (MOSM),phaseiii_labs.csv,LABS,categorical
U_OSMO,URINE OSMOLALITY (MOSM),phaseiii_labs.csv,LABS,categorical
NAIV_CD4,NAIVE CD4 COUNT (/uL),phaseiii_labs.csv,LABS,categorical
NAIV_CD8,NAIVE CD8 COUNT (/uL),phaseiii_labs.csv,LABS,categorical
MEM_CD4,MEMORY CD4 COUNT (/uL),phaseiii_labs.csv,LABS,categorical
MEM_CD8,MEMORY CD8 COUNT (/uL),phaseiii_labs.csv,LABS,categorical
ABS_CD4,ABS CD4 COUNT (/uL),phaseiii_labs.csv,LABS,categorical
ABS_CD8,ABS CD8 COUNT (/uL),phaseiii_labs.csv,LABS,categorical
WBC_IMM,WBC (/uL),phaseiii_labs.csv,LABS,continuous
LYMPHIMM,LYMPHOCYTES %,phaseiii_labs.csv,LABS,continuous
LYMCTIMM,LYMPHOCYTES COUNT (K/mm^3),phaseiii_labs.csv,LABS,categorical
PER_CD3,CD3 %,phaseiii_labs.csv,LABS,continuous
PER_CD4,CD4 %,phaseiii_labs.csv,LABS,continuous
PER_CD8,CD8 %,phaseiii_labs.csv,LABS,continuous
CD4PP,CD4+CD45RA/CD45RO +/+,phaseiii_labs.csv,LABS,continuous
CD4PM,CD4+CD45RA/CD45RO +/-,phaseiii_labs.csv,LABS,continuous
CD4MP,CD4+CD45RA/CD45RO -/+,phaseiii_labs.csv,LABS,continuous
CD4MM,CD4+CD45RA/CD45RO -/-,phaseiii_labs.csv,LABS,continuous
CD8PP,CD8+CD45RA/CD45RO +/+,phaseiii_labs.csv,LABS,continuous
CD8PM,CD8+CD45RA/CD45RO +/-,phaseiii_labs.csv,LABS,continuous
CD8MP,CD8+CD45RA/CD45RO -/+,phaseiii_labs.csv,LABS,continuous
CD8MM,CD8+CD45RA/CD45RO -/-,phaseiii_labs.csv,LABS,continuous
VIS_DT_DAYS,VISIT DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_labs.csv,LABS,continuous
LABDATE_DAYS,DATE RECEIVED BY LAB (recode: number of days after date of eligibility or ineligibility),phaseiii_labs.csv,LABS,continuous
ID,Unique patient identifier (randomized),phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
FORM,FORM NUMBER,phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
VISIT,VISIT NUMBER,phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,categorical
LABEL,SAMPLE LABEL,phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
LAB,LABORATORY TYPE,phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,categorical
HB,HEMOGLOBIN (HB) (g/dL),phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
PCV,PACKED CELL VOLUME (%),phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
HBF,FETAL HEMOGLOBIN (HBF) (%),phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
MCV,MEAN CORPUSCULAR VOLUME (MCV) (fL),phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
PLAT,PLATELET COUNT (K/mm^3),phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
NEUT_PT,NEUTROPHILS (% OF WBC),phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
LYMPH_PT,LYMPHOCYTES (%OF WBC),phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
RETIC_PT,RETICULOCYTES (%OF RBC),phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
NEUT_CT,NEUTROPHIL COUNT (K/mm^3),phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
LYMPH_CT,LYMPHOCYTE COUNT,phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
RETIC_CT,RETICULOCYTE COUNT (K/mm^3),phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
WBC,WHITE BLOOD CELL COUNT (K/mm^3),phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
RBC,RED BLOOD CELL COUNT (M/mm^3),phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
MCH,MEAN CORPUSCULAR HB (PG),phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
MCHC,MEAN CORPUSCULAR HB CONCENTRATION (g/dL),phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
NRBC,NUCLEATED RED BLOOD CELLS (% of WBC),phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
CWBC,CORRECTED WBC (K/mm^3),phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
F_CELL,FETAL CELLS BY CYTOFLOW (%),phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
MONO_CT,MONOCYTE COUNT,phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
MONO_PT,MONOCYTE (%),phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
HBA_PCT,GEL ELECTROPHORESIS %HBA,phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
HBA2_PCT,GEL ELECTROPHORESIS %HBA2,phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
HBS_PCT,GEL ELECTROPHORESIS %HBS,phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
HBF_PCT,GE L ELECTROPHORESIS %HBF,phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
HBOTHR,GEL ELECTROPHHORESIS % OTHER,phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
S_OSMO,SERUM OSMOLALITY (MOSM),phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
U_OSMO,URINE OSMOLALITY (MOSM),phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
CREAT,SERUM CREATININE (mg/dL),phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
T_BILI,TOTAL BILIRUBIN (mg/dL),phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
UREA_N,UREA N (mg/dL),phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
ALT,ALANINE TRANSAMINASE (ALT) (/dL),phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
FERRITIN,FERRITIN (ng/mL),phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
D_BILI,DIRECT BILIRUBIN (mg/dL),phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
CA,CALCIUM (mg/dL),phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
PO4,INORGANIC PHOSPHOROUS (mg/dL),phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
MG,MAGNESIUM (mg/dL),phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
CREAT_H,CREATININE BY HPLC (mg/dL),phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
PIT_CELL,PITTED CELLS (%),phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
PENICIL,PENICILLIN (1 = YES; 2 = NO),phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
NAIV_CD4,NAIVE CD4 COUNT (/uL),phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
NAIV_CD8,NAIVE CD8 COUNT (/uL),phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
MEM_CD4,MEMORY CD4 COUNT (/uL),phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
MEM_CD8,MEMORY CD8 COUNT (/uL),phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
ABS_CD4,ABS CD4 COUNT (/uL),phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
ABS_CD8,ABS CD8 COUNT (/uL),phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
WBC_IMM,WBC (/uL),phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
LYMPHIMM,LYMPHOCYTES %,phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
LYMCTIMM,LYMPHOCYTES COUNT (K/mm^3),phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
PER_CD3,CD3 %,phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
PER_CD4,CD4 %,phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
PER_CD8,CD8 %,phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
CD4PP,CD4+CD45RA/CD45RO +/+,phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
CD4PM,CD4+CD45RA/CD45RO +/-,phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
CD4MP,CD4+CD45RA/CD45RO -/+,phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
CD4MM,CD4+CD45RA/CD45RO -/-,phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
CD8PP,CD8+CD45RA/CD45RO +/+,phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
CD8PM,CD8+CD45RA/CD45RO +/-,phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
CD8MP,CD8+CD45RA/CD45RO -/+,phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
CD8MM,CD8+CD45RA/CD45RO -/-,phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
VIS_DT_DAYS,VISIT DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
LABDATE_DAYS,DATE RECEIVED BY LAB (recode: number of days after date of eligibility or ineligibility),phaseiii_labs_central_numeric.csv,LABS_CENTRAL_NUMERIC,continuous
ID,Unique patient identifier (randomized),phaseiii_labs_history.csv,LABS_HISTORY,continuous
FORM,FORM NUMBER,phaseiii_labs_history.csv,LABS_HISTORY,continuous
VISIT,VISIT NUMBER,phaseiii_labs_history.csv,LABS_HISTORY,categorical
LABEL,SAMPLE LABEL,phaseiii_labs_history.csv,LABS_HISTORY,continuous
LAB,LABORATORY TYPE,phaseiii_labs_history.csv,LABS_HISTORY,categorical
HB,HEMOGLOBIN (HB) (g/dL),phaseiii_labs_history.csv,LABS_HISTORY,categorical
PCV,PACKED CELL VOLUME (%),phaseiii_labs_history.csv,LABS_HISTORY,categorical
HBF,FETAL HEMOGLOBIN (HBF) (%),phaseiii_labs_history.csv,LABS_HISTORY,categorical
MCV,MEAN CORPUSCULAR VOLUME (MCV) (fL),phaseiii_labs_history.csv,LABS_HISTORY,categorical
PLAT,PLATELET COUNT (K/mm^3),phaseiii_labs_history.csv,LABS_HISTORY,categorical
NEUT_PT,NEUTROPHILS (% OF WBC),phaseiii_labs_history.csv,LABS_HISTORY,categorical
LYMPH_PT,LYMPHOCYTES (%OF WBC),phaseiii_labs_history.csv,LABS_HISTORY,categorical
RETIC_PT,RETICULOCYTES (%OF RBC),phaseiii_labs_history.csv,LABS_HISTORY,categorical
NEUT_CT,NEUTROPHIL COUNT (K/mm^3),phaseiii_labs_history.csv,LABS_HISTORY,categorical
LYMPH_CT,LYMPHOCYTE COUNT,phaseiii_labs_history.csv,LABS_HISTORY,categorical
RETIC_CT,RETICULOCYTE COUNT (K/mm^3),phaseiii_labs_history.csv,LABS_HISTORY,categorical
WBC,WHITE BLOOD CELL COUNT (K/mm^3),phaseiii_labs_history.csv,LABS_HISTORY,categorical
RBC,RED BLOOD CELL COUNT (M/mm^3),phaseiii_labs_history.csv,LABS_HISTORY,categorical
MCH,MEAN CORPUSCULAR HB (PG),phaseiii_labs_history.csv,LABS_HISTORY,categorical
MCHC,MEAN CORPUSCULAR HB CONCENTRATION (g/dL),phaseiii_labs_history.csv,LABS_HISTORY,categorical
NRBC,NUCLEATED RED BLOOD CELLS (% of WBC),phaseiii_labs_history.csv,LABS_HISTORY,categorical
CWBC,CORRECTED WBC (K/mm^3),phaseiii_labs_history.csv,LABS_HISTORY,categorical
F_CELL,FETAL CELLS BY CYTOFLOW (%),phaseiii_labs_history.csv,LABS_HISTORY,categorical
MONO_CT,MONOCYTE COUNT,phaseiii_labs_history.csv,LABS_HISTORY,categorical
MONO_PT,MONOCYTE (%),phaseiii_labs_history.csv,LABS_HISTORY,categorical
CREAT,SERUM CREATININE (mg/dL),phaseiii_labs_history.csv,LABS_HISTORY,categorical
T_BILI,TOTAL BILIRUBIN (mg/dL),phaseiii_labs_history.csv,LABS_HISTORY,categorical
UREA_N,UREA N (mg/dL),phaseiii_labs_history.csv,LABS_HISTORY,categorical
ALT,ALANINE TRANSAMINASE (ALT) (/dL),phaseiii_labs_history.csv,LABS_HISTORY,categorical
FERRITIN,FERRITIN (ng/mL),phaseiii_labs_history.csv,LABS_HISTORY,categorical
D_BILI,DIRECT BILIRUBIN (mg/dL),phaseiii_labs_history.csv,LABS_HISTORY,categorical
CA,CALCIUM (mg/dL),phaseiii_labs_history.csv,LABS_HISTORY,categorical
PO4,INORGANIC PHOSPHOROUS (mg/dL),phaseiii_labs_history.csv,LABS_HISTORY,categorical
MG,MAGNESIUM (mg/dL),phaseiii_labs_history.csv,LABS_HISTORY,categorical
CREAT_H,CREATININE BY HPLC (mg/dL),phaseiii_labs_history.csv,LABS_HISTORY,categorical
PIT_CELL,PITTED CELLS (%),phaseiii_labs_history.csv,LABS_HISTORY,continuous
PENICIL,PENICILLIN (1 = YES; 2 = NO),phaseiii_labs_history.csv,LABS_HISTORY,continuous
HBA_PCT,GEL ELECTROPHORESIS %HBA,phaseiii_labs_history.csv,LABS_HISTORY,categorical
HBA2_PCT,GEL ELECTROPHORESIS %HBA2,phaseiii_labs_history.csv,LABS_HISTORY,categorical
HBS_PCT,GEL ELECTROPHORESIS %HBS,phaseiii_labs_history.csv,LABS_HISTORY,categorical
HBF_PCT,GE L ELECTROPHORESIS %HBF,phaseiii_labs_history.csv,LABS_HISTORY,categorical
HBOTHR,GEL ELECTROPHHORESIS % OTHER,phaseiii_labs_history.csv,LABS_HISTORY,categorical
S_OSMO,SERUM OSMOLALITY (MOSM),phaseiii_labs_history.csv,LABS_HISTORY,categorical
U_OSMO,URINE OSMOLALITY (MOSM),phaseiii_labs_history.csv,LABS_HISTORY,categorical
NAIV_CD4,NAIVE CD4 COUNT (/uL),phaseiii_labs_history.csv,LABS_HISTORY,categorical
NAIV_CD8,NAIVE CD8 COUNT (/uL),phaseiii_labs_history.csv,LABS_HISTORY,categorical
MEM_CD4,MEMORY CD4 COUNT (/uL),phaseiii_labs_history.csv,LABS_HISTORY,categorical
MEM_CD8,MEMORY CD8 COUNT (/uL),phaseiii_labs_history.csv,LABS_HISTORY,categorical
ABS_CD4,ABS CD4 COUNT (/uL),phaseiii_labs_history.csv,LABS_HISTORY,categorical
ABS_CD8,ABS CD8 COUNT (/uL),phaseiii_labs_history.csv,LABS_HISTORY,categorical
WBC_IMM,WBC (/uL),phaseiii_labs_history.csv,LABS_HISTORY,continuous
LYMPHIMM,LYMPHOCYTES %,phaseiii_labs_history.csv,LABS_HISTORY,continuous
LYMCTIMM,LYMPHOCYTES COUNT (K/mm^3),phaseiii_labs_history.csv,LABS_HISTORY,categorical
PER_CD3,CD3 %,phaseiii_labs_history.csv,LABS_HISTORY,continuous
PER_CD4,CD4 %,phaseiii_labs_history.csv,LABS_HISTORY,continuous
PER_CD8,CD8 %,phaseiii_labs_history.csv,LABS_HISTORY,continuous
CD4PP,CD4+CD45RA/CD45RO +/+,phaseiii_labs_history.csv,LABS_HISTORY,continuous
CD4PM,CD4+CD45RA/CD45RO +/-,phaseiii_labs_history.csv,LABS_HISTORY,continuous
CD4MP,CD4+CD45RA/CD45RO -/+,phaseiii_labs_history.csv,LABS_HISTORY,continuous
CD4MM,CD4+CD45RA/CD45RO -/-,phaseiii_labs_history.csv,LABS_HISTORY,continuous
CD8PP,CD8+CD45RA/CD45RO +/+,phaseiii_labs_history.csv,LABS_HISTORY,continuous
CD8PM,CD8+CD45RA/CD45RO +/-,phaseiii_labs_history.csv,LABS_HISTORY,continuous
CD8MP,CD8+CD45RA/CD45RO -/+,phaseiii_labs_history.csv,LABS_HISTORY,continuous
CD8MM,CD8+CD45RA/CD45RO -/-,phaseiii_labs_history.csv,LABS_HISTORY,continuous
VIS_DT_DAYS,VISIT DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_labs_history.csv,LABS_HISTORY,continuous
LABDATE_DAYS,DATE RECEIVED BY LAB (recode: number of days after date of eligibility or ineligibility),phaseiii_labs_history.csv,LABS_HISTORY,continuous
ID,Unique patient identifier (randomized),phaseiii_protocol_dev.csv,PROTOCOL_DEV,continuous
DVSEQ,Sequence number,phaseiii_protocol_dev.csv,PROTOCOL_DEV,continuous
VIOLATION_DT_DAYS,VISIT DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_protocol_dev.csv,PROTOCOL_DEV,continuous
ID,Unique patient identifier (randomized),phaseiii_titration.csv,TITRATION,continuous
EXP,EXPECTED VISIT NUMBER,phaseiii_titration.csv,TITRATION,categorical
VISIT,ACTUAL VISIT NUMBER,phaseiii_titration.csv,TITRATION,categorical
TIT_DOSE,TIT_DOSE (mg),phaseiii_titration.csv,TITRATION,continuous
CUR_DOSE,CURRENT DOSE (mg),phaseiii_titration.csv,TITRATION,continuous
TOXSTAT,TOXICITY STATUS(1 = YES; 2 = NO; 3 = MISSED VISIT),phaseiii_titration.csv,TITRATION,continuous
STOPSTAT,STOP REASON (1 = TOXICITY; 2 = PHYSICIAN ORDER),phaseiii_titration.csv,TITRATION,continuous
ISSUE_STOP,ISSUE STOP (1 = YES; 2= NO;),phaseiii_titration.csv,TITRATION,continuous
RESOLVED,ISSUE RESOLVED? (1 = YES; 2 = NO;),phaseiii_titration.csv,TITRATION,continuous
WKNONTOX,TIME WITHOUT TOXICITY (WEEK),phaseiii_titration.csv,TITRATION,continuous
NEW_DOSE,NEW DOSE (mg),phaseiii_titration.csv,TITRATION,continuous
WEIGHT,SUBJECT WEIGHT (kg),phaseiii_titration.csv,TITRATION,continuous
MTD_FLG,MTD FLAG (1 = YES; 0 = NO),phaseiii_titration.csv,TITRATION,continuous
VIS_DT_DAYS,ACTUAL VISIT DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_titration.csv,TITRATION,continuous
STOP_DT_DAYS,STOP DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_titration.csv,TITRATION,continuous
ID,Unique patient identifier (randomized),phaseiii_v_cytogenetics.csv,V_CYTOGENETICS,continuous
VISIT,VISIT NUMBER,phaseiii_v_cytogenetics.csv,V_CYTOGENETICS,categorical
LABEL,LABEL NUMBER,phaseiii_v_cytogenetics.csv,V_CYTOGENETICS,continuous
SPECTYPE,SPECIMEN TYPE,phaseiii_v_cytogenetics.csv,V_CYTOGENETICS,categorical
BANDANL,CHROMOSOME BANDING ANALYSIS,phaseiii_v_cytogenetics.csv,V_CYTOGENETICS,categorical
RESOLUTN,Resolution (Bands),phaseiii_v_cytogenetics.csv,V_CYTOGENETICS,continuous
BA_MPANL,NUMBER OF METAPHASES ANALYZED,phaseiii_v_cytogenetics.csv,V_CYTOGENETICS,continuous
BA_MPKRT,NUMBER OF METAPHASES KARYOTYPED,phaseiii_v_cytogenetics.csv,V_CYTOGENETICS,continuous
CHROMS,NUMBER OF CHROMOSOMES,phaseiii_v_cytogenetics.csv,V_CYTOGENETICS,continuous
CHRTYPE,SEX CHROMOSOME TYPE,phaseiii_v_cytogenetics.csv,V_CYTOGENETICS,categorical
BA_ABN,CLONAL CYTOGENETIC ABNORMALITIES,phaseiii_v_cytogenetics.csv,V_CYTOGENETICS,categorical
BREAKANL,CHROMOSOME BREAKAGE ANALYSIS,phaseiii_v_cytogenetics.csv,V_CYTOGENETICS,categorical
BR_MPANL,NUMBER OF METAPHASES ANALYZED FOR CHROMOSOME BREAKAGE ANALYSIS,phaseiii_v_cytogenetics.csv,V_CYTOGENETICS,continuous
CHRBREAK,NUMBER OF CHROMOSOME BREAKS,phaseiii_v_cytogenetics.csv,V_CYTOGENETICS,continuous
CMBREAK,NUMBER OF CHROMATID BREAKS,phaseiii_v_cytogenetics.csv,V_CYTOGENETICS,continuous
BR_CELL,BREAKS/CELL,phaseiii_v_cytogenetics.csv,V_CYTOGENETICS,continuous
ID.1,,phaseiii_v_cytogenetics.csv,,continuous
VIS_DT_DAYS,VISIT DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_v_cytogenetics.csv,V_CYTOGENETICS,continuous
LABDATE_DAYS,DATE OF SPECIMEN RECEIVED (recode: number of days after date of eligibility or ineligibility),phaseiii_v_cytogenetics.csv,V_CYTOGENETICS,continuous
REPDATE_DAYS,DATE OF REPORT (recode: number of days after date of eligibility or ineligibility),phaseiii_v_cytogenetics.csv,V_CYTOGENETICS,continuous
ID,Unique patient identifier (randomized),phaseiii_v_dna_vdj.csv,V_DNA_VDJ,continuous
LABEL,SAMPLE LABEL,phaseiii_v_dna_vdj.csv,V_DNA_VDJ,categorical
VISIT,VISIT NUMBER,phaseiii_v_dna_vdj.csv,V_DNA_VDJ,categorical
BLOOD_ML,BLOOD(ml),phaseiii_v_dna_vdj.csv,V_DNA_VDJ,continuous
PBMC,PBMC DNA(ug),phaseiii_v_dna_vdj.csv,V_DNA_VDJ,continuous
PMN,PMN TOTAL(ug),phaseiii_v_dna_vdj.csv,V_DNA_VDJ,continuous
TESTING,VDJ TESTING,phaseiii_v_dna_vdj.csv,V_DNA_VDJ,categorical
PCRAVG,AVERAGE PCR,phaseiii_v_dna_vdj.csv,V_DNA_VDJ,continuous
PCRAVGR,INVERSE AVERAGE PCR,phaseiii_v_dna_vdj.csv,V_DNA_VDJ,continuous
HJB_STAT,HJB STATUS,phaseiii_v_dna_vdj.csv,V_DNA_VDJ,categorical
PCTRETIC,YOUNG RETICULOCYTES(%),phaseiii_v_dna_vdj.csv,V_DNA_VDJ,continuous
YRETWHJB,YOUNG RETICULOCYTES WITH HJB(%),phaseiii_v_dna_vdj.csv,V_DNA_VDJ,continuous
PRBCWHJB,MATURE RBC WITH HJB(%),phaseiii_v_dna_vdj.csv,V_DNA_VDJ,continuous
MATRBC,MATURE RBC WITH HJB(No.),phaseiii_v_dna_vdj.csv,V_DNA_VDJ,continuous
LABDATE_DAYS,DATE OF SPECIMEN RECEIVED (recode: number of days after date of eligibility or ineligibility),phaseiii_v_dna_vdj.csv,V_DNA_VDJ,continuous
ID,Unique patient identifier (randomized),phaseiii_v_tcd.csv,V_TCD,continuous
VISIT,VISIT NUMBER,phaseiii_v_tcd.csv,V_TCD,categorical
LABEL,LABEL NUMBER,phaseiii_v_tcd.csv,V_TCD,continuous
RESULTS,RESULTS,phaseiii_v_tcd.csv,V_TCD,categorical
HDIAM,HEAD DIAMETER (cm),phaseiii_v_tcd.csv,V_TCD,continuous
LM1DE,Left Side M-1: Depth,phaseiii_v_tcd.csv,V_TCD,continuous
LM1M,Left Side M-1: Mean Velocity (cm/s),phaseiii_v_tcd.csv,V_TCD,continuous
LM1S,Left Side M-1: Waveform Systolic Measurement (cm/s),phaseiii_v_tcd.csv,V_TCD,continuous
LM1D,Left Side M-1: Waveform Diastolic Measurement (cm/s),phaseiii_v_tcd.csv,V_TCD,continuous
LM1PI,Left Side M-1: Waveform Pulsatility Index,phaseiii_v_tcd.csv,V_TCD,continuous
LM1RI,Left Side M-1: Waveform Resistance Index,phaseiii_v_tcd.csv,V_TCD,continuous
LMCADE,Left Side MCA: Depth,phaseiii_v_tcd.csv,V_TCD,continuous
LMCAM,Left Side MCA: Mean Velocity (cm/s),phaseiii_v_tcd.csv,V_TCD,continuous
LMCAS,Left Side MCA: Waveform Systolic Measurement (cm/s),phaseiii_v_tcd.csv,V_TCD,continuous
LMCAD,Left Side MCA: Waveform Diastolic Measurement (cm/s),phaseiii_v_tcd.csv,V_TCD,continuous
LMCAPI,Left Side MCA: Waveform Pulsatility Index,phaseiii_v_tcd.csv,V_TCD,continuous
LMCARI,Left Side MCA: Waveform Resistance Index,phaseiii_v_tcd.csv,V_TCD,continuous
LBIFDE,Left Side BIF: Depth,phaseiii_v_tcd.csv,V_TCD,continuous
LBIFM,Left Side BIF: Mean Velocity (cm/s),phaseiii_v_tcd.csv,V_TCD,continuous
LBIFS,Left Side BIF: Waveform Systolic Measurement (cm/s),phaseiii_v_tcd.csv,V_TCD,continuous
LBIFD,Left Side BIF: Waveform Diastolic Measurement (cm/s),phaseiii_v_tcd.csv,V_TCD,continuous
LBIFPI,Left Side BIF: Waveform Pulsatility Index,phaseiii_v_tcd.csv,V_TCD,continuous
LBIFRI,Left Side BIF: Waveform Resistance Index,phaseiii_v_tcd.csv,V_TCD,continuous
LACADE,Left Side ACA: Depth,phaseiii_v_tcd.csv,V_TCD,continuous
LACAM,Left Side ACA: Mean Velocity (cm/s),phaseiii_v_tcd.csv,V_TCD,continuous
LACAS,Left Side ACA: Waveform Systolic Measurement (cm/s),phaseiii_v_tcd.csv,V_TCD,continuous
LACAD,Left Side ACA: Waveform Diastolic Measurement (cm/s),phaseiii_v_tcd.csv,V_TCD,continuous
LACAPI,Left Side ACA: Waveform Pulsatility Index,phaseiii_v_tcd.csv,V_TCD,continuous
LACARI,Left Side ACA: Waveform Resistance Index,phaseiii_v_tcd.csv,V_TCD,continuous
LICADE,Left Side dICA: Depth,phaseiii_v_tcd.csv,V_TCD,continuous
LICAM,Left Side dICA: Mean Velocity (cm/s),phaseiii_v_tcd.csv,V_TCD,continuous
LICAS,Left Side dICA: Waveform Systolic Measurement (cm/s),phaseiii_v_tcd.csv,V_TCD,continuous
LICAD,Left Side dICA: Waveform Diastolic Measurement (cm/s),phaseiii_v_tcd.csv,V_TCD,continuous
LICAPI,Left Side dICA: Waveform Pulsatility Index,phaseiii_v_tcd.csv,V_TCD,continuous
LICARI,Left Side dICA: Waveform Resistance Index,phaseiii_v_tcd.csv,V_TCD,continuous
LPCADE,Left Side PCA: Depth,phaseiii_v_tcd.csv,V_TCD,continuous
LPCAM,Left Side PCA: Mean Velocity (cm/s),phaseiii_v_tcd.csv,V_TCD,continuous
LPCAS,Left Side PCA: Waveform Systolic Measurement (cm/s),phaseiii_v_tcd.csv,V_TCD,continuous
LPCAD,Left Side PCA: Waveform Diastolic Measurement (cm/s),phaseiii_v_tcd.csv,V_TCD,continuous
LPCAPI,Left Side PCA: Waveform Pulsatility Index,phaseiii_v_tcd.csv,V_TCD,continuous
LPCARI,Left Side PCA: Waveform Resistance Index,phaseiii_v_tcd.csv,V_TCD,continuous
LTOBDE,Left Side TOB: Depth,phaseiii_v_tcd.csv,V_TCD,continuous
LTOBM,Left Side TOB: Mean Velocity (cm/s),phaseiii_v_tcd.csv,V_TCD,continuous
LTOBS,Left Side TOB: Waveform Systolic Measurement (cm/s),phaseiii_v_tcd.csv,V_TCD,continuous
LTOBD,Left Side TOB: Waveform Diastolic Measurement (cm/s),phaseiii_v_tcd.csv,V_TCD,continuous
LTOBPI,Left Side TOB: Waveform Pulsatility Index,phaseiii_v_tcd.csv,V_TCD,continuous
LTOBRI,Left Side TOB: Waveform Resistance Index,phaseiii_v_tcd.csv,V_TCD,continuous
RM1DE,Right Side M-1: Depth,phaseiii_v_tcd.csv,V_TCD,continuous
RM1M,Right Side M-1: Mean Velocity (cm/s),phaseiii_v_tcd.csv,V_TCD,continuous
RM1S,Right Side M-1: Waveform Systolic Measurement (cm/s),phaseiii_v_tcd.csv,V_TCD,continuous
RM1D,Right Side M-1: Waveform Diastolic Measurement (cm/s),phaseiii_v_tcd.csv,V_TCD,continuous
RM1PI,Right Side M-1: Waveform Pulsatility Index,phaseiii_v_tcd.csv,V_TCD,continuous
RM1RI,Right Side M-1: Waveform Resistance Index,phaseiii_v_tcd.csv,V_TCD,continuous
RMCADE,Right Side MCA: Depth,phaseiii_v_tcd.csv,V_TCD,continuous
RMCAM,Right Side MCA: Mean Velocity (cm/s),phaseiii_v_tcd.csv,V_TCD,continuous
RMCAS,Right Side MCA: Waveform Systolic Measurement (cm/s),phaseiii_v_tcd.csv,V_TCD,continuous
RMCAD,Right Side MCA: Waveform Diastolic Measurement (cm/s),phaseiii_v_tcd.csv,V_TCD,continuous
RMCAPI,Right Side MCA: Waveform Pulsatility Index,phaseiii_v_tcd.csv,V_TCD,continuous
RMCARI,Right Side MCA: Waveform Resistance Index,phaseiii_v_tcd.csv,V_TCD,continuous
RBIFDE,Right Side BIF: Depth,phaseiii_v_tcd.csv,V_TCD,continuous
RBIFM,Right Side BIF: Mean Velocity (cm/s),phaseiii_v_tcd.csv,V_TCD,continuous
RBIFS,Right Side BIF: Waveform Systolic Measurement (cm/s),phaseiii_v_tcd.csv,V_TCD,continuous
RBIFD,Right Side BIF: Waveform Diastolic Measurement (cm/s),phaseiii_v_tcd.csv,V_TCD,continuous
RBIFPI,Right Side BIF: Waveform Pulsatility Index,phaseiii_v_tcd.csv,V_TCD,continuous
RBIFRI,Right Side BIF: Waveform Resistance Index,phaseiii_v_tcd.csv,V_TCD,continuous
RACADE,Right Side ACA: Depth,phaseiii_v_tcd.csv,V_TCD,continuous
RACAM,Right Side ACA: Mean Velocity (cm/s),phaseiii_v_tcd.csv,V_TCD,continuous
RACAS,Right Side ACA: Waveform Systolic Measurement (cm/s),phaseiii_v_tcd.csv,V_TCD,continuous
RACAD,Right Side ACA: Waveform Diastolic Measurement (cm/s),phaseiii_v_tcd.csv,V_TCD,continuous
RACAPI,Right Side ACA: Waveform Pulsatility Index,phaseiii_v_tcd.csv,V_TCD,continuous
RACARI,Right Side ACA: Waveform Resistance Index,phaseiii_v_tcd.csv,V_TCD,continuous
RICADE,Right Side dICA: Depth,phaseiii_v_tcd.csv,V_TCD,continuous
RICAM,Right Side dICA: Mean Velocity (cm/s),phaseiii_v_tcd.csv,V_TCD,continuous
RICAS,Right Side dICA: Waveform Systolic Measurement (cm/s),phaseiii_v_tcd.csv,V_TCD,continuous
RICAD,Right Side dICA: Waveform Diastolic Measurement (cm/s),phaseiii_v_tcd.csv,V_TCD,continuous
RICAPI,Right Side dICA: Waveform Pulsatility Index,phaseiii_v_tcd.csv,V_TCD,continuous
RICARI,Right Side dICA: Waveform Resistance Index,phaseiii_v_tcd.csv,V_TCD,continuous
RPCADE,Right Side PCA: Depth,phaseiii_v_tcd.csv,V_TCD,continuous
RPCAM,Right Side PCA: Mean Velocity (cm/s),phaseiii_v_tcd.csv,V_TCD,continuous
RPCAS,Right Side PCA: Waveform Systolic Measurement (cm/s),phaseiii_v_tcd.csv,V_TCD,continuous
RPCAD,Right Side PCA: Waveform Diastolic Measurement (cm/s),phaseiii_v_tcd.csv,V_TCD,continuous
RPCAPI,Right Side PCA: Waveform Pulsatility Index,phaseiii_v_tcd.csv,V_TCD,continuous
RPCARI,Right Side PCA: Waveform Resistance Index,phaseiii_v_tcd.csv,V_TCD,continuous
RTOBDE,Right Side TOB: Depth,phaseiii_v_tcd.csv,V_TCD,continuous
RTOBM,Right Side TOB: Mean Velocity (cm/s),phaseiii_v_tcd.csv,V_TCD,continuous
RTOBS,Right Side TOB: Waveform Systolic Measurement (cm/s),phaseiii_v_tcd.csv,V_TCD,continuous
RTOBD,Right Side TOB: Waveform Diastolic Measurement (cm/s),phaseiii_v_tcd.csv,V_TCD,continuous
RTOBPI,Right Side TOB: Waveform Pulsatility Index,phaseiii_v_tcd.csv,V_TCD,continuous
RTOBRI,Right Side TOB: Waveform Resistance Index,phaseiii_v_tcd.csv,V_TCD,continuous
VIS_DT_DAYS,VISIT DATE (recode: number of days after date of eligibility or ineligibility),phaseiii_v_tcd.csv,V_TCD,continuous
ID,Unique patient identifier (randomized),phaseiii_visit_vis_stat.csv,VISIT_VIS_STAT,continuous
VISIT,VISIT NUMBER,phaseiii_visit_vis_stat.csv,VISIT_VIS_STAT,categorical
VIS_STAT,VISIT STATUS (1 = VISITED; 2 = MISSED; 3 = UNEXPECTED),phaseiii_visit_vis_stat.csv,VISIT_VIS_STAT,continuous
LIWIN_DAYS,LOWER VISIT WINDOW: IDEAL (recode: number of days after date of eligibility or ineligibility),phaseiii_visit_vis_stat.csv,VISIT_VIS_STAT,continuous
UIWIN_DAYS,UPPER VISIT WINDOW: IDEAL (recode: number of days after date of eligibility or ineligibility),phaseiii_visit_vis_stat.csv,VISIT_VIS_STAT,continuous
LWIN_DAYS,LOWER VISIT WINDOW: EXTENDED (recode: number of days after date of eligibility or ineligibility),phaseiii_visit_vis_stat.csv,VISIT_VIS_STAT,continuous
UWIN_DAYS,UPPER VISIT WINDOW: EXTENDED (recode: number of days after date of eligibility or ineligibility),phaseiii_visit_vis_stat.csv,VISIT_VIS_STAT,continuous
